CURRICULUM VITAE 2025-12-22

Name: Carl-Henrik Heldin

Present appointment: Professor in Molecular Cell Biology
Dept. of Medical Biochemistry and Microbiology
Box 582, Biomedical Center
Uppsala University
SE-751 23 Uppsala, Sweden
Phone: +46-707-342547
E-mail: C-H.Heldin@imbim.uu.se

Home address: Rättarvägen 12
S-756 45 Uppsala, Sweden
Phone: +46-18-300844

Date and place of birth: August 9, 1952, Växjö, Sweden

Nationality: Swedish

Marital status: Married, two children, born 1982 and 1988

ORCID number: 0000-0002-9508-896X

University education

1971-1975	First four years of Medical School completed (University of Uppsala).
1972-1981	Bachelor of Science (Mathematics 1.5 year, Numeric analysis 0.5 year, Psychology 0.5 year, Greek 0.5 year) completed July 28, 1981 (Univ. of Uppsala).
1975-1980	Thesis work at Dept. of Medical and Physiological Chemistry (Univ. of Uppsala). Dissertation May 10, 1980. "Studies on growth factors for human cultured cells".

Academic positions

1972-1974	Part time teaching positions at Depts. of Anatomy, Medical and Physiological Chemistry, and Physiology (in total 200 hours).
750701-800331	Graduate student scholarship at Dept of Medical and Physiological Chemistry combined with a part time teaching position (in total 1100 hours).
800401-801031	Research Assistant at Dept of Medical and Physiological Chemistry.
810101-810331	Lecturer at Dept of Medical and Physiological Chemistry.
810701-831231	Cancer Research Scholarship from the Swedish Cancer Society.
840101-851231	Senior Scientist of the Swedish Cancer Society.
860101-170731	Director, Ludwig Institute for Cancer Research (Uppsala Branch).
920801--	Professor in Molecular Cell Biology at the Medical Faculty of Uppsala Univ.
250101--	Science Secretary, the Wenner-Gren Foundations

Positions as physician

750623-750816	Geriatric Clinic at Härnösand's Hospital.
790625-790801	Clinical Chemistry at Sundsvall's Hospital.

Academic honors

Elected member of learned societies

1989 European Molecular Biology Organization.
1991 Royal Swedish Academy of Sciences, Med. Class.
1995 Royal Scientific Society (Uppsala).
1999 Academia Europea.
2002 Japanese Association for Cancer Research.
2006 Finnish Scientific Society.
2006 Scan Balt Academy.
2007 Hellenic Biochemical Society
2009 Norwegian Academy of Sciences and Letters
2009 European Academy of Cancer Sciences
2016 American Academy of Arts and Science
2020 Japan Academy

Doctor honoris causa

2009 University of Patras, Greece.
2010 University of Helsinki, Finland.
2011 University of Turku, Finland.
2011 University of Heidelberg, Germany.

Awards

1984 The The Svedberg Prize, the Swedish Biochemical Society.
1984 King Oscar II:s Prize, Univ. of Uppsala (shared with K. Söderhäll).
1984 The Alvarenga Prize, Swedish Medical Society (shared with B. Westermark).
1984 The Thureus Prize, Royal Society of Sciences (Uppsala).
1986 Anders Jahre's Medical Prize for Younger Scientists, Univ. of Oslo (with B. Gustafsson).
1989 Prix Antoine Lacassagne, French Nat. Org. against Cancer (shared with D. Gospodarowicz).
1989 K. Fernström's Medical Prize for Young Swedish Scientists, Med. Faculty of Uppsala Univ.
1990 The Jubilee Prize, Swedish Medical Society (shared with B. Westermark).
1992 The EMBO Medal, EMBO Council.
1993 K. Fernström's Large Medical Prize for Nordic Scientists, Lund Univ. (with B. Westermark).
1999 Meyenburg Prize, German Cancer Center, Heidelberg.
2002 Pezcoller-AACR Award, Pezcoller Foundation and American Ass. for Cancer Research.
2003 Rudbeck Award, Medical Society in Uppsala.
2006 K.-J. Öbrink Lecture, Uppsala Univ.
2011 The Rudbeck Medal, Uppsala Univ.
2011 The Berzelius Medal, Swedish Medical Society.
2012 Honorary Medal of the Signal Transduction Society.
2016 H.M. The King´s Medal, 12th size gold medal on Seraphim Order ribbon.
2018 ERC Advanced Researcher Grant.
2019 Anders Jahre´s Large Medical Prize, Univ. of Oslo.
2019 Christian de Duve Lecture, Brussels Univ.
2021 Göran Gustafsson Lecture, Uppsala Univ.
2023 The Order of the Rising Sun, Gold and Silver Stars, the Ministry of Foreign Affairs of Japan

Other academic honors

1981 Appointed docent in Medical and Physiological Chemistry at Uppsala Univ.
1986 Appointed adjunct professor in Medical and Physiol. Chemistry at Uppsala Univ.
2010 Honorary member, Norrland's student association.

Thesis adviser

Thesis adviser for 16 graduate students:
Bo Ek (dissertation 1985), Ann Johnsson (1986), Lars Rönnstrand (1989), Annet Hammacher (1989), Arne Östman (1990), Kensuke Usuki (1992), Maria Andersson (1994), Flemming Vassbotn (1994), Anders Olofsson (1995), Peter Blume-Jensen (1995), Klaus Hansen (1996), Jan Saras (1997), Roya Hooshmand-Rad (1999), Maria Tsioumpekou (2019), Niki Sarri (2023), Kehuan Wang (2023).

Assistant thesis adviser for 52 graduate students:
Christer Betsholtz (1986), Monica Nistér (1987), Karin Mellström (1988), Ylva Paulsson (1988), Anders Tingström (1991), Anders Eriksson (1992), Anja Smits (1992), Monica Hermanson (1993), Petra Franzén (1995), Koutaro Yokote (1996), Sigrídur Valgeirsdóttir (1998), Simon Ekman (2000), Greger Brodin (2002), Kristian Pietras (2002), Tobias Sjöblom (2002), Camilla Persson (2003), Sofia Edlund (2003), Fumiko Itoh (2003), Anders Kallin (2003), Gudrun Valdimarsdóttir (2004), Katarzyna Kowanetz (2004), Marcin Kowanetz (2005), Katerina Pardali (2005), Rosita Bergström (2008), Susann Karlsson (2009), Agnieszka Kłosowska-Wardęga (2010), Piotr Wardęga (2010), Peter Lönn (2010), Michael Vanlandewyck (2011), Maria Ekman (2011), Markus Dahl (2012), Erna Raja (2012), Berit Bernert (2013), Helena Porsch (2013), E-Jean Tan (2013), Shyam Kumar Gudey (2014), Haisha Ma (2015), Reshma Sundar (2015), Anahita Hamidi (2015), Glenda Eger (2016), Merima Mehic (2017), Varun Maturi (2018), Claudia Bellomo (2018), Masha Dadras (2018), Giulia Pilia (2018), Panagiotis Papoutsoglou (2018), Ana Rosa Saez Ibanez (2019), Kalliopi Tzavlaki (2021), Constantinos Kolliopoulos (2021), Chrysoula Tsirigoti (2023), Caroline Gélabert (2023), Yu Bai (2024).

Thesis examiner (faculty opponent; 31 occasions)

Ylva Engström, Karolinska Institute, Stockholm, December 17, 1985.
Eva Dafgård, Karolinska Institute, Stockholm, February 1, 1991.
Kristian Helin, University of Copenhagen, June 25, 1991.
Eva Jacobson, University of Stockholm, May 9, 1994.
Pia Ljungquist-Höddelius, University of Linköping, Sept. 30, 1994.
Tim Wood, Karolinska Institute, Stockholm, December 19, 1996.
Martin Ridderstråle, University of Lund, February 28, 1997.
Mikael Rydén, Karolinska Institute, Stockholm, April 25, 1997.
Lone Rønnov-Jessen, University of Copenhagen, May 16, 1997.
Panu Jaakkola, University of Turku, May 20, 1998.
Stephen Miller, University of Uppsala, October 2, 1998.
Michael Jeltsch, University of Helsinki, November 29, 2002.
Alexandra Mandic, Karolinska Institute, Stockholm, February 28, 2003.
Sailaja Paruchuri, University of Lund, June 4, 2004.
Johanna Lahdenranta, University of Helsinki, June 23, 2004.
Lotta Gustafsson, University of Lund, May 20, 2005.
Anders Bratt, Karolinska Institute, Stockholm, September 16, 2005.
Anna-Lotta Hallbeck, University of Linköping, November 23, 2007.
Daniel Wetterskog, University of Gothenburg, October 17, 2008.
Magdalena Laska, University of Århus, March 6, 2009.
Sofia Halin, University of Umeå, January 22, 2010.
Federica Toffalini, University of Brussels, March 1, 2010.
Kanutte Huse, University of Oslo, June 29, 2011.
Toril Holien, University of Trondheim, February 16, 2012.
Katja Karjalainen, University of Helsinki, May 29, 2015.
Anna Knittle, University of Turku, February 10, 2017.
Yanhong Wang, University of Melbourne, February 13, 2018.
Lauren Skye Strathearn, University of Dundee, November 7, 2018.
Adilson Fonseca Teixeira, University of Melbourne, May 27, 2023.

Chuannan Fan, University of Leiden, June 26, 2024
Tilen Trselic, Karolinska Institute, December 16, 2025

Referee for professorships (26 occasions)

Professor in Medical Biochemistry, Oulu University, Finland, 1989.
Professor in Cell Biology, Linköping University, Sweden, 1992.
Professor in Cell Biology/Physiology, Linköping University, Sweden, 1992.
Professor in Molecular Cell Biology, Helsinki University, Finland, 1993.
Professor in Molecular Cell Biology, Lund University, Sweden, 1995.
Professor in Cell Biology, Oulu University, Finland, 1999.
Professor in Tissue Biology, Karolinska Institute, Stockholm, Sweden, 1999.
Professor of the Academy of Finland, 2000.
Professor/Lecturer in Molecular Developmental Biology, Karolinska Inst., 2000.
Professor in Medical Technology and Biotechnology, Tampere, 2002.
Professor in Molecular Cell Biology, Copenhagen University, 2002.
Professor in Vascular Biology, Karolinska Institute, 2004.
Professor in Cancer Genetics, Tampere University, 2004.
Professor in Functional Genomics in Biomedicine, Copenhagen University, 2005.
Professor in Medical Technology and Biotechnology, Tampere University, 2006.
Professor in Medical Biochemistry, Oslo University, 2008.
Professor in Genetics, Helsinki University, 2009.
Professor/Lecturer in Medical Biotechnology, Tampere University, 2013.
Professor/Lecturer in Medical Biotechnology, Tampere University, 2014.
Professor/Lecturer in Cell and Molecular Biology, Tampere University, 2016.
Professor/Lecturer in Cell and Tissue Engineering, Tampere University, 2016.
Professor in Biosciences, Institute for Cancer Research, Oslo University, 2016.
Professor/Lecturer in Cell Biology, Tampere University, 2018.
Professor/Lecturer in Cell Biology, Tampere University, 2020.
Professor/Lecturer in Cancer Research, Tampere University, 2021.
Professor/Lecturer in Cancer Biology, Tampere University, 2024.

Participation in scientific conferences

Participated in 314 conferences outside Sweden between 1977 and 2025 (in 299 as an invited lecturer) and several within Sweden.
Co-organized 34 international meetings or courses between 1987 and 2025.
Elected chairman for the Gordon Conference on Peptide Growth Factors 2000 (vice chair 1998).

Member of scientific advisory committees for academic institutes (34 former; 15 present)

1988-1995 Heinrich-Pette-Institut für Virologie, Hamburg (member).
1989-1991 European Science Foundation Network on Developmental Biology (member).
1989-1991 European Organization for Research and Treatment of Cancer (member).
1990-1995 Danish Biotechnology Program (member).
1994-1996 Medical Bioscience, Foundation for Strategic Research, Sweden (member).
1996-2010 Division of Cancer Biology, Danish Cancer Society, Copenhagen (chair).
1998-2000 LICR/Oxford GlycoSciences collaboration (member).
1998-2004 EMBL, Heidelberg (member; 2001-2004 chair).
1998-2011 European Institute for Oncology, Milan (member).
1998-2010 Max-Planck Institut für Biochemie, Martinsried (member).
2000-2005 Progr. in Cancer Biol. Growth Control and Angiogenesis, Helsinki Univ. (member).
2000-2006 Karolinska Institute – BMS effort in oncogenomics (member).
2001-2004 Swegene effort in Functional Genomics (chair).
2001- Institute of Medical Technology, Tampere (chair).
2002-2010 German Cancer Center, Heidelberg (member; 2006-2010 chair).
2003-2009 Bio-City, Turku (chair).

2004-2010 Bio-X, Uppsala (member).
2004-2004 Institute of Molecular Biology, University of Copenhagen (member).
2004-2005 Research and Training in Parasitic Diseases at the S. Cone of Latin Am. (member).
2004-2007 International Affairs Committee, American Association for Cancer Res. (member).
2005-2011 Biotechnology Center, Oslo (member).
2005-2008 Membership Committee, EMBO (member; 2008 chair).
2005-2011 Structural Genomics Consortium, Oxford, Toronto and Stockholm (member).
2005-2006 Ensemble, EBI, Hinxton (member).
2006-2006 FUGE effort in Functional Genomics, Norwegian Research Council (member).
2007-2019 Cluster of Excellence, Frankfurt (member).
2007- FIMM, Helsinki (member).
2008-2024 Center for Molecular Medicine, Vienna (member; since 2018 chair).
2009- Biocenter Finland (chair).
2010-2012 External Expert Group, FET Flagships Science Forum (member).
2014- Institute for Cancer Research, Oslo University (chair).
2014-2024 Center for Cancer Biomarkers, Bergen (chair).
2014-2014 Inst. Genetics and Molecular Medicine, University of Edinburgh (member).
2016- University of Cologne (vice chair).
2016- K.G. Jebsen Foundation, Bergen (member).
2018-2020 Oslo University Hospital Comprehensive Cancer Center (chair).
2018- Danish Cancer Institute, Copenhagen (chair).
2019-2022 AICR Consortium on Cancer of Unknown Origin, Turin (member).
2019-2025 Oslo University Hospital (member).
2019- National Center for Scientific Research “Demokritos”, Athens (member).
2020- European Association for Cancer Research (member).
2021- Academia Europea (member)
2022-2024 EMTHERA, Frankfurt University (chair)
2024- Uppsala Comprehensive Cancer Center (chair)
2024- Zebrafish, Facility, Uppsala University (member)
2024- Falling Walls Foundation, Berlin (member)
2025- AIRC (member)

Member of scientific advisory committees for companies (7 former; 3 present)

1998-2001 Nycomed-Amersham, Amersham (member).
2000-2007 Innoventus AB, Uppsala (member).
2001-2005 Actar AB, Stockholm (member).
2007-2016 MolMed, Milan (member).
2009-2016 Kolltan, New Haven (member).
2009-2016 ModPro, Uppsala (member).
2013-2017 Merck, Darmstadt (member).
2021- PhageNova Bio (member).
2022- Papyrus Therapeutics (member).
2024- Rarity, Uppsala (member)

Member of grant review committees (66 calls; 35 times as chair)

1989-2001 Priority Committee A, Swedish Cancer Society (member; 1997-2001 chair; 12 calls).
1993-1994 Priority Committee Chemistry I, Swedish Medical Research Council (member).
1999-2004 Review Committee, Progr. on Angiogenesis, Deutsche Forschungsgem. (member; 3 calls).
1998 Grant Review Committee, Italian Association of Cancer Research (AICR) (member).
2000 Grant Review Committee, Norwegian Research Council (chair).
2001 Evaluation of applications for Centers of Excellence, Academy of Finland (chair).
2001-2002 Evaluation of appl. for Centers of Excellence, Norwegian Res. Council (member).
2002 Grant Review Committee, Fortis Insurance Cancer Foundation, Belgium (member).
2003 Grant Review Committee, FUGENE Program, Norwegian Res. Council (member).
2003 Grant Review Committee, Biocentrum Helsinki (member).
2003-2004 Selection of Future Research Leaders, Foundation for Strategic Res. (member).

2003 Biocenter funding, Helsinki University (member).
2004 Grant Review Committee, Norwegian Research Council (chair).
2004 Evaluation of appl. for Centers in Oncogenomics, Italian Ass. for Cancer Res. (member).
2004 Program for Outstanding Young Investigators, Norwegian Res. Council (chair).
2004-2005 Evaluation of appl. for Centers of Excellence, Foundation for Strategic Res. (member).
2005 Grant Review Committee, ALF funding, Karolinska Institute (member).
2006 Evaluation of appl. for Centers of Excellence, Norwegian Res. Council (chair).
2008-2009 Grant Review Committee, molecular biology, Norwegian Res. Council (chair; 2 calls).
2009 Grant Review Committee, cancer, Norwegian Res. Council (chair).
2009-2024 BioCenter Finland, Infrastructure funding (chair; 6 calls).
2012-2018 Grant Rev. Comm., Outstanding Young Scientists, R. Söderberg Found. (chair; 7 calls).
2012-2016 Grant Review Committee, FCT, Portuguese Government (chair; 3 calls).
2012 Grant Review Committee, WELBIO, Belgium (member).
2013-2015 Grant Review Committee, Cluster of Excellence, Frankfurt University (member; 3 calls).
2017-2024 Grant Review Committee, WELBIO, Belgium (chair; 4 calls).
2016-2017 Grant Review Committee, Norwegian Cancer Society (chair; 2 calls).
2018-2019 Grant Review Committee, AICR, Italy, 5 per mille, metastatic disease (member).
2021-2024 Grant Review Committee, AICR, Italy, young scientists (member; 4 calls).
2023- Knut and Alice Wallenberg Foundation (member; 1 call)

Participation in visits by scientific evaluation committees (87 times; 34 times as chair)

1991 Differentiation Program, EMBL, Heidelberg (member).
1993 CRC Growth Factor Research Group, Oxford (member).
1994 ICRF Laboratories, Inst. of Mol. Med. and Clinical Oncology Unit, Oxford (member).
1995 Differentiation Program, EMBL, Heidelberg (member).
1996 Biocenter, Oulu (member).
1997 CRC Growth Factor Research Group, Birmingham (member).
1998 Max-Delbrück-Center, Berlin (member).
1999 Developmental Biology Program, EMBL, Heidelberg (member).
1999 ICRF Laboratories, Inst. of Mol. Med. and Clinical Oncology Unit, Oxford (member).
1999 Evaluation of Biology at Helsinki University (member).
1999 Max Planck Institute for Biochemistry, Martinsried (member).
2000 Evaluation of Biomedical Research in Norway (member).
2001 Cell Biology and Biophysics Programme, EMBL, Heidelberg (chair).
2002 CRC Growth Factor Research Group, Birmingham (member).
2002 Grad. Progr. on Signal Transd. and Cell Regul., Austrian Res. Council (member).
2002 Cancer Research UK unit at Lincoln's Inns Field, London (member).
2002 Max Planck Institute for Biochemistry, Martinsried (member).
2003 Developmental Biology Programme, EMBL, Heidelberg (chair).
2003 Inst. for Biochem. and Biophys. and Nenski Inst., Polish Acad. Sci., Warsaw (member).
2003 Structural and Functional Genomics Program, DKFZ, Heidelberg (member).
2004 Cancer Research UK unit at Hammersmith Hospital, London (member).
2005 Biotechnology Center, Oslo (member).
2005 Max Planck Institute for Biochemistry, Martinsried (member).
2005 Center of Biotechnology, Madrid (member).
2005 Cell and Tumor Biology Program, DKFZ, Heidelberg (member).
2006 Biotechnology Center, Oslo (member).
2006 Swegene, Gothenburg and Lund (chair).
2006 IMT, Tampere (chair).
2007 Biotechnology Center, Oslo (member).
2007 Max Planck Institute for Biochemistry, Martinsried (member).
2008 Biotechnology Center, Oslo (member).
2008 Structural and Functional Genomics Program, DKFZ, Heidelberg (member).
2008 Center for Molecular Medicine, Vienna (member).
2008 EPFL, Lausanne (chair).
2009 SCIBLU Center, Lund (chair).
2009 ICRSET, Dublin (member).

2009 Biotechnology Center, Oslo (member).
2009 Biocenter, Finland (chair)
2009 VIB11, Leuven (member).
2009 Center for Molecular Medicine, Vienna (member).
2010 Center of Excellence in Integrative Life Science, Tokyo University (chair).
2011 IMT, Tampere (chair).
2011 Biotechnology Center, Oslo (member).
2011 FIMM, Helsinki (member).
2011 Center for Molecular Medicine, Vienna (member).
2011 Department of Biomedicine, University of Bergen (member).
2012 Leiden University Medical School (member).
2012 University of Debrecen (member).
2012 Center for Molecular Medicine, Vienna (member).
2013 FIMM, Helsinki (member).
2014 Center for Cancer Biomarkers, Bergen (chair).
2014 Center for Molecular Medicine, Vienna (member).
2015 Center for Cancer Biomarkers, Bergen (chair).
2015 FIMM, Helsinki (member).
2015 Helsinki Life Science Center, Helsinki (chair).
2015 Institute for Cancer Research, Oslo (chair).
2015 Center for Molecular Medicine, Vienna (member).
2016 Center for Cancer Biomarkers, Bergen (chair).
2017 Center for Cancer Biomarkers, Bergen (chair).
2017 Center for Molecular Medicine, Vienna (member).
2017 FIMM, Helsinki (member).
2018 Oslo University Hospital Comprehensive Cancer Center (chair).
2018 Center for Cancer Biomarkers, Bergen (chair).
2018 Max Delbruck Center, Berlin (member).
2019 Danish Cancer Society Research Center, Copenhagen (chair).
2019 DanStem, Novo Nordisk Center for Stem Cell Research, Copenhagen (chair).
2019 Center for Cancer Biomarkers, Bergen (chair).
2019 Center for Molecular Medicine, Vienna (chair).
2019 FIMM, Helsinki (member).
2020 MET Faculty, Tampere University (chair).
2021 Institute for Cancer Research, Oslo (chair).
2021 Oslo University Hospital Comprehensive Cancer Center (member).
2021 Danish Cancer Society Research Center (chair).
2021 VIB program, Belgium (member).
2021 Center for Molecular Medicine, Vienna (chair).
2022 Center for Cancer Biomarkers, Bergen (chair).
2022 FIMM, Helsinki (member).
2022 Center for Molecular Medicine, Vienna (chair).
2022 Danish Cancer Society Research Center (chair).
2023 Institute if Cancer Research, Oslo (chair).
2023 Center for Cancer Biomarkers, Bergen (chair).
2024 Center for Molecular Medicine, Vienna (chair).
2024 Center for Cancer Biomarkers, Bergen (chair).
2025 Danish Cancer Institute, Copenhagen (chair).
2025 Cell Biology at Linköping University (chair).
2025 FIMM, Helsinki (member).
2025 AIRC, Milan (Member).

Scientific award committees (27 occasions)

1988-1990 Sloan Prize Selection Comm., General Motors Cancer Res. Awards (member; 2 occasions).
1992-1995 Prix Antoine Lacassagne Selection Committee, French Nat. Org. Cancer (member).
1997-1998 Pezcollar-AACR Cancer Research Award Committee (member; 2 occasions).
1999-2013 Crafoord Prize in Polyarthritis Selection Comm. (member; since 2011 chair; 3 occasions).

2000 Interbrew-Baillet Latour Health Prize Committee (member).
2000 Van Gysel Prize for Biomedical Research Committee (member).
2003-2005 Pezcoller-AACR Cancer Research Award Comm. (member; 2004-2005 chair; 2 occasions).
2005-2006 Landon-AACR Prize for Basic Cancer Research Selection Committee (member).
2016-2024 Ernst Schering Award Committee (member; 9 occasions).
2017-2021 King Olav V´s Cancer Research Prize (member; 4 occasions)
2024 Family Blix Cancer Research Prize (member)

Boards (12 former; 5 present)

1978-1980 Faculty of Medicine, Uppsala University (member).
1993-1999 Faculty of Medicine, Uppsala Univ. and subcommittees (member).
2001-2006 Swedish Research Council (member).
2004-2005 WCN consortium in Functional Genomics (member).
2005-2014 European Research Council (coordinator for Life Sciences; 2011-2014 Vice President).
2006-2010 German Cancer Center, Heidelberg (member).
2008-2010 EMBO Council (member; 2010 chair).
2009- EMBL node Molecular Infection Medicine Sweden, Umeå (chair).
2012-2025 Kancera (member).
2013-2023 Nobel Foundation (chair).
2014-2024 Falling Walls Foundation (member).
2015-2020 EMBO Council (member; 2016-2020 chair).
2015-2021 SciLifeLab (providing infrastructure in life science in Sweden; chair).
2022- Swedish Young Academy (member)
2024- Karolinska Institutet (member)
2025- Mesenkia (member)
2025- Wenner-Gren Foundations

Search committees for positions (16 occasions; 8 times as chair)

2004 Director General of EMBL (member).
2007-2008 EMBO Director (member).
2012 Head of Swedish Cancer Society (member).
2017 Director General of EMBL (member).
2017 Director of Molecular Infection Medicine Sweden (chair).
2017 Director of the Danish Cancer Society Research Center (member).
2018-2019 President of the European Research Council (member).
2020 Executive Director of the Nobel Foundation (chair).
2020-2025 Standing Identification Committee for ERC Council members (chair; 6 occasions).
2022 Director of the Danish Cancer Society Research Center (member).
2024-2025 Director for Center of Molecular Medicine, Vienna (member)

Senior editor

2003-2009 Cancer Research.

Associate editor

1988- Growth Factors.
1989-2020 Molecular Biology of the Cell.
1993-2000 Cancer Research.
1995- Genes to Cells.

Editorial boards for journals (18 former; 17 present)

1987-1992 European Journal of Biochemistry.
1988-2000 In Vitro Cellular and Developmental Biology.
1988-1995 Progress in Growth Factor Research.

1989-1992 Biochemistry.
1989-1998 Journal of Vascular Medicine and Biology.
1989- International Journal of Cancer.
1989-1996 Oncogenes and Growth Factors Abstracts.
1990-1992 EMBO Journal.
1990-2000 European Journal of Cancer.
1990-2025 Trends in Biological Sciences.
1991-2000 Journal of Vascular Research.
1996-2001 Pathobiology.
1996- Journal of Cellular Physiology.
1996- Cytokine and Growth Factor Reviews.
1996-2015 Journal of Cell Science.
1999-2004 EMBO Journal.
1999-2006 Matrix Biology.
1999-2002 IUBMB Life.
2000-2004 EMBO Reports.
2001- Signal Transduction - Receptors, Mediators and Genes.
2004-2010 International Journal of Cancer Prevention.
2004-2024 Cancer Science.
2005- Current Cancer Therapy Reviews.
2006- Molecular Oncology.
2007- Cancer Genomics and Proteomics.
2007- Journal of Molecular Signaling
2007- The Open Cell and Developmental Biology Journal
2007- The Open Cancer Journal
2008- EMBO Molecular Medicine
2008- Chinese Journal of Cancer
2010- DNA and Cell Biology
2010- Cancers
2013- Frontiers in Endocrinology
2017- Journal of Molecular Oncology Research
2017- Apoptosis

Publications

471 research papers published in peer-reviewed journals, and 213 review articles. 45 patents approved. Cited >82 000 times, H-index 150 (Web of Science).

Carl-Henrik Heldin

RESEARCH ARTICLES
2025-12-22

1. Heldin, C.-H., Wasteson, Å., and Westermark, B. (1977). Partial purification and characterization of platelet factors stimulating the multiplication of normal human glial cells. *Exp. Cell Res.* 109, 429-437.

2. Wasteson, Å., Glimelius, B., Busch, C., Westermark, B., Heldin, C.-H., and Norling, B. (1977). Effect of a platelet endoglycosidase on cell surface associated heparan sulphate of human cultured endothelial and glial cells. *Thrombosis Res.* 11, 309-321.

3. Heldin, C.-H., Westermark, B., and Wasteson, Å. (1979). Platelet-derived growth factor: Purification and partial characterization. *Proc. Natl. Acad. Sci. USA* 76, 3722-3726.

4. Heldin, C.-H., Westermark, B., and Wasteson, Å. (1979). Desensitisation of cultured glial cells to epidermal growth factor by receptor down-regulation. *Nature* 282, 419-420.

5. Heldin, C.-H., Westermark, B., and Wasteson, Å. (1980). Chemical and biological properties of a growth factor from human-cultured osteosarcoma cells: Resemblance with platelet-derived growth factor. *J. Cell. Physiol.* 105, 235-246.

6. Oldberg, Å., Heldin, C.-H., Wasteson, Å., Busch, C., and Höök, M. (1980). Characterization of a platelet endoglycosidase degrading heparin-like polysaccharides. *Biochemistry* 19, 5755-5762.

7. Heldin, C.-H., Wasteson, Å., and Westermark, B. (1980). Growth of normal human glial cells in a defined medium containing platelet-derived growth factor. *Proc. Natl. Acad. Sci. USA* 77, 6611-6615.

8. Heldin, C.-H., Westermark, B., and Wasteson, Å. (1981). Platelet-derived growth factor: Isolation by a large-scale procedure and analysis of subunit composition. *Biochem. J.* 193, 907-913.

9. Heldin, C.-H., Wasteson, Å., Fryklund, L., and Westermark, B. (1981). Somatomedin B: Mitogenic activity derived from contaminant epidermal growth factor. *Science* 213, 1122-1123.

10. Heldin, C.-H., Westermark, B., and Wasteson, Å. (1981). Demonstration of an antibody against platelet-derived growth factor. *Exp. Cell Res.* 136, 255-261.

11. Heldin, C.-H., Westermark, B., and Wasteson, Å. (1981). Specific receptors for platelet-derived growth factor on cells derived from connective tissue and glia. *Proc. Natl. Acad. Sci. USA* 78, 3664-3668.

12. Ek, B., Westermark, B., Wasteson, Å., and Heldin, C.-H. (1982). Stimulation of tyrosine-specific phosphorylation by platelet-derived growth factor. *Nature* 295, 419-420.

13. Heldin, C.-H., Wasteson, Å., and Westermark, B. (1982). Interaction of platelet-derived growth factor with its fibroblast receptor. Demonstration of ligand degradation and receptor modulation. *J. Biol. Chem.* 257, 4216-4221.

14. Johnsson, A., Heldin, C.-H., Westermark, B., and Wasteson, Å. (1982). Platelet-derived growth factor: Identification of constituent polypeptide chains. *Biochem. Biophys. Res. Commun.* 104, 66-74.

15. Ek, B., and Heldin, C.-H. (1982). Characterization of a tyrosine-specific kinase activity in human fibroblast membranes stimulated by platelet-derived growth factor. *J. Biol. Chem.* 257, 10486-10492.

16. Edlund, B., Heldin, C.-H., and Engström, L. (1982). Effect of chemical modification of a histidine and a lysine residue of pea seed nucleoside diphosphate kinase. *J. Med. Sci.* 87, 243-250.

17. Westermark, B., Magnusson, A., and Heldin, C.-H. (1982). Effect of epidermal growth factor on membrane motility and cell locomotion in cultures of human clonal glioma cells. *J. Neuroscience Res.* 8, 491-507.

18. King, G.L., Kahn, C.R., and Heldin, C.-H. (1983). Sharing of biological effect and receptors between guinea pig insulin and platelet-derived growth factor. *Proc. Natl. Acad. Sci. USA* 80, 1308-1312.

19. Nilsson, J., Ksiazek, T., Heldin, C.-H., and Thyberg, J. (1983). Demonstration of stimulatory effects of platelet-derived growth factor on cultivated rat arterial smooth muscle cells: Differences between cells from young and adult animals. *Exp. Cell Res.* 145, 231-237.

20. Mellström, K., Höglund, A.-S., Nistér, M., Heldin, C.-H., Westermark, B., and Lindberg, U. (1983). The effect of platelet-derived growth factor on morphology and motility of human glial cells. *J. Musc. Res. Cell Motility* 4, 589-609.

21. Heldin, C.-H., Ek, B., and Rönnstrand, L. (1983). Characterization of the receptor for platelet-derived growth factor on human fibroblasts. Demonstration of an intimate relationship with a 185,000-dalton substrate for the platelet-derived growth factor-stimulated kinase. *J. Biol. Chem.* 258, 10054-10061.

22. Nilsson, J., Thyberg, J., Heldin, C.-H., Westermark, B., and Wasteson, Å. (1983). Surface binding and internalization of platelet-derived growth factor in human fibroblasts. *Proc. Natl. Acad. Sci. USA* 80, 5592-5596.

23. Waterfield, M.D., Scrace, G.T., Whittle, N., Stroobant, P., Johnsson, A., Wasteson, Å., Westermark, B., Heldin, C.-H., Huang, J.S., and Deuel, T.F. (1983). Platelet-derived growth factor is structurally related to the putative transforming protein $p28^{sis}$ of simian sarcoma virus. *Nature (London)* 304, 35-39.

24. Betsholtz, C., Heldin, C.-H., Nistér, M., Ek, B., Wasteson, Å., and Westermark, B. (1983). Synthesis of a PDGF-like growth factor in human glioma and sarcoma cells suggests the expression of the cellular homologue to the transforming protein of simian sarcoma virus. *Biochem. Biophys. Res. Commun.* 117, 176-182.

25. Nistér, M., Heldin, C.-H., Wasteson, Å., and Westermark, B. (1984). A glioma-derived analog to platelet-derived growth factor: Demonstration of receptor competing activity and immunological cross-reactivity. *Proc. Natl. Acad. Sci. USA* 81, 926-930.

26. Ek, B., and Heldin, C.-H. (1984). Use of an antiserum against phospho-tyrosine for the identification of phosphorylated components in human fibroblasts stimulated by platelet-derived growth factor. *J. Biol. Chem.* 259, 11145-11152.

27. Johnsson, A., Heldin, C.-H., Wasteson, Å., Westermark, B., Deuel, T.F., Huang, J.S., Seeburg, P.H., Gray, A., Ullrich, A., Scrace, G., Stroobant, P., and Waterfield, M.D. (1984). The c-*sis* gene encodes a precursor of the B chain of platelet-derived growth factor. *EMBO J.* 3, 921-928.

28. Betsholtz, C., Westermark, B., Ek, B., and Heldin, C.-H. (1984). Co-expression of a PDGF-like growth factor and PDGF receptors in a human osteosarcoma cell line: Implications for autocrine receptor activation. *Cell* 39, 447-457.

29. Johnsson, A., Betsholtz, C., von der Helm, K., Heldin, C.-H., and Westermark, B. (1985). Platelet-derived growth factor agonist activity of a secreted form of the v-*sis* oncogene product. *Proc. Natl. Acad. Sci. USA* 82, 1721-1725.

30. Westermark, B., and Heldin, C.-H. (1985). Similar action of platelet-derived growth factor and epidermal growth factor in the pre-replicative phase of human fibroblasts suggests a common intracellular pathway. *J. Cell. Physiol.* 124, 43-48.

31. Goustin, A.S., Betsholtz, C., Pfeifer-Ohlsson, S., Persson, H., Rydnert, J., Bywater, M., Holmgren, G., Heldin, C.-H., Westermark, B., and Ohlsson, R. (1985). Co-expression of the *sis* and *myc* proto-oncogenes in developing human placenta suggests autocrine control of trophoblast growth. *Cell* 41, 301-312.

32. Betsholtz, C., Bywater, M., Westermark, B., Burk, R.R., and Heldin, C.-H. (1985). Expression of the c-*sis* gene and secretion of a platelet-derived growth factor-like protein by simian virus 40-transformed BHK cells. *Biochem. Biophys. Res. Commun.* 130, 753-760.

33. Nilsson, J., Sjölund, M., Palmberg, L., Thyberg, J., and Heldin, C.-H. (1985). Arterial smooth muscle cells in primary culture produce a platelet-derived growth factor-like protein. *Proc. Natl. Acad. Sci. USA* 82, 4418-4422.

34. Bauer, G., Birnbaum, U., Höfler, P., and Heldin, C.-H. (1985). EBV-inducing factor from platelets exhibits growth-promoting activity for NIH 3T3 cells. *EMBO J.* 4, 1957-1961.

35. van Zoelen, E.J.J., van de Ven, W.J.M., Franssen, H.J., van Oostwaard, T.M.J., van der Saag, P.T., Heldin, C.-H., and de Laat, S.W. (1985). Neuroblastoma cells express c-sis and produce a transforming growth factor antigenically related to the platelet-derived growth factor. *Mol. Cell. Biol.* 5, 2289-2297.

36. Johnsson, A., Betsholtz, C., Heldin, C.-H., and Westermark, B. (1985). Antibodies against platelet-derived growth factor inhibit acute transformation by simian sarcoma virus. *Nature* 317, 438-440.

37. Nistér, M., Heldin, C.-H., and Westermark, B. (1986). Clonal variation in the production of a platelet-derived growth factor-like protein and expression of corresponding receptors in a human malignant glioma. *Cancer Research* 46, 332-340.

38. Ek, B., and Heldin, C.-H. (1986). Specific cleavage of the fibroblast receptor for platelet-derived growth factor by an endogenous Ca^{2+}-dependent thiol protease. *Eur. J. Biochem.* 155, 409-413.

39. Heldin, C.-H., Johnsson, A., Wennergren, S., Wernstedt, C., Betsholtz, C., and Westermark, B. (1986). A human osteosarcoma cell line secretes a growth factor structurally related to a homodimer of PDGF A-chains. *Nature* 319, 511-514.

40. Betsholtz, C., Johnsson, A., Heldin, C.-H., and Westermark, B. (1986). Efficient reversion of simian sarcoma virus-transformation and inhibition of growth factor-induced mitogenesis by suramin. *Proc. Natl. Acad. Sci. USA* 83, 6440-6444.

41. Betsholtz, C., Johnsson, A., Heldin, C.-H., Westermark, B., Lind, P., Urdea, M.S., Eddy, R., Shows, T.B., Philpott, K., Mellor, A.L., Knott, T.J., and Scott, J. (1986). cDNA sequence and chromosomal localization of human platelet-derived growth factor A-chain and its expression in tumour cell lines. *Nature* 320, 695-699.

42. Johnsson, A., Betsholtz, C., Heldin, C.-H., and Westermark, B. (1986). The phenotypic characteristics of simian sarcoma virus-transformed human fibroblasts suggest that the v-*sis* gene product acts solely as a PDGF receptor agonist in cell transformation. *EMBO J.* 5, 1535-1541.

43. Westermark, B., Johnsson, A., Paulsson, Y., Betsholtz, C., Heldin, C.-H., Herlyn, M., Rodeck, U., and Koprowski, H. (1986). Human melanoma cell lines of primary and metastatic origin express the genes encoding the chains of platelet-derived growth factor (PDGF) and produce a PDGF-like growth factor. *Proc. Natl. Acad. Sci. USA* 83, 7197-7200.

44. Sejersen, T., Betsholtz, C., Sjölund, M., Heldin, C.-H., Westermark, B., and Thyberg, J. (1986). Rat skeletal myoblasts and arterial smooth muscle cells express the gene for the A chain but not the gene for the B chain (*c-sis*) of platelet-derived growth factor (PDGF) and produce a PDGF-like protein. *Proc. Natl. Acad. Sci. USA* 83, 6844-6848.

45. Paulsson, Y., Bywater, M., Pfeifer-Ohlsson, S., Ohlsson, R., Nilsson, S., Heldin, C.-H., Westermark, B., and Betsholtz, C. (1986). Growth factors induce early pre-replicative changes in senescent human fibroblasts. *EMBO J.* 5, 2157-2162.

46. Cooper, C.S., Tempest, P.R., Beckmann, M.P., Heldin, C.-H., and Brookes, P. (1986). Amplification and overexpression of the *met* gene in spontaneously transformed NIH3T3 mouse fibroblasts. *EMBO J.* 5, 2623-2628.

47. Betsholtz, C., Bergh, J., Bywater, M., Pettersson, M., Johnsson, A., Heldin, C.-H., Ohlsson, R., Knott, T.J., Scott, J., Bell, G.I., and Westermark, B. (1987). Expression of multiple growth factors in a human lung cancer cell line. *Int. J. Cancer* 39, 502-507.

48. Rönnstrand, L., Beckmann, M.P., Faulders, B., Östman, A., Ek, B., and Heldin, C.-H. (1987). Purification of the receptor for platelet-derived growth factor from porcine uterus. *J. Biol. Chem.* 262, 2929-2932.

49. Collins, T., Pober, J.S., Gimbrone, M.A.J., Hammacher, A., Betsholtz, C., Westermark, B., and Heldin, C.-H. (1987). Cultured human endothelial cells express platelet-derived growth factor A chain. *Am. J. Pathol.* 126, 7-12.

50. Paulsson, Y., Bywater, M., Heldin, C.-H., and Westermark, B. (1987). Effects of epidermal growth factor and platelet-derived growth factor on c-*fos* and c-*myc* mRNA levels in normal human fibroblasts. *Exp. Cell Res.* 171, 186-194.

51. Peres, R., Betsholtz, C., Westermark, B., and Heldin, C.-H. (1987). Frequent expression of growth factors for mesenchymal cells in human mammary carcinoma cell lines. *Cancer Res.* 47, 3425-3429.

52. Miyazono, K., Okabe, T., Urabe, A., Takaku, F., and Heldin, C.-H. (1987). Purification and properties of an endothelial cell growth factor from human platelets. *J. Biol. Chem.* 262, 4098-4103.

53. Paulsson, Y., Hammacher, A., Heldin, C.-H., and Westermark, B. (1987). Possible positive autocrine feedback in the pre-replicative phase of human fibroblasts. *Nature* 328, 715-717.

54. Böhmer, F.-D., Kraft, R., Otto, A., Wernstedt, C., Hellman, U., Kurtz, A., Müller, T., Rohde, K., Etzold, G., Lehmann, W., Langen, P., Heldin, C.-H., and Grosse, R. (1987). Identification of a polypeptide growth inhibitor from bovine mammary gland. *J. Biol. Chem.* 262, 15137-15143.

55. Alitalo, R., Andersson, L.C., Betsholtz, C., Nilsson, K., Westermark, B., Heldin, C.-H., and Alitalo, K. (1987). Induction of platelet-derived growth factor gene expression during megakaryoblastic and monocytic differentiation of human leukemia cell lines. *EMBO J.* 6, 1213-1218.

56. Mäkelä, T.P., Alitalo, R., Paulsson, Y., Westermark, B., Heldin, C.-H., and Alitalo, K. (1987). Regulation of platelet-derived growth factor gene expression by transforming growth factor β and phorbol ester in human leukemia cell lines. *Mol. Cell. Biol.* 7, 3656-3662.

57. Claesson-Welsh, L., Rönnstrand, L., and Heldin, C.-H. (1987). Biosynthesis and intracellular transport of the receptor for platelet-derived growth factor. *Proc. Natl. Acad. Sci. USA* 84, 8796-8800.

58. Frampton, G., Hildreth, G., Hartley, B., Cameron, J.S., Heldin, C.-H., and Wasteson, Å. (1988). Could platelet-derived growth factor have a role in the pathogenesis of lupus nephritis? *Lancet* 332, 343.

59. Rubin, K., Terracio, L., Rönnstrand, L., Heldin, C.-H., and Klareskog, L. (1988). Expression of platelet-derived growth factor receptors is induced on connective tissue cells during chronic synovial inflammation. *Scand. J. Immunol.* 27, 285-294.

60. Rönnstrand, L., Terracio, L., Claesson-Welsh, L., Heldin, C.-H., and Rubin, K. (1988). Characterization of two monoclonal antibodies reactive with the external domain of the platelet-derived growth factor receptor. *J. Biol. Chem.* 263, 10429-10435.

61. Sjölund, M., Hedin, U., Sejersen, T., Heldin, C.-H., and Thyberg, J. (1988). Arterial smooth muscle cells express platelet-derived growth factor (PDGF) A chain mRNA, secrete a PDGF-like mitogen, and bind exogenous PDGF in a phenotype- and growth state-dependent manner. *J. Cell Biol.* 106, 403-413.

62. Nistér, M., Libermann, T.A., Betsholtz, C., Pettersson, M., Claesson-Welsh, L., Heldin, C.-H., Schlessinger, J., and Westermark, B. (1988). Expression of messenger RNAs for platelet-derived growth factor and transforming growth factor-α and their receptors in human malignant glioma cell lines. *Cancer Res.* 48, 3910-3918.

63. Beckmann, M.P., Betsholtz, C., Heldin, C.-H., Westermark, B., Di Marco, E., Di Fiore, P.P., Robbins, K.C., and Aaronson, S.A. (1988). Comparison of biological properties and transforming potential of human PDGF-A and PDGF-B chains. *Science* 241, 1346-1349.

64. Swenne, I., Heldin, C.-H., Hill, D.J., and Hellerström, C. (1988). Effects of platelet-derived growth factor and somatomedin-C/insulin-like growth factor I on the deoxyribonucleic acid replication of fetal rat islets of Langerhans in tissue culture. *Endocrinology* 122, 214-218.

65. Hammacher, A., Hellman, U., Johnsson, A., Östman, A., Gunnarsson, K., Westermark, B., Wasteson, Å., and Heldin, C.-H. (1988). A major part of platelet-derived growth factor purified from human platelets is a heterodimer of one A and one B chain. *J. Biol. Chem.* 263, 16493-16498.

66. Hammacher, A., Nistér, M., Westermark, B., and Heldin, C.-H. (1988). A human glioma cell line secretes three structurally and functionally different dimeric forms of platelet-derived growth factor. *Eur. J. Biochem.* 176, 179-186.

67. Nistér, M., Hammacher, A., Mellström, K., Siegbahn, A., Rönnstrand, L., Westermark, B., and Heldin, C.-H. (1988). A glioma-derived PDGF A chain homodimer has different functional activities from a PDGF AB heterodimer purified from human platelets. *Cell* 52, 791-799.

68. Miyazono, K., Hellman, U., Wernstedt, C., and Heldin, C.-H. (1988). Latent high molecular weight complex of transforming growth factor β1. Purification from human platelets and structural characterization. *J. Biol. Chem.* 263, 6407-6415.

69. Mellström, K., Heldin, C.-H., and Westermark, B. (1988). Induction of circular membrane ruffling on human fibroblasts by platelet-derived growth factor. *Exp. Cell Res.* 177, 347-359.

70. Östman, A., Rall, L., Hammacher, A., Wormstead, M.A., Coit, D., Valenzuela, P., Betsholtz, C., Westermark, B., and Heldin, C.-H. (1988). Synthesis and assembly of a functionally active recombinant platelet-derived growth factor AB heterodimer. *J. Biol. Chem.* 263, 16202-16208.

71. Claesson-Welsh, L., Eriksson, A., Morén, A., Severinsson, L., Ek, B., Östman, A., Betsholtz, C., and Heldin, C.-H. (1988). cDNA cloning and expression of a human platelet-derived growth factor (PDGF) receptor specific for B-chain-containing PDGF molecules. *Mol. Cell. Biol.* 8, 3476-3486.

72. Bywater, M., Rorsman, F., Bongcam-Rudloff, E., Mark, G., Hammacher, A., Heldin, C.-H., Westermark, B., and Betsholtz, C. (1988). Expression of recombinant platelet-derived growth factor A- and B-chain homodimers in Rat-1 cells and human fibroblasts reveals differences in protein processing and autocrine effects. *Mol. Cell. Biol.* 8, 2753-2762.

73. Hermanson, M., Nistér, M., Betsholtz, C., Heldin, C.-H., Westermark, B., and Funa, K. (1988). Endothelial cell hyperplasia in human glioblastoma: Co-expression of mRNA for platelet-derived growth factor (PDGF) B chain and PDGF receptor suggests autocrine growth stimulation. *Proc. Natl. Acad. Sci. USA* 85, 7748-7752.

74. Heldin, C.-H., Bäckström, G., Östman, A., Hammacher, A., Rönnstrand, L., Rubin, K., Nistér, M., and Westermark, B. (1988). Binding of different dimeric forms of PDGF to human fibroblasts: evidence for two separate receptor types. *EMBO J.* 7, 1387-1393.

75. Rubin, K., Tingström, A., Hansson, G.K., Larsson, E., Rönnstrand, L., Klareskog, L., Claesson-Welsh, L., Heldin, C.-H., Fellström, B., and Terracio, L. (1988). Induction of B-type receptors for platelet-derived growth factor in vascular inflammation: Possible implications for development of vascular proliferative lesions. *Lancet* 1, 1353-1356.

76. Terracio, L., Rönnstrand, L., Tingström, A., Rubin, K., Claesson-Welsh, L., Funa, K., and Heldin, C.-H. (1988). Induction of platelet-derived growth factor receptor expression in smooth muscle cells and fibroblasts upon tissue culturing. *J. Cell Biol.* 107, 1947-1957.

77. Paulsson, Y., Beckmann, M.P., Westermark, B., and Heldin, C.-H. (1988). Density-dependent inhibition of cell growth by transforming growth factor-β1 in normal human fibroblasts. *Growth Factors* 1, 19-27.

78. Heldin, N.-E., Gustavsson, B., Claesson-Welsh, L., Hammacher, A., Mark, J., Heldin, C.-H., and Westermark, B. (1988). Aberrant expression of receptors for platelet-derived growth factor in an anaplastic thyroid carcinoma cell line. *Proc. Natl. Acad. Sci. USA* 85, 9302-9306.

79. Paulsson, Y., Austgulen, R., Hofsli, E., Heldin, C.-H., Westermark, B., and Nissen-Meyer, J. (1989). Tumor necrosis factor-induced expression of platelet-derived growth factor A-chain messenger RNA in fibroblasts. *Exp. Cell Res.* 180, 490-496.

80. Miyazono, K., and Heldin, C.-H. (1989). High-yield purification of platelet-derived endothelial cell growth factor: Structural characterization and establishment of a specific antiserum. *Biochemistry* 28, 1704-1710.

81. Heldin, N.-E., Paulsson, Y., Forsberg, K., Heldin, C.-H., and Westermark, B. (1989). Induction of cyclic AMP synthesis by forskolin is followed by a reduction in the expression of c-*myc* messenger RNA and inhibition of ^{3}H-thymidine incorporation in human fibroblasts. *J. Cell. Physiol.* 138, 17-23.

82. Severinsson, L., Claesson-Welsh, L., and Heldin, C.-H. (1989). A B-type PDGF receptor lacking most of the intracellular domain escapes degradation after ligand binding. *Eur. J. Biochem.* 182, 679-686.

83. Claesson-Welsh, L., Hammacher, A., Westermark, B., Heldin, C.-H., and Nistér, M. (1989). Identification and structural analysis of the A type receptor for platelet-derived growth factor. Similarities with the B type receptor. *J. Biol. Chem.* 264, 1742-1747.

84. Claesson-Welsh, L., Eriksson, A., Westermark, B., and Heldin, C.-H. (1989). cDNA cloning and expression of the human A-type platelet-derived growth factor (PDGF) receptor establishes structural similarity to the B-type PDGF receptor. *Proc. Natl. Acad. Sci. USA* 86, 4917-4921.

85. Östman, A., Bäckström, G., Fong, N., Betsholtz, C., Wernstedt, C., Hellman, U., Westermark, B., Valenzuela, P., and Heldin, C.-H. (1989). Expression of three recombinant homo-dimeric isoforms of PDGF in *Saccharomyces cerevisiae*: Evidence for difference in receptor binding and functional activities. *Growth Factors* 1, 271-281.

86. Fellström, B., Klareskog, L., Heldin, C.-H., Larsson, E., Rönnstrand, L., Terracio, L., Tufveson, G., Wahlberg, J., and Rubin, K. (1989). Platelet-derived growth factor receptors in the kidney - Upregulated expression in inflammation. *Kidney Int.* 36, 1099-1102.

87. Heldin, C.-H., Ernlund, A., Rorsman, C., and Rönnstrand, L. (1989). Dimerization of B-type platelet-derived growth factor receptors occur after ligand binding and is closely associated with receptor kinase activation. *J. Biol. Chem.* 264, 8905-8912.

88. Heldin, P., Laurent, T.C., and Heldin, C.-H. (1989). Effect of growth factors on hyaluronan synthesis in cultured human fibroblasts. *Biochem. J.* 258, 919-922.

89. Miyazono, K., and Heldin, C.-H. (1989). Role for carbohydrate structures in TGF-b1 latency. *Nature* 338, 158-160.

90. Kovacina, K.S., Steele-Perkins, G., Purchio, A.F., Lioubin, M., Miyazono, K., Heldin, C.-H., and Roth, R.A. (1989). Interactions of recombinant and platelet transforming growth factor-b1 precursor with the insulin-like growth factor II/mannose 6-phosphate receptor. *Biochem. Biophys. Res. Commun.* 160, 393-403.

91. Ishikawa, F., Miyazono, K., Hellman, U., Drexler, H., Wernstedt, C., Hagiwara, K., Usuki, K., Takaku, F., Risau, W., and Heldin, C.-H. (1989). Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. *Nature* 338, 557-562.

92. Hart, I.K., Richardson, W.D., Heldin, C.-H., Westermark, B., and Raff, M.C. (1989). PDGF receptors on cells of the oligodendrocyte-type-2 astrocyte (O-2A) cell lineage. *Development* 105, 595-603.

93. Pringle, N., Collarini, E.J., Mosley, M.J., Heldin, C.-H., Westermark, B., and Richardson, W.D. (1989). PDGF A chain homodimers drive proliferation of bipotential (O-2A) glial progenitor cells in the developing rat optic nerve. *EMBO J.* 8, 1049-1056.

94. Usuki, K., Heldin, N.-E., Miyazono, K., Ishikawa, F., Takaku, F., Westermark, B., and Heldin, C.-H. (1989). Production of platelet-derived endothelial cell growth factor by normal and transformed human cells in culture. *Proc. Natl. Acad. Sci. USA* 86, 7427-7431.

95. Hammacher, A., Nistér, M., and Heldin, C.-H. (1989). The A-type receptor for platelet-derived growth factor mediates protein tyrosine phosphorylation, receptor trans-modulation and a mitogenic response. *Biochem. J.* 264, 15-20.

96. Smits, A., Hermanson, M., Nistér, M., Karnushina, I., Heldin, C.-H., Westermark, B., and Funa, K. (1989). Rat brain capillary endothelial cells express functional PDGF B-type receptors. *Growth Factors* 2, 1-8.

97. Hammacher, A., Mellström, K., Heldin, C.-H., and Westermark, B. (1989). Isoform-specific induction of actin reorganization by platelet-derived growth factor suggests that the functionally active receptor is a dimer. *EMBO J.* 8, 2489-2495.

98. Severinsson, L., Ek, B., Mellström, K., Claesson-Welsh, L., and Heldin, C.-H. (1990). Deletion of the kinase insert sequence of the platelet-derived growth factor β-receptor affects receptor kinase activity and signal transduction. *Mol. Cell. Biol.* 10, 801-809.

99. Siegbahn, A., Hammacher, A., Westermark, B., and Heldin, C.-H. (1990). Differential effects of the various isoforms of platelet-derived growth factor on chemotaxis of fibroblasts, monocytes, and granulocytes. *J. Clin. Invest.* 85, 916-920.

100. Westermark, B., Siegbahn, A., Heldin, C.-H., and Claesson-Welsh, L. (1990). B-type receptor for platelet-derived growth factor mediates a chemotactic response by means of ligand-induced activation of the receptor protein-tyrosine kinase. *Proc. Natl. Acad. Sci. USA* 87, 128-132.

101. Funa, K., Papanicolaou, V., Juhlin, C., Rastad, J., Åkerström, G., Heldin, C.-H., and Öberg, K. (1990). Expression of platelet-derived growth factor β–receptors on stromal tissue cells in human carcinoid tumors. *Cancer Res.* 50, 748-753.

102. Rönnstrand, L., Sorokin, A., Engström, U., and Heldin, C.-H. (1990). Characterization of the platelet-derived growth factor β-receptor kinase activity by use of synthetic peptides. *Biochem. Biophys. Res. Commun.* 167, 1333-1340.

103. Werner, S., Hofschneider, P.H., Heldin, C.-H., Östman, A., and Roth, W.K. (1990). Cultured Kaposi's sarcoma-derived cells express functional PDGF A-type and B-type receptors. *Exp. Cell Res.* 187, 98-103.

104. Welsh, M., Claesson-Welsh, L., Hallberg, A., Welsh, N., Betsholtz, C., Arkhammar, P., Nilsson, T., Heldin, C.-H., and Berggren, P.-O. (1990). Co-expression of the platelet-derived growth factor (PDGF) B chain and the PDGF β receptor in isolated pancreatic islet cells stimulates DNA synthesis. *Proc. Natl. Acad. Sci. USA* 87, 5807-5811.

105. Jin, P., Rahm, M., Claesson-Welsh, L., Heldin, C.-H., and Sejersen, T. (1990). Expression of PDGF A-chain and β-receptor genes during rat myoblast differentiation. *J. Cell Biol.* 110, 1665-1672.

106. Kurtz, A., Vogel, F., Funa, K., Heldin, C.-H., and Grosse, R. (1990). Developmental regulation of mammary-derived growth inhibitor expression in bovine mammary tissue. *J. Cell Biology* 110, 1779-1789.

107. Levéen, P., Claesson-Welsh, L., Heldin, C.-H., Westermark, B., and Betsholtz, C. (1990). Expression of messenger RNAs for platelet-derived growth factor and its receptors in human sarcoma cell lines. *Int. J. Cancer* 46, 1066-1070.

108. Sjölund, M., Rahm, M., Claesson-Welsh, L., Sejersen, T., Heldin, C.-H., and Thyberg, J. (1990). Expression of PDGF α- and β-receptors in rat arterial smooth muscle cells is phenotype and growth state dependent. *Growth Factors* 3, 191-203.

109. Usuki, K., Norberg, L., Larsson, E., Miyazono, K., Hellman, U., Wernstedt, C., Rubin, K., and Heldin, C.-H. (1990). Localization of platelet-derived endothelial cell growth factor in human placenta and purification of an alternatively processed form. *Cell Regulation* 1, 577-584.

110. Kanzaki, T., Olofsson, A., Morén, A., Wernstedt, C., Hellman, U., Miyazono, K., Claesson-Welsh, L., and Heldin, C.-H. (1990). TGF-β1 binding protein: A component of the large latent complex of TGF-β1 with multiple repeat sequences. *Cell* 61, 1051-1061.

111. Thyberg, J., Östman, A., Bäckström, G., Westermark, B., and Heldin, C.-H. (1990). Localization of platelet-derived growth factor (PDGF) in CHO cells transfected with PDGF A- or B-chain cDNA: retention of PDGF-BB in the endoplasmic reticulum and Golgi complex. *J. Cell Science* 97, 219-229.

112. Sorkin, A., Westermark, B., Heldin, C.-H., and Claesson-Welsh, L. (1991). Effect of receptor kinase inactivation on the rate of internalization and degradation of PDGF and the PDGF β-receptor. *J. Cell Biol.* 112, 469-478.

113. Östman, A., Andersson, M., Betsholtz, C., Westermark, B., and Heldin, C.-H. (1991). Identification of a cell retention signal in the B-chain of platelet-derived growth factor and in the long splice version of the A-chain. *Cell Regul.* 2, 503-512.

114. Reuterdahl, C., Tingström, A., Terracio, L., Funa, K., Heldin, C.-H., and Rubin, K. (1991). Characterization of platelet-derived growth factor β-receptor expressing cells in the vasculature of human rheumatoid synovium. *Lab. Invest.* 64, 321-329.

115. Östman, A., Andersson, M., Hellman, U., and Heldin, C.-H. (1991). Identification of three amino acids in the platelet-derived growth factor (PDGF) B-chain that are important for binding to the PDGF b-receptor. *J. Biol. Chem.* 266, 10073-10077.

116. Miyazono, K., Olofsson, A., Colosetti, P., and Heldin, C.-H. (1991). A role of the latent TGF-β1-binding protein in the assembly and secretion of TGF-b1. *EMBO J.* 10, 1091-1101.

117. Smits, A., Kato, M., Westermark, B., Nistér, M., Heldin, C.-H., and Funa, K. (1991). Neurotrophic activity of platelet-derived growth factor (PDGF): Rat neuronal cells possess functional PDGF β-type receptors and respond to PDGF. *Proc. Natl. Acad. Sci. USA* 88, 8159-8163.

118. Ichijo, H., Rönnstrand, L., Miyagawa, K., Ohashi, H., Heldin, C.-H., and Miyazono, K. (1991). Purification of transforming growth factor-β1 binding proteins from porcine uterus membranes. *J. Biol. Chem.* 266, 22459-22464.

119. Hagiwara, K., Stenman, G., Honda, H., Sahlin, P., Andersson, A., Miyazono, K., Heldin, C.-H., Ishikawa, F., and Takaku, F. (1991). Organization and chromosomal localization of the human platelet-derived endothelial cell growth factor gene. *Mol. Cell. Biol.* 11, 2125-2132.

120. Heldin, P., Pertoft, H., Nordlinder, H., Heldin, C.-H., and Laurent, T.C. (1991). Differential expression of platelet-derived growth factor α- and β-receptors on fat-storing cells and endothelial cells of rat liver. *Exp. Cell Res.* 193, 364-369.

121. Usuki, K., Miyazono, K., and Heldin, C.-H. (1991). Covalent linkage between nucleotides and platelet-derived endothelial cell growth factor. *J. Biol. Chem.* 266, 20525-20531.

122. Blume-Jensen, P., Claesson-Welsh, L., Siegbahn, A., Zsebo, K.M., Westermark, B., and Heldin, C.-H. (1991). Activation of the human c-*kit* product by ligand-induced dimerization mediates circular actin reorganization and chemotaxis. *EMBO J.* 10, 4121-4128.

123. Nistér, M., Claesson-Welsh, L., Eriksson, A., Heldin, C.-H., and Westermark, B. (1991). Differential expression of platelet-derived growth factor receptors in human malignant glioma cell lines. *J. Biol. Chem.* 266, 16755-16763.

124. Eriksson, A., Nistér, M., Levéen, P., Westermark, B., Heldin, C.-H., and Claesson-Welsh, L. (1991). Induction of platelet-derived growth factor α- and β-receptor mRNA and protein by platelet-derived growth factor BB. *J. Biol. Chem.* 266, 21138-21144.

125. Versnel, M.A., Claesson-Welsh, L., Hammacher, A., Bouts, M.J., van der Kwast, T.H., Eriksson, A., Willemsen, R., Weima, S.M., Hoogsteden, H.C., Hagemeijer, A., and Heldin, C.-H. (1991). Human malignant mesothelioma cell lines express PDGF β-receptors whereas cultured normal mesothelial cells express predominantly PDGF a-receptors. *Oncogene* 6, 2005-2011.

126. Mori, S., Claesson-Welsh, L., and Heldin, C.-H. (1991). Identification of a hydrophobic region in the carboxyl terminus of the platelet-derived growth factor β-receptor which is important for ligand-mediated endocytosis. *J. Biol. Chem.* 266, 21158-21164.

127. Eriksson, A., Rorsman, C., Ernlund, A., Claesson-Welsh, L., and Heldin, C.-H. (1992). Ligand-induced homo- and hetero-dimerization of platelet-derived growth factor α- and β-receptors in intact cells. *Growth Factors* 6, 1-14.

128. Stenman, G., Sahlin, P., Dumanski, J.P., Hagiwara, K., Ishikawa, F., Miyazono, K., Collins, V.P., and Heldin, C.-H. (1992). Regional localization of the human platelet-derived endothelial cell growth factor (ECGF1) gene to chromosome 22q13. *Cytogenet. Cell Genet.* 59, 22-23.

129. Lepistö, J., Laato, M., Niinikoski, J., Lundberg, C., Gerdin, B., and Heldin, C.-H. (1992). Effects of homo-dimeric isoforms of platelet-derived growth factor (PDGF-AA and PDGF-BB) on wound healing in rat. *J. Surgical Research* 53, 596-601.

130. Östman, A., Thyberg, J., Westermark, B., and Heldin, C.-H. (1992). PDGF-AA and PDGF-BB biosynthesis: Proprotein processing in the Golgi complex and lysosomal degradation of PDGF-BB retained intracellularly. *J. Cell. Biol.* 118, 509-519.

131. Smits, A., Funa, K., Vassbotn, F.S., Beausang-Linder, M., af Ekenstam, F., Heldin, C.-H., Westermark, B., and Nistér, M. (1992). Expression of platelet-derived growth factor and its receptors in proliferative disorders of fibroblastic origin. *Am. J. Pathol.* 140, 639-648.

132. Vassbotn, F.S., Östman, A., Siegbahn, A., Holmsen, H., and Heldin, C.-H. (1992). Neomycin is a platelet-derived growth factor (PDGF) antagonist that allows discrimination of PDGF α- and β-receptor signals in cells expressing both receptor types. *J. Biol. Chem.* 267, 15635-15641.

133. Tingström, A., Heldin, C.-H., and Rubin, K. (1992). Regulation of fibroblast-mediated collagen gel contraction by platelet-derived growth factor, interleukin-1α and transforming growth factor-β1. *J. Cell Sci.* 102, 315-322.

134. Tingström, A., Reuterdahl, C., Lindahl, P., Heldin, C.-H., and Rubin, K. (1992). Expression of platelet-derived growth factor-β receptors on human fibroblasts. Regulation by recombinant platelet-derived growth factor-BB, IL-1, and tumor necrosis factor-α. *J. Immunol.* 148, 546-554.

135. Holmgren, L., Claesson-Welsh, L., Heldin, C.-H., and Ohlsson, R. (1992). The expression of PDGF α- and β-receptors in subpopulations of PDGF-producing cells implicates autocrine stimulatory loops in the control of proliferation in cytotrophoblasts that have invaded the maternal endometrium. *Growth Factors* 6, 219-231.

136. Chaudhry, A., Papanicolaou, V., Öberg, K., Heldin, C.-H., and Funa, K. (1992). Expression of platelet-derived growth factor and its receptors in neuroendocrine tumors of the digestive system. *Cancer Res.* 52, 1006-1012.

137. Miyazono, K., Thyberg, J., and Heldin, C.-H. (1992). Retention of the transforming growth factor-β1 precursor in the Golgi complex in a latent endoglycosidase H-sensitive form. *J. Biol. Chem.* 267, 5668-5675.

138. Versnel, M.A., Bouts, M.J., Langerak, A.W., van der Kwast, T.H., Hoogsteden, H.C., Hagemeijer, A., and Heldin, C.-H. (1992). Hydrocortisone-induced increase of PDGF β-receptor expression in a human malignant mesothelioma cell line. *Exp. Cell Res.* 200, 83-88.

139. Eriksson, A., Siegbahn, A., Westermark, B., Heldin, C.-H., and Claesson-Welsh, L. (1992). PDGF α- and β-receptors activate unique and common signal transduction pathways. *EMBO J.* 11, 543-550.

140. Rönnstrand, L., Mori, S., Arvidsson, A.-K., Eriksson, A., Wernstedt, C., Hellman, U., Claesson-Welsh, L., and Heldin, C.-H. (1992). Identification of two C-terminal autophosphorylation sites in the PDGF β-receptor: involvement in the interaction with phospholipase C-g. *EMBO J.* 11, 3911-3919.

141. Mori, S., Heldin, C.-H., and Claesson-Welsh, L. (1992). Ligand-induced polyubiquitination of the platelet-derived growth factor β-receptor. *J. Biol. Chem.* 267, 6429-6434.

142. Waltenberger, J., Usuki, K., Fellström, B., Funa, K., and Heldin, C.-H. (1992). Platelet-derived endothelial cell growth factor. Pharmacokinetics, organ distribution and degradation after intravenous administration in rats. *FEBS Lett.* 313, 129-132.

143. Olofsson, A., Miyazono, K., Kanzaki, T., Colosetti, P., Engström, U., and Heldin, C.-H. (1992). Transforming growth factor-β1, -β2 and -β3 secreted by a human glioblastoma cell line: Identification of small and different forms of large latent complexes. *J. Biol. Chem.* 267, 19482-19488.

144. Hermanson, M., Funa, K., Hartman, M., Claesson-Welsh, L., Heldin, C.-H., Westermark, B., and Nistér, M. (1992). Platelet-derived growth factor and its receptors in human glioma tissue: Expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. *Cancer Res.* 52, 3213-3219.

145. Engström, U., Engström, Å., Ernlund, A., Westermark, B., and Heldin, C.-H. (1992). Identification of a peptide antagonist for platelet-derived growth factor. *J. Biol. Chem.* 267, 16581-16587.

146. Risau, W., Drexler, H., Mironov, V., Smits, A., Siegbahn, A., Funa, K., and Heldin, C.-H. (1992). Platelet-derived growth factor is angiogenic *in vivo*. *Growth Factors* 7, 261-266.

147. Andersson, M., Östman, A., Bäckström, G., Hellman, U., George-Nascimento, C., Westermark, B., and Heldin, C.-H. (1992). Assignment of interchain disulfide bonds in platelet-derived growth factor (PDGF) and evidence for agonist activity of monomeric PDGF. *J. Biol. Chem.* 267, 11260-11266.

148. Usuki, K., Saras, J., Waltenberger, J., Miyazono, K., Pierce, G., Thomason, A., and Heldin, C.-H. (1992). Platelet-derived endothelial cell growth factor has thymidine phosphorylase activity. *Biochem. Biophys. Res. Commun.* 184, 1311-1316.

149. Arvidsson, A.-K., Heldin, C.-H., and Claesson-Welsh, L. (1992). Transduction of circular membrane ruffling by the platelet-derived growth factor β-receptor is dependent on its kinase insert. *Cell Growth & Diff.* 3, 881-887.

150. Mori, S., Heldin, C.-H., and Claesson-Welsh, L. (1993). Ligand-induced ubiquitination of the platelet-derived growth factor b-receptor plays a negative regulatory role in its mitogenic signaling. *J. Biol. Chem.* 268, 577-583.

151. Forsberg, K., Valyi-Nagy, I., Heldin, C.-H., Herlyn, M., and Westermark, B. (1993). Platelet-derived growth factor (PDGF) in oncogenesis: Development of a vascular connective tissue stroma in xeno-transplanted human melanoma producing PDGF-BB. *Proc. Natl. Acad. Sci. USA* 90, 393-397.

152. Waltenberger, J., Lundin, L., Öberg, K., Wilander, E., Miyazono, K., Heldin, C.-H., and Funa, K. (1993). Involvement of transforming growth factor-β in the formation of fibrotic lesions in carcinoid heart disease. *Am. J. Pathol.* 142, 71-78.

153. ten Dijke, P., Ichijo, H., Franzén, P., Schulz, P., Saras, J., Toyoshima, H., Heldin, C.-H., and Miyazono, K. (1993). Activin receptor-like kinases: a novel subclass of cell-surface receptors with predicted serine/threonine kinase activity. *Oncogene* 8, 2879-2887.

154. Franzén, P., ten Dijke, P., Ichijo, H., Yamashita, H., Schulz, P., Heldin, C.-H., and Miyazono, K. (1993). Cloning of a TGFβ type I receptor that forms a heteromeric complex with the TGFβ type II receptor. *Cell* 75, 681-692.

155. Sorkin, A., Eriksson, A., Heldin, C.-H., Westermark, B., and Claesson-Welsh, L. (1993). Pool of ligand-bound platelet-derived growth factor β-receptors remain activated and tyrosine phosphorylated after internalization. *J. Cell. Physiol.* 156, 373-382.

156. Colosetti, P., Hellman, U., Heldin, C.-H., and Miyazono, K. (1993). Ca^{2+} binding of latent transforming growth factor-β1 binding protein. *FEBS Lett.* 320, 140-144.

157. Eccleston, P.A., Funa, K., and Heldin, C.-H. (1993). Expression of platelet-derived growth factor (PDGF) and PDGF α- and β-receptors in the peripheral nervous system: An analysis of sciatic nerve and dorsal root ganglia. *Dev. Biol.* 155, 459-470.

158. Vassbotn, F.S., Andersson, M., Westermark, B., Heldin, C.-H., and Östman, A. (1993). Reversion of autocrine transformation by a dominant negative platelet-derived growth factor mutant. *Mol. Cell. Biol.* 13, 4066-4076.

159. Waltenberger, J., Wanders, A., Fellström, B., Miyazono, K., Heldin, C.-H., and Funa, K. (1993). Induction of transforming growth factor-β during cardiac allograft rejection. *J. Immunol.* 151, 1147-1157.

160. Flaumenhaft, R., Abe, M., Sato, Y., Miyazono, K., Harpel, J., Heldin, C.-H., and Rifkin, D.B. (1993). Role of the latent TGF-β binding protein in the activation of latent TGF-β by co-cultures of endothelial and smooth muscle cells. *J. Cell Biol.* 120, 995-1002.

161. Mori, S., Rönnstrand, L., Yokote, K., Engström, Å., Courtneidge, S.A., Claesson-Welsh, L., and Heldin, C.-H. (1993). Identification of two juxtamembrane autophosphorylation sites in the PDGF β-receptor; involvement in the interaction with Src family tyrosine kinases. *EMBO J.* 12, 2257-2264.

162. Smits, A., Odin, P., Duan, W.-M., Brundin, P., Widner, H., Heldin, C.-H., Lindwall, O., and Funa, K. (1993). Expression of platelet-derived growth factor in and around intra-striatal embryonic mesencephalic grafts. *Cell Transplant.* 2, 151-162.

163. Böhmer, F.-D., Böhmer, S.-A., and Heldin, C.-H. (1993). The dephosphorylation characteristics of the receptors for epidermal growth factor and platelet-derived growth factor in Swiss 3T3 cell membranes suggest differential regulation of receptor signalling by endogenous protein-tyrosine phosphatases. *FEBS Letters* 331, 276-280.

164. van Zoelen, E.J.J., van Rotterdam, W., van de Wetering, R.A.C., and Heldin, C.-H. (1993). Differential effects of PDGF isoforms on proliferation of normal rat kidney cells. *Growth Factors* 9, 329-339.

165. Ichijo, H., Yamashita, H., ten Dijke, P., Eto, Y., Heldin, C.-H., and Miyazono, K. (1993). Characterization of *in vivo* phosphorylation of activin type II receptor. *Biochem. Biophys. Res. Comm.* 194, 1508-1514.

166. Paulsson, Y., Karlsson, C., Heldin, C.-H., and Westermark, B. (1993). Density-dependent inhibitory effect of transforming growth factor-β1 on human fibroblasts involves the down-regulation of platelet-derived growth factor α-receptors. *J. Cell. Physiol.* 157, 97-103.

167. Heldin, N.-E., Usuki, K., Bergh, J., Westermark, B., and Heldin, C.-H. (1993). Differential expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human lung carcinoma cell lines. *Br. J. Cancer* 68, 708-711.

168. Ichijo, H., Hellman, U., Wernstedt, C., Gonez, L.J., Claesson-Welsh, L., Heldin, C.-H., and Miyazono, K. (1993). Molecular cloning and characterization of ficolin, a multimeric protein with fibrinogen- and collagen-like domains. *J. Biol. Chem.* 268, 14505-14513.

169. Östman, A., Andersson, M., Bäckström, G., and Heldin, C.-H. (1993). Assignment of intrachain disulfide bonds in platelet-derived growth factor B-chain. *J. Biol. Chem.* 268, 13372-13377.

170. Blume-Jensen, P., Siegbahn, A., Stabel, S., Heldin, C.-H., and Rönnstrand, L. (1993). Increased Kit/SCF receptor induced mitogenicity but abolished cell motility after inhibition of protein kinase C. *EMBO J.* 12, 4199-4209.

171. Pekny, M., Östman, A., Hermansson, A., Nistér, M., Heldin, C.-H., and Westermark, B. (1994). Differences in binding to the solid substratum and extracellular matrix may explain isoform-specific paracrine effects of platelet-derived growth factor. *Growth Factors* 10, 77-87.

172. Vassbotn, F.S., Östman, A., Langeland, N., Holmsen, H., Westermark, B., Heldin, C.-H., and Nistér, M. (1994). Activated platelet-derived growth factor autocrine pathway drives the transformed phenotype of a human glioblastoma cell line. *J. Cell. Physiol.* 158, 381-389.

173. Rupp, E., Siegbahn, A., Rönnstrand, L., Wernstedt, C., Claesson-Welsh, L., and Heldin, C.-H. (1994). A unique autophosphorylation site in the platelet-derived growth factor α receptor from a heterodimeric receptor complex. *Eur. J. Biochem.* 225, 29-41.

174. Wennström, S., Siegbahn, A., Yokote, K., Arvidsson, A.-K., Heldin, C.-H., Mori, S., and Claesson-Welsh, L. (1994). Membrane ruffling and chemotaxis transduced by the PDGF β-receptor require the binding site for phosphatidylinositol 3' kinase. *Oncogene* 9, 651-660.

175. Nistér, M., Enblad, P., Bäckström, G., Söderman, T., Persson, L., Heldin, C.-H., and Westermark, B. (1994). Platelet-derived growth factor (PDGF) in neoplastic and non-neoplastic cystic lesions of the central nervous system and in cerebrospinal fluid. *Br. J. Cancer* 69, 952-956.

176. Usuki, K., Gonez, L.J., Wernstedt, C., Morén, A., Miyazono, K., Claesson-Welsh, L., and Heldin, C.-H. (1994). Structural properties of 3.0 kb and 3.2 kb transcripts encoding platelet-derived endothelial cell growth factor/thymidine phosphorylase in A431 cells. *Biochim. Biophys. Acta* 1222, 411-414.

177. Mori, S., Rönnstrand, L., Claesson-Welsh, L., and Heldin, C.-H. (1994). A tyrosine residue in the juxta-membrane segment of the platelet-derived growth factor b-receptor is critical for ligand-mediated endocytosis. *J. Biol. Chem.* 269, 4917-4921.

178. Ming, X.-F., Burgering, B.M.T., Wennström, S., Claesson-Welsh, L., Heldin, C.-H., Bos, J.L., Kozma, S.C., and Thomas, G. (1994). Activation of p70/p85 S6 kinase by a pathway independent of $p21^{ras}$. *Nature* 371, 426-429.

179. Andersson, M., Östman, A., Westermark, B., and Heldin, C.-H. (1994). Characterization of the retention motif in the C-terminal part of the long splice form of platelet-derived growth factor A-chain. *J. Biol. Chem.* 269, 926-930.

180. Taketazu, F., Kato, M., Gobl, A., Ichijo, H., ten Dijke, P., Itoh, J., Kyogoku, M., Rönnelid, J., Miyazono, K., Heldin, C.-H., and Funa, K. (1994). Enhanced expression of transforming growth factor-βs and transforming growth factor-β type II receptor in the synovial tissues of patients with rheumatoid arthritis. *Lab. Invest.* 70, 620-630.

181. Taipale, J., Miyazono, K., Heldin, C.-H., and Keski-Oja, J. (1994). Latent transforming growth factor-β1 associates to fibroblast extracellular matrix via latent TGF-β binding protein. *J. Cell Biology* 124, 171-181.

182. Chaudhry, A., Öberg, K., Gobl, A., Heldin, C.-H., and Funa, K. (1994). Expression of transforming growth factors β1, β2, β3 in neuroendocrine tumors of the digestive system. *Anticancer Res.* 14, 2085-2091.

183. Blume-Jensen, P., Rönnstrand, L., Gout, I., Waterfield, M.D., and Heldin, C.-H. (1994). Modulation of Kit/stem cell factor receptor-induced signaling by protein kinase C. *J. Biol. Chem.* 269, 21793-21802.

184. Arvidsson, A.-K., Rupp, E., Nånberg, E., Downward, J., Rönnstrand, L., Wennström, S., Schlessinger, J., Heldin, C.-H., and Claesson-Welsh, L. (1994). Tyr-716 in the platelet-derived growth factor β-receptor kinase insert is involved in GRB2 binding and Ras activation. *Mol. Cell. Biol.* 14, 6715-6726.

185. ten Dijke, P., Yamashita, H., Ichijo, H., Franzén, P., Laiho, M., Miyazono, K., and Heldin, C.-H. (1994). Characterization of type I receptors for transforming growth factor-β and activin. *Science* 264, 101-104.

186. Okadome, T., Yamashita, H., Franzén, P., Morén, A., Heldin, C.-H., and Miyazono, K. (1994). Distinct roles of the intracellular domains of transforming growth factor-β type I and type II receptors in signal transduction. *J. Biol. Chem.* 269, 30753-30756.

187. Yokote, K., Mori, S., Hansen, K., McGlade, J., Pawson, T., Heldin, C.-H., and Claesson-Welsh, L. (1994). Direct interaction between Shc and the platelet-derived growth factor β-receptor. *J. Biol. Chem.* 269, 15337-15343.

188. Vassbotn, F.S., Havnen, O.K., Heldin, C.-H., and Holmsen, H. (1994). Negative feedback regulation of human platelets via autocrine activation of the platelet-derived growth factor α-receptor. *J. Biol. Chem.* 269, 13874-13879.

189. Saras, J., Claesson-Welsh, L., Heldin, C.-H., and Gonez, L.J. (1994). Cloning and characterization of PTPL1, a protein tyrosine phosphatase with similarities to cytoskeletal-associated proteins. *J. Biol. Chem.* 269, 24082-24089.

190. Waltenberger, J., Claesson-Welsh, L., Siegbahn, A., Shibuya, M., and Heldin, C.-H. (1994). Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. *J. Biol. Chem.* 269, 26988-26995.

191. Yamashita, H., ten Dijke, P., Franzén, P., Miyazono, K., and Heldin, C.-H. (1994). Formation of hetero-oligomeric complexes of type I and type II receptors for transforming growth factor-β. *J. Biol. Chem.* 269, 20172-20178.

192. Morén, A., Olofsson, A., Stenman, G., Sahlin, P., Kanzaki, T., Claesson-Welsh, L., ten Dijke, P., Miyazono, K., and Heldin, C.-H. (1994). Identification and characterization of LTBP-2, a novel latent transforming growth factor-β-binding protein. *J. Biol. Chem.* 269, 32469-32478.

193. ten Dijke, P., Yamashita, H., Sampath, T.K., Reddi, A.H., Estevez, M., Riddle, D.L., Ichijo, H., Heldin, C.-H., and Miyazono, K. (1994). Identification of type I receptors for osteogenic protein-1 and bone morphogenetic protein-4. *J. Biol. Chem.* 269, 16985-16988.

194. Kovalenko, M., Gazit, A., Böhmer, A., Rorsman, C., Rönnstrand, L., Heldin, C.-H., Waltenberger, J., Böhmer, F.-D., and Levitzki, A. (1994). Selective platelet-derived growth factor receptor kinase blockers reverse *sis*-transformation. *Cancer Res.* 54, 6106-6114.

195. Yamashita, H., Okadome, T., Franzén, P., ten Dijke, P., Heldin, C.-H., and Miyazono, K. (1995). A rat pituitary tumor cell line (GH_3) expresses type I and type II receptors and other cell surface binding protein(s) for transforming growth factor-b. *J. Biol. Chem.* 270, 770-774.

196. Eriksson, A., Nånberg, E., Rönnstrand, L., Engström, U., Hellman, U., Rupp, E., Carpenter, G., Heldin, C.-H., and Claesson-Welsh, L. (1995). Demonstration of functionally different interactions between phospholipase C-γ and the two types of platelet-derived growth factor receptors. *J. Biol. Chem.* 270, 7773-7781.

197. Franzén, P., Heldin, C.-H., and Miyazono, K. (1995). The GS domain of the transforming growth factor-b type I receptor is important in signal transduction. *Biochem. Biophys. Res. Commun.* 207, 682-689.

198. Kato, M., Ishizaki, A., Hellman, U., Wernstedt, C., Kyogoku, M., Miyazono, K., Heldin, C.-H., and Funa, K. (1995). A human keratinocyte cell line produces two autocrine growth inhibitors, transforming growth factor−β and insulin-like growth factor binding protein-6, in a calcium- and cell density-dependent manner. *J. Biol. Chem.* 270, 12373-12379.

199. Hellman, U., Wernstedt, C., Góñez, J., and Heldin, C.-H. (1995). Improvement of an "in-gel" digestion procedure for the micro-preparation of internal protein fragments for amino acid sequencing. *Anal. Biochem.* 224, 451-455.

200. Valgeirsdóttir, S., Eriksson, A., Nistér, M., Heldin, C.-H., Westermark, B., and Claesson-Welsh, L. (1995). Compartmentalization of autocrine signal transduction pathways in Sis-transformed NIH 3T3 cells. *J. Biol. Chem.* 270, 10161-10170.

201. Suzuki, M., Asplund, T., Yamashita, H., Heldin, C.-H., and Heldin, P. (1995). Stimulation of hyaluronan biosynthesis by platelet-derived growth factor-BB and transforming growth factor-β1 involves activation of protein kinase C. *Biochem. J.* 307, 817-821.

202. Yamashita, H., ten Dijke, P., Huylebroeck, D., Sampath, T.K., Andries, M., Smith, J., C., Heldin, C.-H., and Miyazono, K. (1995). Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects. *J. Cell Biol.* 130, 217-226.

203. Andersson, M., Östman, A., Kreysing, J., Bäckström, G., van de Poll, M., and Heldin, C.-H. (1995). Involvement of loop 2 of platelet-derived growth factor-AA and -BB in receptor binding. *Growth Factors* 12, 159-164.

204. Pekny, M., Pekna, M., Östman, A., Törnell, J., Feinstein, R., Forsberg-Nilsson, K., Heldin, C.-H., Westermark, B., and Betsholtz, C. (1995). Luteal failure in transgenic mice carrying a PDGF dominant-negative mutant/GH hybrid transgene. *Transgenics* 1, 515-523.

205. Blume-Jensen, P., Wernstedt, C., Heldin, C.-H., and Rönnstrand, L. (1995). Identification of the major phosphorylation sites for protein kinase C in Kit/stem cell factor receptor *in vitro* and in intact cells. *J. Biol. Chem.* 270, 14192-14200.

206. Eccleston, P.A., Funa, K., and Heldin, C.-H. (1995). Neurons of the peripheral nervous system express thymidine phosphorylase. *Neurosci. Lett.* 192, 137-141.

207. Verschueren, K., Dewulf, N., Goumans, M.-J., Lonnoy, O., Feijen, A., Grimsby, S., Vande Spiegle, K., ten Dijke, P., Morén, A., Vanscheeuwijck, P., Heldin, C.-H., Miyazono, K., Mummery, C., van den Eijnden-van Raaij, J., and Huylebroeck, D. (1995). Expression of type I and type IB receptors for activin in mid-gestation mouse embryos suggests distinct functions in organogenesis. *Mechanisms of Development* 52, 109-123.

208. Yamada, N., Kato, M., Yamashita, H., Nistér, M., Miyazono, K., Heldin, C.-H., and Funa, K. (1995). Enhanced expression of transforming growth factor-β and its type-I and type-II receptors in human glioblastoma. *Int. J. Cancer* 62, 386-392.

209. Rosenzweig, B.L., Imamura, T., Okadome, T., Cox, G.N., Yamashita, H., ten Dijke, P., Heldin, C.-H., and Miyazono, K. (1995). Cloning and characterization of a human type II receptor for bone morphogenetic proteins. *Proc. Natl. Acad. Sci. USA* 92, 7632-7636.

210. Olofsson, A., Ichijo, H., Morén, A., ten Dijke, P., Miyazono, K., and Heldin, C.-H. (1995). Efficient association of an amino-terminally extended form of human latent transforming growth factor-β binding protein with the extracellular matrix. *J. Biol. Chem.* 270, 31294-31297.

211. Nishiyama, A., Lin, X.-H., Giese, N., Heldin, C.-H., and Stallcup, W.B. (1996). Co-localization of NG2 proteoglycan and PDGF α-receptor on O2A progenitor cells in the developing rat brain. *J. Neurosci. Res.* 43, 299-314.

212. Nishiyama, A., Lin, X.-H., Giese, N., Heldin, C.-H., and Stallcup, W.B. (1996). Interaction between NG2 proteoglycan and PDGF α-receptor on O2A progenitor cells is required for optimal response to PDGF. *J. Neurosci. Res.* 43, 315-330.

213. Hermanson, M., Funa, K., Koopmann, J., Maintz, D., Waha, A., Westermark, B., Heldin, C.-H., Wiestler, O.D., Louis, D.N., von Deimling, A., and Nistér, M. (1996). Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor α receptor expression in human malignant gliomas. *Cancer Res.* 56, 164-171.

214. Yokote, K., Margolis, B., Heldin, C.-H., and Claesson-Welsh, L. (1996). Grb7 is a downstream signaling component of platelet-derived growth factor α- and β-receptors. *J. Biol. Chem.* 271, 30942-30949.

215. Green, L.S., Jellinek, D., Jenison, R., Östman, A., Heldin, C.-H., and Janjic, N. (1996). Inhibitory DNA ligands to platelet-derived growth factor B-chain. *Biochem.* 35, 14413-14424.

216. Yamada, N., Kato, M., ten Dijke, P., Yamashita, H., Sampath, T.K., Heldin, C.-H., Miyazono, K., and Funa, K. (1996). Bone morphogenetic protein type IB receptor is progressively expressed in malignant glioma tumours. *Br. J. Cancer* 73, 624-629.

217. Yokote, K., Mori, S., Siegbahn, A., Rönnstrand, L., Wernstedt, C., Heldin, C.-H., and Claesson-Welsh, L. (1996). Structural determinants in the platelet-derived growth factor α-receptor implicated in modulation of chemotaxis. *J. Biol. Chem.* 271, 5101-5111.

218. Souchelnytskyi, S., ten Dijke, P., Miyazono, K., and Heldin, C.-H. (1996). Phosphorylation of Ser165 in TGF-β type I receptor modulates TGF-b1-induced cellular responses. *EMBO J.* 15, 6231-6240.

219. Hulth, A., Johnell, O., Miyazono, K., Lindberg, L., Heinegård, D., and Heldin, C.-H. (1996). Effect of transforming growth factor-β and platelet-derived growth factor-BB on articular cartilage in rats. *J. Orthop. Res.* 14, 547-553.

220. Hansen, K., Johnell, M., Siegbahn, A., Rorsman, C., Engström, U., Wernstedt, C., Heldin, C.-H., and Rönnstrand, L. (1996). Mutation of a Src phosphorylation site in the PDGF β-receptor leads to increased PDGF-stimulated chemotaxis but decreased mitogenesis. *EMBO J.* 15, 5299-5313.

221. Kreysing, J., Östman, A., van de Poll, M., Bäckström, G., and Heldin, C.-H. (1996). Identification of three amino acid residues in the B-chain of platelet-derived growth factor with different importance for binding to PDGF α- and β-receptors. *FEBS Lett.* 385, 181-184.

222. Omura, T., Heldin, C.-H., and Östman, A. (1997). Immunoglobulin-like domain 4-mediated receptor-receptor interactions contribute to platelet-derived growth factor-induced receptor dimerization. *J. Biol. Chem.* 272, 12676-12682.

223. Hooshmand-Rad, R., Claesson-Welsh, L., Wennström, S., Yokote, K., Siegbahn, A., and Heldin, C.-H. (1997). Involvement of phosphatidylinositide 3'-kinase and Rac in platelet-derived growth factor-induced actin reorganization and chemotaxis. *Exp. Cell Res.* 234, 434-441.

224. Persson, U., Souchelnytskyi, S., Franzén, P., Miyazono, K., ten Dijke, P., and Heldin, C.-H. (1997). Transforming growth factor (TGF-β)-specific signaling by chimeric TGF-β type II receptor with intracellular domain of activin type IIB receptor. *J. Biol. Chem.* 272, 21187-21194.

225. Olofsson, A., Hellman, U., ten Dijke, P., Grimsby, S., Ichijo, H., Morén, A., Miyazono, K., and Heldin, C.-H. (1997). Latent transforming growth factor-β complex in Chinese hamster ovary cells contains the multifunctional cysteine-rich fibroblast growth factor receptor, also termed E-selectin-ligand or MG-160. *Biochem. J.* 324, 427-434.

226. Kozawa, O., Blume-Jensen, P., Heldin, C.-H., and Rönnstrand, L. (1997). Involvement of phosphatidylinositol 3'-kinase in stem-cell-factor-induced phospholipase D activation and arachidonic acid release. *Eur. J. Biochem.* 248, 149-155.

227. Hansen, K., Rönnstrand, L., Rorsman, C., Hellman, U., and Heldin, C.-H. (1997). Association of coatomer proteins with the β-receptor for platelet-derived growth factor. *Biochem. Biophys. Res. Commun.* 235, 455-460.

228. Souchelnytskyi, S., Tamaki, K., Engström, U., Wernstedt, C., ten Dijke, P., and Heldin, C.-H. (1997). Phosphorylation of Ser^{465} and Ser^{467} in the C terminus of Smad2 mediates interaction with Smad4 and is required for transforming growth factor-β signaling. *J. Biol. Chem.* 272, 28107-28115.

229. Nakao, A., Röijer, E., Imamura, T., Souchelnytskyi, S., Stenman, G., Heldin, C.-H., and ten Dijke, P. (1997). Identification of Smad2, a human Mad-related protein in the transforming growth factor β signaling pathway. *J. Biol. Chem.* 272, 2896-2900.

230. Omura, T., Miyazawa, K., Östman, A., and Heldin, C.-H. (1997). Identification of a 190-kDa vascular endothelial growth factor 165 cell surface binding protein on a human glioma cell line. *J. Biol. Chem.* 272, 23317-23322.

231. Saras, J., Franzén, P., Aspenström, P., Hellman, U., Góñez, L.J., and Heldin, C.-H. (1997). A novel GTPase-activating protein for Rho interacts with a PDZ domain of the protein-tyrosine phosphatase PTPL1. *J. Biol. Chem.* 272, 24333-24338.

232. Kovalenko, M., Rönnstrand, L., Heldin, C.-H., Loubtchenkov, M., Gazit, A., Levitzki, A., and Böhmer, F.D. (1997). Phosphorylation site-specific inhibition of platelet-derived growth factor β-receptor autophosphorylation by the receptor blocking tyrphostin AG1296. *Biochemistry* 36, 6260-6269.

233. Piek, E., Franzén, P., Heldin, C.-H., and ten Dijke, P. (1997). Characterization of a 60-kDa cell surface-associated transforming growth factor-β binding protein that can interfere with transforming growth factor-b receptor binding. *J. Cell. Physiol.* 173, 447-459.

234. Hansen, K., Rönnstrand, L., Claesson-Welsh, L., and Heldin, C.-H. (1997). Phosphorylation of a 72-kDa protein in PDGF-stimulated cells which forms complex with c-Crk, c-Fyn and Eps15. *FEBS Lett.* 409, 195-200.

235. Saras, J., Engström, U., Góñez, L.J., and Heldin, C.-H. (1997). Characterization of the interactions between PDZ domains of the protein-tyrosine phosphatase PTPL1 and the carboxyl-terminal tail of Fas. *J. Biol. Chem.* 272, 20979-20981.

236. Nakao, A., Imamura, T., Souchelnytskyi, S., Kawabata, M., Ishisaki, A., Oeda, E., Tamaki, K., Hanai, J.-i., Heldin, C.-H., Miyazono, K., and ten Dijke, P. (1997). TGF-β receptor-mediated signalling through Smad2, Smad3 and Smad4. *EMBO J.* 16, 5353-5362.

237. Nakao, A., Afrakhte, M., Morén, A., Nakayama, T., Christian, J.L., Heuchel, R., Itoh, S., Kawabata, M., Heldin, N.-E., Heldin, C.-H., and ten Dijke, P. (1997). Identification of Smad7, a TGFβ-inducible antagonist of TGF-β signalling. *Nature* 389, 631-635.

238. Hansen, K., Alonso, G., Courtneidge, S.A., Rönnstrand, L., and Heldin, C.-H. (1997). PDGF-induced phosphorylation of Tyr28 in the N-terminus of Fyn affects Fyn activation. *Biochem. Biophys. Res. Commun.* 241, 355-362.

239. Valgeirsdóttir, S., Paukku, K., Silvennoinen, O., Heldin, C.-H., and Claesson-Welsh, L. (1998). Activation of Stat5 by platelet-derived growth factor (PDGF) is dependent on phosphorylation sites in PDGF b-receptor juxta-membrane and kinase insert domains. *Oncogene* 16, 505-515.

240. Ruusala, A., Sundberg, C., Arvidsson, A.-K., Rupp-Thuresson, E., Heldin, C.-H., and Claesson-Welsh, L. (1998). Platelet-derived growth factor (PDGF)-induced actin rearrangement is deregulated in cells expressing a mutant Y778F PDGF β-receptor. *J. Cell Sci.* 111, 111-120.

241. Yokote, K., Hellman, U., Ekman, S., Saito, Y., Rönnstrand, L., Saito, Y., Heldin, C.-H., and Mori, S. (1998). Identification of Tyr-762 in the platelet-derived growth factor α-receptor as the binding site for Crk proteins. *Oncogene* 16, 1229-1239.

242. Shimizu, A., Mitsuyasu, K., Nakao, A., Imamura, T., ten Dijke, P., Heldin, C.-H., Kawabata, M., Shimada, S., and Miyazono, K. (1998). Identification of receptors and Smad proteins involved in activin signalling in a human epidermal keratinocyte cell line. *Genes to Cells* 3, 125-134.

243. Göhring, W., Sasaki, T., Heldin, C.-H., and Timpl, R. (1998). Mapping of the binding of platelet-derived growth factor to distinct domains of the basement membrane proteins BM-40 and perlecan and distinction from the BM-40 collagen-binding epitope. *Eur. J. Biochem.* 255, 60-66.

244. Hooshmand-Rad, R., Yokote, K., Heldin, C.-H., and Claesson-Welsh, L. (1998). PDGF α-receptor mediated cellular responses are not dependent on Src family kinases in endothelial cells. *J. Cell Sci.* 111, 607-614.

245. Miyazawa, K., Bäckström, G., Leppänen, O., Persson, C., Wernstedt, C., Hellman, U., Heldin, C.-H., and Östman, A. (1998). Role of immunoglobulin-like domains 2-4 of the platelet-derived growth factor α-receptor in ligand-receptor complex assembly. *J. Biol. Chem.* 273, 25495-25502.

246. Afrakhte, M., Morén, A., Jossan, S., Itoh, S., Sampath, K., Westermark, B., Heldin, C.-H., Heldin, N.-E., and ten Dijke, P. (1998). Induction of inhibitory Smad6 and Smad7 mRNA by TGF-β family members. *Biochem. Biophys. Res. Commun.* 249, 505-511.

247. Persson, U., Izumi, H., Souchelnytskyi, S., Itoh, S., Grimsby, S., Engström, U., Heldin, C.-H., Funa, K., and ten Dijke, P. (1998). The L45 loop in type I receptors for TGF-β family members is a critical determinant in specifying Smad isoform activation. *FEBS Lett.* 434, 83-87.

248. Itoh, S., Landström, M., Hermansson, A., Itoh, F., Heldin, C.-H., Heldin, N.-E., and ten Dijke, P. (1998). Transforming growth factor β1 induces nuclear export of inhibitory Smad7. *J. Biol. Chem.* 273, 29195-29201.

249. Hyytiäinen, M., Taipale, J., Heldin, C.-H., and Keski-Oja, J. (1998). Recombinant latent TGF-β binding protein 2 assembles to fibroblast extracellular matrix and is susceptible to proteolytic processing and release. *J. Biol. Chem.* 273, 20669-20676.

250. Jonk, L.J.C., Itoh, S., Heldin, C.-H., ten Dijke, P., and Kruijer, W. (1998). Identification and functional characterization of a Smad binding element (SBE) in the *JunB* promoter that acts as a transforming growth factor-β, activin, and bone morphogenetic protein-inducible enhancer. *J. Biol. Chem.* 273, 21145-21152.

251. Souchelnytskyi, S., Nakayama, T., Nakao, A., Morén, A., Heldin, C.-H., Christian, J.L., and ten Dijke, P. (1998). Physical and functional interaction of murine and *Xenopus* Smad7 with bone morphogenetic protein receptors and transforming growth factor-β receptors. *J. Biol. Chem.* 273, 25364-25370.

252. Valgeirsdóttir, S., Claesson-Welsh, L., Bongcam-Rudloff, E., Hellman, U., Westermark, B., and Heldin, C.-H. (1998). PDGF induces reorganization of vimentin filaments. *J. Cell Sci.* 111, 1973-1980.

253. Tamaki, K., Souchelnytskyi, S., Itoh, S., Nakao, A., Sampath, K., Heldin, C.-H., and ten Dijke, P. (1998). Intracellular signaling of osteogenic protein-1 through Smad5 activation. *J. Cell. Physiol.* 177, 355-363.

254. Scolding, N., Franklin, R., Stevens, S., Heldin, C.-H., Compston, A., and Newcombe, J. (1998). Oligodendrocyte progenitors are present in the normal adult human CNS and in the lesions of multiple sclerosis. *Brain* 121, 2221-2228.

255. Rönnstrand, L., Arvidsson, A.-K., Kallin, A., Rorsman, C., Hellman, U., Engström, U., Wernstedt, C., and Heldin, C.-H. (1999). SHP-2 binds to Tyr763 and Tyr1009 in the PDGF β-receptor and mediates PDGF-induced activation of the Ras/MAP kinase pathway and chemotaxis. *Oncogene* 18, 3696-3702.

256. Wollina, U., Lange, D., ten Dijke, P., Heldin, C.-H., and Funa, K. (1999). Eccrine sweat glands: expression of transforming growth factor-β and bone morphogenetic protein type I receptors and their intracellular signalling Smad proteins. *Acta Derm. Venereol.* 79, 183-186.

257. Piek, E., Westermark, U., Kastemar, M., Heldin, C.-H., van Zoelen, E.J., Nistér, M., and ten Dijke, P. (1999). Expression of transforming-growth-factor (TGF)-β receptors and Smad proteins in glioblastoma cell lines with distinct responses to TGF-β1. *Int. J. Cancer* 80, 756-763.

258. Piek, E., Afrakhte, M., Sampath, K., van Zoelen, E.J., Heldin, C.-H., and ten Dijke, P. (1999). Functional antagonism between activin and osteogenic protein-1 in human embryonal carcinoma cells. *J. Cell Phys.* 180, 141-149.

259. Ekman, S., Rupp Thuresson, E., Heldin, C.-H., and Rönnstrand, L. (1999). Increased mitogenicity of an ab heterodimeric PDGF receptor complex correlates with lack of RasGAP binding. *Oncogene* 18, 2481-2488.

260. Heuchel, R., Berg, A., Tallquist, M., Åhlén, K., Reed, R.K., Rubin, K., Claesson-Welsh, L., Heldin, C.-H., and Soriano, P. (1999). Platelet-derived growth factor β receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3' kinase signaling. *Proc. Natl. Acad. Sci. USA* 96, 11410-11415.

261. Emaduddin, M., Ekman, S., Rönnstrand, L., and Heldin, C.-H. (1999). Functional co-operation between the subunits in heterodimeric platelet-derived growth factor receptor complexes. *Biochem. J.* 341, 523-528.

262. Brodin, G., ten Dijke, P., Funa, K., Heldin, C.-H., and Landström, M. (1999). Increased Smad expression and activation are associated with apoptosis in normal and malignant prostate after castration. *Cancer Res.* 59, 2731-2738.

263. Sjöblom, T., Boureux, A., Rönnstrand, L., Heldin, C.-H., Ghysdael, J., and Östman, A. (1999). Characterization of the chronic myelomonocytic leukemia associated TEL-PDGFβR fusion protein. *Oncogene* 18, 7055-7062.

264. Shimizu, A., O'Brien, K.P., Sjöblom, T., Pietras, K., Buchdunger, E., Collins, V.P., Heldin, C.-H., Dumanski, J.P., and Östman, A. (1999). The dermatofibrosarcoma protuberans-associated collagen type Iα1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. *Cancer Res.* 59, 3719-3723.

265. Valgeirsdóttir, S., Ruusala, A., and Heldin, C.-H. (1999). MEK is a negative regulator of Stat5b in PDGF-stimulated cells. *FEBS Lett.* 450, 1-7.

266. Korchynskyi, O., Landström, M., Stoika, R., Funa, K., Heldin, C.-H., ten Dijke, P., and Souchelnytskyi, S. (1999). Expression of Smad proteins in human colorectal cancer. *Int. J. Cancer* 82, 197-202.

267. Rönnstrand, L., Siegbahn, A., Rorsman, C., Johnell, M., Hansen, K., and Heldin, C.-H. (1999). Overactivation of phospholipase C-γ1 renders platelet-derived growth factor b-receptor-expressing cells independent of the phosphatidylinositol 3-kinase pathway for chemotaxis. *J. Biol. Chem.* 274, 22089-22094.

268. Piek, E., Moustakas, A., Kurisaki, A., Heldin, C.-H., and ten Dijke, P. (1999). TGF-β type I receptor/ALK5 and SMAD proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells. *J. Cell Sci.* 112, 4557-4568.

269. Leppänen, O., Miyazawa, K., Bäckström, G., Pietras, K., Sjöblom, T., Heldin, C.-H., and Östman, A. (2000). Predimerization of recombinant platelet-derived growth factor receptor extracellular domains increases antagonistic potency. *Biochemistry* 39, 2370-2375.

270. Paukku, K., Valgeirsdóttir, S., Saharinen, P., Bergman, M., Heldin, C.-H., and Silvennoinen, O. (2000). Platelet-derived growth factor (PDGF)-induced activation of signal transducer and activator of transcription (Stat) 5 is mediated by PDGF β-receptor and is not dependent on c-Src, Fyn, Jak1 or Jak2 kinases. *Biochem. J.* 345, 759-766.

271. Landström, M., Heldin, N.-E., Bu, S., Hermansson, A., Itoh, S., ten Dijke, P., and Heldin, C.-H. (2000). Smad7 mediates apoptosis induced by transforming growth factor β in prostatic carcinoma cells. *Curr. Biol.* 10, 535-538.

272. Morén, A., Itoh, S., Moustakas, A., ten Dijke, P., and Heldin, C.-H. (2000). Functional consequences of tumorigenic missense mutations in the amino-terminal domain of Smad4. *Oncogene* 19, 4396-4404.

273. Hooshmand-Rad, R., Hájková, L., Klint, P., Karlsson, R., Vanhaesebroeck, B., Claesson-Welsh, L., and Heldin, C.-H. (2000). The PI 3-kinase isoforms p110α and p110β have differential roles in PDGF- and insulin-mediated signaling. *J. Cell Sci.* 113, 207-214.

274. Brodin, G., Åhgren, A., ten Dijke, P., Heldin, C.-H., and Heuchel, R. (2000). Efficient TGF-β induction of the Smad7 gene requires cooperation between AP-1, Sp1, and Smad proteins on the mouse Smad7 promoter. *J. Biol. Chem.* 275, 29023-29030.

275. Siegbahn, A., Johnell, M., Rorsman, C., Ezban, M., Heldin, C.-H., and Rönnstrand, L. (2000). Binding of factor VIIα to tissue factor on human fibroblasts leads to activation of phospholipase C and enhanced PDGF-BB-stimulated chemotaxis. *Blood* 96, 3452-3458.

276. Hooshmand-Rad, R., Lu, L., Heldin, C.-H., Claesson-Welsh, L., and Welsh, M. (2000). Platelet-derived growth factor-mediated signaling through the Shb adaptor protein: Effects on cytoskeletal organization. *Exp. Cell Res.* 257, 245-254.

277. Leppänen, O., Janjic, N., Carlsson, M.-A., Pietras, K., Levin, M., Vargeese, C., Green, L.S., Bergqvist, D., Östman, A., and Heldin, C.-H. (2000). Intimal hyperplasia recurs after removal of PDGF-AB and -BB inhibition in the rat carotid artery injury model. *Arterioscler. Thromb. Vasc. Biol.* 20, E89-E95.

278. Pardali, E., Xie, X.-Q., Tsapogas, P., Itoh, S., Arvanitidis, K., Heldin, C.-H., ten Dijke, P., Grundström, T., and Sideras, P. (2000). Smad and AML proteins synergistically confer transforming growth factor β1 responsiveness to human germ-line IgA genes. *J. Biol. Chem.* 275, 3552-3560.

279. Itoh, S., Ericsson, J., Nishikawa, J.-i., Heldin, C.-H., and ten Dijke, P. (2000). The transcriptional co-activator P/CAF potentiates TGF-β/Smad signaling. *Nucl. Acid. Res.* 28, 4291-4298.

280. Li, X., Pontén, A., Aase, K., Karlsson, L., Abramsson, A., Uutela, M., Bäckström, G., Hellström, M., Boström, H., Li, H., Soriano, P., Betsholtz, C., Heldin, C.-H., Alitalo, K., Östman, A., and Eriksson, U. (2000). PDGF-C is a new protease-activated ligand for the PDGF α-receptor. *Nature Cell Biol.* 2, 302-309.

281. Asano, T., Kanda, A., Katagiri, H., Nawano, M., Ogihara, T., Inukai, K., Anai, M., Fukushima, Y., Yazaki, Y., Kikuchi, M., Hooshmand-Rad, R., Heldin, C.-H., Oka, Y., and Funaki, M. (2000). p110β is upregulated during differentiation of 3T3-L1 cells and contributes to the highly insulin-responsive glucose transport activity. *J. Biol. Chem.* 275, 17671-17676.

282. Tallquist, M.D., Klinghoffer, R.A., Heuchel, R., Mueting-Nelsen, P.F., Corrin, P.D., Heldin, C.-H., Johnson, R.J., and Soriano, P. (2000). Retention of PDGFR-β function in mice in the absence of phosphatidylinositol-3' kinase and phospholipase Cγ signaling pathways. *Genes Dev.* 14, 3179-3190.

283. Yakymovych, I., ten Dijke, P., Heldin, C.-H., and Souchelnytskyi, S. (2001). Regulation of Smad signaling by protein kinase C. *FASEB J.* 15, 553-555.

284. Pietras, K., Östman, A., Sjöquist, M., Buchdunger, E., Reed, R.K., Heldin, C.-H., and Rubin, K. (2001). Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. *Cancer Res.* 61, 2929-2934.

285. Itoh, F., Asao, H., Sugamura, K., Heldin, C.-H., ten Dijke, P., and Itoh, S. (2001). Promoting bone morphogenetic protein signaling through negative regulation of inhibitory Smads. *EMBO J.* 20, 4132-4142.

286. Rosendahl, A., Checchin, D., Fehniger, T.E., ten Dijke, P., Heldin, C.-H., and Sideras, P. (2001). Activation of the TGF-β/activin-Smad2 pathway during allergic airway inflammation. *Am. J. Respir. Cell Mol. Biol.* 25, 60-68.

287. Kurisaki, A., Kose, S., Yoneda, Y., Heldin, C.-H., and Moustakas, A. (2001). Transforming growth factor-b induces nuclear import of Smad3 in an importin-β1 and Ran-dependent manner. *Mol. Biol. Cell* 12, 1079-1091.

288. Pulaski, L., Landström, M., Heldin, C.-H., and Souchelnytskyi, S. (2001). Phosphorylation of Smad7 at Ser-249 does not interfere with its inhibitory role in transforming growth factor-β-dependent signaling but affects Smad7-dependent transcriptional activation. *J. Biol. Chem.* 276, 14344-14349.

289. Bergsten, E., Uutela, M., Li, X., Pietras, K., Östman, A., Heldin, C.-H., Alitalo, K., and Eriksson, U. (2001). PDGF-D is a specific, protease-activated ligand for the PDGF β-receptor. *Nature Cell Biol.* 3, 512-516.

290. Sjöblom, T., Shimizu, A., O'Brien, K.P., Pietras, K., Dal Cin, P., Buchdunger, E., Dumanski, J.P., Östman, A., and Heldin, C.-H. (2001). Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. *Cancer Res.* 61, 5778-5783.

291. Shimizu, A., Persson, C., Heldin, C.-H., and Östman, A. (2001). Ligand stimulation reduces platelet-derived growth factor β-receptor susceptibility to tyrosine dephosphorylation. *J. Biol. Chem.* 276, 27749-27752.

292. Eichner, A., Brock, J., Heldin, C.-H., and Souchelnytskyi, S. (2002). Bone morphogenetic protein-7 (OP1) and transforming growth factor-β1 modulate 1,25(OH)$_2$-vitamin D$_3$-induced differentiation of human osteoblasts. *Exp. Cell. Res.* 275, 132-142.

293. Pietras, K., Rubin, K., Sjöblom, T., Buchdunger, E., Sjöquist, M., Heldin, C.-H., and Östman, A. (2002). Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. *Cancer Res.* 62, 5476-5484.

294. Kanamoto, T., Hellman, U., Heldin, C.-H., and Souchelnytskyi, S. (2002). Functional proteomics of transforming growth factor-β1-stimulated Mv1Lu epithelial cells: Rad51 as a target of TGFβ1-dependent regulation of DNA repair. *EMBO J.* 21, 1219-1230.

295. Palumbo, R., Gaetano, C., Antonini, A., Pompilio, G., Bracco, E., Rönnstrand, L., Heldin, C.-H., and Capogrossi, M.C. (2002). Different effects of high and low shear stress on platelet-derived growth factor isoform release by endothelial cells: consequences for smooth muscle cell migration. *Arterioscler. Thromb. Vasc. Biol.* 22, 405-411.

296. Yakymovych, I., Engström, U., Grimsby, S., Heldin, C.-H., and Souchelnytskyi, S. (2002). Inhibition of transforming growth factor-β signaling by low molecular weight compounds interfering with ATP- or substrate-binding sites of the TGFβ type I receptor kinase. *Biochem.* 41, 11000-11007.

297. Grönroos, E., Hellman, U., Heldin, C.-H., and Ericsson, J. (2002). Control of Smad7 stability by competition between acetylation and ubiquitination. *Mol. Cell* 10, 483-493.

298. Ekman, S., Kallin, A., Engström, U., Heldin, C.-H., and Rönnstrand, L. (2002). SHP-2 is involved in heterodimer specific loss of phosphorylation of Tyr771 in the PDGF β-receptor. *Oncogene* 21, 1870-1875.

299. Edlund, S., Landström, M., Heldin, C.-H., and Aspenström, P. (2002). Transforming growth factor-β-induced mobilization of actin cytoskeleton requires signaling by small GTPases Cdc42 and RhoA. *Mol. Biol. Cell* 13, 902-914.

300. Rosendahl, A., Pardali, E., Speletas, M., ten Dijke, P., Heldin, C.-H., and Sideras, P. (2002). Activation of bone morphogenetic protein/Smad signaling in bronchial epithelial cells during airway inflammation. *Am. J. Respir. Cell Mol. Biol.* 27, 160-169.

301. Preobrazhenska, O., Yakymovych, M., Kanamoto, T., Yakymovych, I., Stoika, R., Heldin, C.-H., and Souchelnytskyi, S. (2002). BRCA2 and Smad3 synergize in regulation of gene transcription. *Oncogene* 21, 5660-5664.

302. Gizatullina, Z.Z., Grapengiesser, E., Shabalina, I.G., Nedergaard, J., Heldin, C.-H., and Aspenström, P. (2003). Effect of transforming growth factor-β on calcium homeostasis in prostate carcinoma cells. *Biochem. Biophys. Res. Commun.* 304, 643-649.

303. Demoulin, J.-B., Seo, J.K., Ekman, S., Grapengiesser, E., Hellman, U., Rönnstrand, L., and Heldin, C.-H. (2003). Ligand-induced recruitment of Na^+/H^+ exchanger regulatory factor to the PDGF (platelet-derived growth factor) receptor regulates actin cytoskeleton reorganization by PDGF. *Biochem. J.* 376, 505-510.

304. Edlund, S., Bu, S., Schuster, N., Aspenström, P., Heuchel, R., Heldin, N.-E., ten Dijke, P., Heldin, C.-H., and Landström, M. (2003). Transforming growth factor-β1 (TGF-β)-induced apoptosis of prostate cancer cells involves Smad7-dependent activation of p38 by TGF-β-activated kinase 1 and mitogen-activated protein kinase kinase 3. *Mol. Biol. Cell* 14, 529-544.

305. Kurisaki, K., Kurisaki, A., Valcourt, U., Terentiev, A.A., Pardali, K., ten Dijke, P., Heldin, C.-H., Ericsson, J., and Moustakas, A. (2003). Nuclear factor YY1 inhibits transforming growth factor β- and bone morphogenetic protein-induced cell differentiation. *Mol. Cell. Biol.* 23, 4494-4510.

306. Morén, A., Hellman, U., Inada, Y., Imamura, T., Heldin, C.-H., and Moustakas, A. (2003). Differential ubiquitination defines the functional status of the tumor suppressor Smad4. *J. Biol. Chem.* 278, 33571-33582.

307. Pietras, K., Stumm, M., Hubert, M., Buchdunger, E., Rubin, K., Heldin, C.-H., McSheehy, P., Wartmann, M., and Östman, A. (2003). STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. *Clin. Cancer Res.* 9, 3779-3787.

308. Itoh, S., Thorikay, M., Kowanetz, M., Moustakas, A., Itoh, F., Heldin, C.-H., and ten Dijke, P. (2003). Elucidation of Smad requirement in transforming growth factor-β type I receptor-induced responses. *J. Biol. Chem.* 278, 3751-3761.

309. Chiara, F., Bishayee, S., Heldin, C.-H., and Demoulin, J.-B. (2004). Autoinhibition of the platelet-derived growth factor β receptor tyrosine kinase by its C-terminal tail. *J. Biol. Chem.* 279, 19732-19738.

310. Sjöblom, T., Yakymovych, I., Heldin, C.-H., Östman, A., and Souchelnytskyi, S. (2004). Smad2 suppresses the growth of Mv1Lu cells subcutaneously inoculated in mice. *Eur. J. Cancer* 40, 267-274.

311. Yakymovych, I., Heldin, C.-H., and Souchelnytskyi, S. (2004). Smad2 phosphorylation by type I receptor: Contribution of arginine 462 and cysteine 463 in the C-terminus of Smad2 for specificity. *J. Biol. Chem.* 279, 35781-35787.

312. Chiara, F., Goumans, M.-J., Forsberg, H., Åhgren, A., Rasola, A., Aspenström, P., Wernstedt, C., Hellberg, C., Heldin, C.-H., and Heuchel, R. (2004). A Gain of function mutation in the activation loop of platelet-derived growth factor β-receptor deregulates its kinase activity. *J. Biol. Chem.* 279, 42516-42527.

313. Persson, C., Sjöblom, T., Groen, A., Kappert, K., Engström, U., Hellman, U., Heldin, C.-H., den Hertog, J., and Östman, A. (2004). Preferential oxidation of the second phosphatase domain of RPTPα revealed by a new antibody-based method for detection of oxidized PTPs. *Proc. Natl. Acad. Sci. USA* 101, 1886-1891.

314. Edlund, S., Landström, M., Heldin, C.-H., and Aspenström, P. (2004). Smad7 is required for TGF-β-induced activation of the small GTPase Cdc42. *J. Cell Sci.* 117, 1835-1847.

315. Leppänen, O., Rutanen, J., Hiltunen, M.O., Rissanen, T.T., Turunen, M.P., Sjöblom, T., Brüggen, J., Bäckström, G., Carlsson, M., Buchdunger, E., Bergqvist, D., Alitalo, K., Heldin, C.-H., Östman, A., and Ylä-Herttuala, S. (2004). Oral imatinib mesylate (STI571/gleevec) improves the efficacy of local intravascular vascular endothelial growth factor-C gene transfer in reducing neointimal growth in hypercholesterolemic rabbits. *Circulation* 109, 1140-1146.

316. Kowanetz, M., Valcourt, U., Bergström, R., Heldin, C.-H., and Moustakas, A. (2004). Id2 and Id3 define the potency of cell proliferation and differentiation responses to transforming growth factor β and bone morphogenetic protein. *Mol. Cell. Biol.* 24, 4241-4254.

317. Kowanetz, K., Crosetto, N., Haglund, K., Schmidt, M.H., Heldin, C.-H., and Dikic, I. (2004). Suppressors of T-cell receptor signaling Sts-1 and Sts-2 bind to Cbl and inhibit endocytosis of receptor tyrosine kinases. *J. Biol. Chem.* 279, 32786-32795.

318. Furuhashi, M., Sjöblom, T., Abramsson, A., Ellingsen, J., Micke, P., Li, H., Bergsten-Folestad, E., Eriksson, U., Heuchel, R., Betsholtz, C., Heldin, C.-H., and Östman, A. (2004). Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate. *Cancer Res.* 64, 2725-2733.

319. Persson, C., Sävenhed, C., Bourdeau, A., Tremblay, M.L., Markova, B., Böhmer, F.D., Haj, F.G., Neel, B.G., Elson, A., Heldin, C.-H., Rönnstrand, L., Östman, A., and Hellberg, C. (2004). Site-selective regulation of platelet-derived growth factor β receptor tyrosine phosphorylation by T-cell protein tyrosine phosphatase. *Mol. Cell. Biol.* 24, 2190-2201.

320. Kallin, A., Demoulin, J.-B., Nishida, K., Hirano, T., Rönnstrand, L., and Heldin, C.-H. (2004). Gab1 contributes to cytoskeletal reorganization and chemotaxis in response to platelet-derived growth factor. *J. Biol. Chem.* 279, 17897-17904.

321. Demoulin, J.-B., Ericsson, J., Kallin, A., Rorsman, C., Rönnstrand, L., and Heldin, C.-H. (2004). Platelet-derived growth factor stimulates membrane lipid synthesis through activation of phosphatidylinositol 3-kinase and sterol regulatory element-binding proteins. *J. Biol. Chem.* 279, 35392-35402.

322. Edlund, S., Lee, S.Y., Grimsby, S., Zhang, S., Aspenström, P., Heldin, C.-H., and Landström, M. (2005). Interaction between Smad7 and β-catenin: Importance for transforming growth factor b-induced apoptosis. *Mol. Cell. Biol.* 25, 1475-1488.

323. Li, X., Tjwa, M., Moons, L., Fons, P., Noel, A., Ny, A., Zhou, J.M., Lennartsson, J., Li, H., Luttun, A., Pontén, A., Devy, L., Bouché, A., Oh, H., Manderveld, A., Blacher, S., Communi, D., Savi, P., Bono, F., Dewerchin, M., Foidart, J.-M., Autiero, M., Herbert, J.-M., Collen, D., Heldin, C.-H., Eriksson, U., and Carmeliet, P. (2005). Revascularization of ischemic tissues by PDGF-CC via effects on endothelial cells and their progenitors. *J. Clin. Invest.* 115, 118-127.

324. Pardali, K., Kowanetz, M., Heldin, C.-H., and Moustakas, A. (2005). Smad pathway-specific transcriptional regulation of the cell cycle inhibitor $p21^{(WAF1/Cip1)}$. *J. Cell. Physiol.* 204, 260-272.

325. Siegbahn, A., Johnell, M., Sorensen, B.B., Petersen, L.C., and Heldin, C.-H. (2005). Regulation of chemotaxis by the cytoplasmic domain of tissue factor. *Thromb. Haemost.* 93, 27-34.

326. Stasyk, T., Dubrovska, A., Lomnytska, M., Ihor, Y., Wernstedt, C., Heldin, C.-H., Hellman, U., and Souchelnytskyi, S. (2005). Phosphoproteome profiling of transforming growth factor (TGF)-β signaling: Abrogation of TGFβ1-dependent phosphorylation of transcription factor-II-I (TFII-I) enhances cooperation of TFII-I and Smad3 in transcription. *Mol. Biol. Cell* 16, 4765-4780.

327. Dubrovska, A., Kanamoto, T., Lomnytska, M., Heldin, C.-H., Volodko, N., and Souchelnytskyi, S. (2005). TGFβ1/Smad3 counteracts BRCA1-dependent repair of DNA damage. *Oncogene* 24, 2289-2297.

328. Valcourt, U., Kowanetz, M., Niimi, H., Heldin, C.-H., and Moustakas, A. (2005). TGF-β and the Smad signaling pathway support transcriptomic reprogramming during epithelial mesenchymal cell transition. *Mol. Biol. Cell* 16, 1987-2002.

329. Morén, A., Imamura, T., Miyazono, K., Heldin, C.-H., and Moustakas, A. (2005). Degradation of the tumor suppressor Smad4 by WW and HECT domain ubiquitin ligases. *J. Biol. Chem.* 280, 22115-22123.

330. Simonsson, M., Heldin, C.-H., Ericsson, J., and Grönroos, E. (2005). The balance between acetylation and deacetylation controls Smad7 stability. *J. Biol. Chem.* 280, 21797-21803.

331. Kurisaki, A., Kurisaki, K., Kowanetz, M., Sugino, H., Yoneda, Y., Heldin, C.-H., and Moustakas, A. (2006). The mechanism of nuclear export of Smad3 involves exportin 4 and Ran. *Mol. Cell. Biol.* 26, 1318-1332.

332. Hägerstrand, D., Hesselager, G., Achterberg, S., Wickenberg Bolin, U., Kowanetz, M., Kastemar, M., Heldin, C.-H., Isaksson, A., Nistér, M., and Östman, A. (2006). Characterization of an imatinib-sensitive subset of high-grade human glioma cultures. *Oncogene* 25, 4913-4922.

333. Demoulin, J.-B., Enarsson, M., Larsson, J., Essaghir, A., Heldin, C.-H., and Forsberg-Nilsson, K. (2006). The gene expression profile of PDGF-treated neural stem cells corresponds to partially differentiated neurons and glia. *Growth Factors* 24, 184-196.

334. Karlsson, S., Kowanetz, K., Sandin, Å., Persson, C., Östman, A., Heldin, C.-H., and Hellberg, C. (2006). Loss of T-cell protein tyrosine phosphatase induces recycling of the platelet-derived growth factor (PDGF) β-receptor but not the PDGF α-receptor. *Mol. Biol. Cell* 17, 4846-4855.

335. Li, R., Rosendahl, A., Brodin, G., Cheng, A.M., Åhgren, A., Sundquist, C., Kulkarni, S., Pawson, T., Heldin, C.-H., and Heuchel, R. (2006). Deletion of exon I of Smad7 in mice results in altered B cell responses. *J. Immunol.* 176, 6777-6784.

336. Lennartsson, J., Wardega, P., Engström, U., Hellman, U., and Heldin, C.-H. (2006). Alix facilitates the interaction between c-Cbl and platelet-derived growth factor β-receptor and thereby modulates receptor downregulation. *J. Biol. Chem.* 281, 39152-39158.

337. Li, L., Heldin, C.-H., and Heldin, P. (2006). Inhibition of platelet-derived growth factor-BB-induced receptor activation and fibroblast migration by hyaluronan activation of CD44. *J. Biol. Chem.* 281, 26512-26519.

338. Valdimarsdóttir, G., Goumans, M.-J., Itoh, F., Itoh, S., Heldin, C.-H., and ten Dijke, P. (2006). Smad7 and protein phosphatase 1α are critical determinants in the duration of TGFβ/ALK1 signaling in endothelial cells. *BMC Cell Biology* 7, 16.

339. Thuault, S., Valcourt, U., Petersen, M., Manfioletti, G., Heldin, C.-H., and Moustakas, A. (2006). Transforming growth factor-β employs HMGA2 to elicit epithelial–mesenchymal transition. *J. Cell Biol.* 174, 175-183.

340. Amagasaki, K., Kaneto, H., Heldin, C.-H., and Lennartsson, J. (2006). c-Jun N-terminal kinase is necessary for platelet-derived growth factor-mediated chemotaxis in primary fibroblasts. *J. Biol. Chem.* 281, 22173-22179.

341. Kappert, K., Leppänen, O., Paulsson, J., Furuhashi, M., Carlsson, M.-A., Heldin, C.-H., Fätkenheuer, G., Rosenkranz, S., and Östman, A. (2006). Highly active antiretroviral therapy attenuates re-endothelialization and alters neointima formation in the rat carotid artery after balloon injury. *J. Acquir. Immune Defic. Syndr.* 43, 383-392.

342. Zhang, S., Ekman, M., Thakur, N., Bu, S., Davoodpour, P., Grimsby, S., Tagami, S., Heldin, C.-H., and Landström, M. (2006). TGF-β1-induced activation of ATM and p53 mediates apoptosis in a Smad7-dependent manner. *Cell Cycle* 5, 2787-2795.

343. Simonsson, M., Kanduri, M., Grönroos, E., Heldin, C.-H., and Ericsson, J. (2006). The DNA binding activities of Smad2 and Smad3 are regulated by coactivator-mediated acetylation. *J. Biol. Chem.* 281, 39870-39880.

344. Looman, C., Sun, T., Yu, Y., Zieba, A., Åhgren, A., Feinstein, R., Forsberg, H., Hellberg, C., Heldin, C.-H., Zhang, X.-Q., Forsberg-Nilsson, K., Khoo, N., Fundele, R., and Heuchel, R. (2007). An activating mutation in the PDGF receptor-β causes abnormal morphology in the mouse placenta. *Int. J. Dev. Biol.* 51, 361-370.

345. Suzuki, S., Heldin, C.-H., and Heuchel, R.L. (2007). Platelet-derived growth factor receptor-β, carrying the activating mutation D849N, accelerates the establishment of B16 melanoma. *BMC Cancer* 7, 224.

346. Kallin, A., Johannessen, L.E., Cani, P.D., Marbehant, C.Y., Essaghir, A., Foufelle, F., Ferré, P., Heldin, C.-H., Delzenne, N.M., and Demoulin, J.-B. (2007). SREBP-1 regulates the expression of heme oxygenase 1 and the phosphatidylinositol-3 kinase regulatory subunit p55γ. *J. Lipid Res.* 48, 1628-1636.

347. Li, L., Asteriou, T., Bernert, B., Heldin, C.-H., and Heldin, P. (2007). Growth factor regulation of hyaluronan synthesis and degradation in human dermal fibroblasts: Importance of hyaluronan for the mitogenic response of PDGF-BB. *Biochem. J.* 404, 327-336.

348. Niimi, H., Pardali, K., Vanlandewijck, M., Heldin, C.-H., and Moustakas, A. (2007). Notch signaling is necessary for epithelial growth arrest by TGF-β. *J. Cell Biol.* 176, 695-707.

349. Hasumi, Y., Klosowska-Wardega, A., Furuhashi, M., Östman, A., Heldin, C.-H., and Hellberg, C. (2007). Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling. *Int. J. Cancer* 121, 2606-2614.

350. Micke, P., Kappert, K., Ohshima, M., Sundqvist, C., Scheidl, S., Lindahl, P., Heldin, C.-H., Botling, J., Pontén, F., and Östman, A. (2007). *In situ* identification of genes regulated specifically in fibroblasts of human basal cell carcinoma. *J. Invest. Dermatol.* 127, 1516-1523.

351. Valcourt, U., Thuault, S., Pardali, K., Heldin, C.-H., and Moustakas, A. (2007). Functional role of Meox2 during the epithelial cytostatic response to TGF-β. *Mol. Oncology* 1, 55-71.

352. Li, Y., Zhang, F., Nagai, N., Tang, Z., Zhang, S., Scotney, P., Lennartsson, J., Zhu, C., Qu, Y., Fang, C., Hua, J., Matsuo, O., Fong, G.-H., Ding, H., Cao, Y., Becker, K.G., Nash, A., Heldin, C.-H., and Li, X. (2008). VEGF-B inhibits apoptosis via VEGFR-1-mediated suppression of the expression of BH3-only protein genes in mice and rats. *J. Clin. Invest.* 118, 913-923

353. Sorrentino, A., Thakur, N., Grimsby, S., Marcusson, A., von Bulow, V., Schuster, N., Zhang, S., Heldin, C.-H., and Landström, M. (2008). The type I TGF-β receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. *Nature Cell Biol.* 10, 1199-1207.

354. Kowanetz, M., Lönn, P., Vanlandewijck, M., Kowanetz, K., Heldin, C.-H., and Moustakas, A. (2008). TGFβ induces SIK to negatively regulate type I receptor kinase signaling. *J. Cell Biol.* 182, 655-662.

355. Ruusala, A., Pawson, T., Heldin, C.-H., and Aspenström, P. (2008). Nck adapters are involved in formation of dorsal ruffles, cell migration, and Rho signaling downstream of the platelet-derived growth factor β-receptor. *J. Biol. Chem.* 283, 30034-30044.

356. Krampert, M., Heldin, C.-H., and Heuchel, R. (2008). A gain-of-function mutation in the PDGFR-β alters the kinetics of injury response in liver and skin. *Lab. Invest.* 88, 1204-1214.

357. Rosengren Pielberg, G., Golovko, A., Sundström, E., Curik, I., Lennartsson, J., Seltenhammer, M.H., Druml, T., Binns, M., Fitzsimmons, C., Lindgren, G., Sandberg, K., Baumung, R., Vetterlein, M., Strömberg, S., Grabherr, M., Wade, C., Lindblad-Toh, K., Pontén, F., Heldin, C.-H., Sölkner, J., and Andersson, L. (2008). A cis-acting regulatory mutation causes premature hair graying and susceptibility to melanoma in the horse. *Nat. Genet.* 40, 1004-1009.

358. Thuault, S., Tan, E.-J., Peinado, H., Cano, A., Heldin, C.-H., and Moustakas, A. (2008). HMGA2 and Smads coregulate SNAIL1 expression during induction of epithelial-to-mesenchymal transition. *J. Biol. Chem.* 283, 33437-33446.

359. Paulsson, J., Sjöblom, T., Micke, P., Pontén, F., Landberg, G., Heldin, C.-H., Bergh, J., Brennan, D.J., Jirström, K., and Östman, A. (2009). Prognostic significance of stromal platelet-derived growth factor β-receptor expression in human breast cancer. *Am. J. Pathol.* 175, 334-341

360. Kłosowska-Wardęga, A., Hasumi, Y., Burmakin, M., Åhgren, A., Stuhr, L., Moen, I., Reed, R.K., Rubin, K., Hellberg, C., and Heldin, C.-H. (2009). Combined anti-angiogenic therapy targeting PDGF and VEGF receptors lowers the interstitial fluid pressure in a murine experimental carcinoma. *PLoS ONE* 4, e8149.

361. Jurek, A., Amagasaki, K., Gembarska, A., Heldin, C.-H., and Lennartsson, J. (2009). Negative and positive regulation of MAPK phosphatase 3 controls platelet-derived growth factor-induced Erk activation. *J. Biol. Chem.* 284, 4626-4634.

362. Hellberg, C., Schmees, C., Karlsson, S., Åhgren, A., and Heldin, C.-H. (2009). Activation of protein kinase C a is necessary for sorting the PDGF β-receptor to Rab4a-dependent recycling. *Mol. Biol. Cell* 20, 2856-2863.

363. Huminiecki, L., Goldovsky, L., Freilich, S., Moustakas, A., Ouzounis, C.A., and Heldin, C.-H. (2009). Emergence, development and diversification of the TGF-β signalling pathway within the animal kingdom. *BMC Evol. Biol.* 9, 28-.

364. Cunha, S.I., Pardali, E., Thorikay, M., Anderberg, C., Hawinkles, L., Goumans, M.-J., Seehra, J., Heldin, C.-H., ten Dijke, P., and Pietras, K. (2010). Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis. *J. Exp. Med.* 207, 85-100.

365. Wardęga, P., Heldin, C.-H., and Lennartsson, J. (2010). Mutation of tyrosine residue 857 in the PDGF β-receptor affects cell proliferation but not migration. *Cell. Signal.* 22, 1363-1368.

366. Lennartsson, J., Burovic, F., Witek, B., Jurek, A., and Heldin, C.-H. (2010). Erk 5 is necessary for sustained PDGF-induced Akt phosphorylation and inhibition of apoptosis. *Cell. Signal.* 22, 955-960.

367. Huminiecki, L., and Heldin, C.-H. (2010). 2R and remodeling of vertebrate signal transduction engine. *BMC Biol.* 8, 146.

368. Krampert, M., Chirasani, S.R., Wachs, F.-P., Aigner, R., Bogdahn, U., Yingling, J.M., Heldin, C.-H., Aigner, L., and Heuchel, R. (2010). Smad7 regulates the adult neural stem/progenitor cell pool in a transforming growth factor β- and bone morphogenetic protein-independent manner. *Mol. Cell Biol.* 30, 3685-3694.

369. Lönn, P., van der Heide, L., Dahl, M., Hellman, U., Heldin, C.-H., and Moustakas, A. (2010). PARP-1 attenuates Smad-mediated transcription. *Mol. Cell* 40, 521-532.

370. Tian, F., Zhou, A.-X., Smits, A.M., Larsson, E., Goumans, M.-J., Heldin, C.-H., Borén, J., and Akyürek, L.M. (2010). Endothelial cells are activated during hypoxia via endoglin/ALK-1/SMAD1/5 signaling *in vivo* and *in vitro*. *Biochem. Biophys. Res. Commun.* 392, 283-288.

371. Karousou, E., Kamiryo, M., Skandalis, S.S., Ruusala, A., Asteriou, T., Passi, A., Yamashita, H., Hellman, U., Heldin, C.-H., and Heldin, P. (2010). The activity of hyaluronan synthase 2 is regulated by dimerization and ubiquitination. *J. Biol. Chem.* 285, 23647-23654.

372. Bergström, R., Savary, K., Morén, A., Guibert, S., Heldin, C.-H., Ohlsson, R., and Moustakas, A. (2010). Transforming growth factor β promotes complexes between Smad proteins and the CCCTC-binding factor on the H19 imprinting control region chromatin. *J. Biol. Chem.* 285, 19727-19737.

373. Suzuki, S., Dobashi, Y., Hatakeyama, Y., Tajiri, R., Fujimura, T., Heldin, C.-H., and Ooi, A. (2010). Clinicopathological significance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor-A expression, PDGF receptor-beta phosphorylation, and microvessel density in gastric cancer. *BMC Cancer* 10, 659.

374. Jurek, A., Heldin, C.-H., and Lennartsson, J. (2011). Platelet-derived growth factor-induced signaling pathways interconnect to regulate the temporal pattern of Erk1/2 phosphorylation. *Cell. Signal.* 23, 280-287.

375. Zhou, A.-X., Toylu, A., Nallapalli, R.K., Nilsson, G., Atabey, N., Heldin, C.-H., Borén, J., Bergö, M.O., and Akyürek, L.M. (2011). Filamin A mediates HGF/c-MET signaling in tumor cell migration. *Int. J. Cancer* 128, 839-846.

376. Kłosowska-Wardęga, A., Hasumi, Y., Åhgren, A., Heldin, C.-H., and Hellberg, C. (2011). Combination therapy using imatinib and vatalanib improves the therapeutic efficiency of paclitaxel towards a mouse melanoma tumor. *Melanoma Research* 21, 57-65.

377. Buschke, S., Stark, H.-J., Cerezo, A., Prätzel-Wunder, S., Boehnke, K., Kollar, J., Langbein, L., Heldin, C.-H., and Boukamp, P. (2011). A decisive function of transforming growth factor-β/Smad signaling in tissue morphogenesis and differentiation of human HaCaT keratinocytes. *Mol. Biol. Cell* 22, 782-794.

378. Morén, A., Raja, E., Heldin, C.-H., and Moustakas, A. (2011). Negative regulation of TGFβ signaling by the kinase LKB1 and the scaffolding protein LIP1. *J. Biol. Chem.* 286, 341-353.

379. Mu, Y., Sundar, R., Thakur, N., Ekman, M., Gudey, S.K., Yakymovych, M., Hermansson, A., Dimitriou, H., Bengoechea-Alonso, M.T., Ericsson, J., Heldin, C.-H., and Landström, M. (2011). TRAF6 ubiquitinates TGFβ type I receptor to promote its cleavage and nuclear translocation in cancer. *Nature Communications* 2, 330.

380. Morikawa, M., Koinuma, D., Tsutsumi, S., Vasilaki, E., Kanki, Y., Heldin, C.-H., Aburatani, H., and Miyazono, K. (2011). ChIP-seq reveals cell type-specific binding patterns of BMP-specific Smads and a novel binding motif. *Nucl. Acid Res.* 39, 8712-8727.

381. Zheng, W., Lennartsson, J., Hendricks, W., Heldin, C.-H., and Hellberg, C. (2011). The LAR protein tyrosine phosphatase enables PDGF b-receptor activation through attenuation of the c-Abl kinase activity. *Cell. Signal.* 23, 1050-1056.

382. Hamidi, A., von Bulow, V., Hamidi, R., Winssinger, N., Barluenga, S., Heldin, C.-H., and Landström, M. (2012). Polyubiquitination of transforming growth factor β (TGFβ)-associated kinase 1 mediates nuclear factor-κB activation in response to different inflammatory stimuli. *J. Biol. Chem.* 287, 123–133.

383. Razmara, M., Eger, G., Rorsman, C., Heldin, C.-H., and Lennartsson, J. (2012). MKP3 negatively modulates PDGF-induced Akt and Erk5 phosphorylation as well as chemotaxis. *Cell. Signal.* 24, 635-640.

384. Tan, E.-J., Thuault, S., Caja, L., Carletti, T., Heldin, C.-H., and Moustakas, A. (2012). Regulation of transcription factor Twist expression by the DNA architectural protein high mobility group A2 during epithelial-to-mesenchymal transition. *J. Biol. Chem.* 287, 7134-7145.

385. Lönn, P., Vanlandewijck, M., Raja, E., Kowanetz, M., Watanabe, Y., Kowanetz, K., Vasilaki, E., Heldin, C.-H., and Moustakas, A. (2012). Transcriptional induction of salt-inducible kinase 1 by transforming growth factor β leads to negative regulation of type I receptor signaling in cooperation with the Smurf2 ubiquitin ligase. *J. Biol. Chem.* 287, 12867-12878.

386. Schmees, C., Villaseñor, R., Zheng, W., Ma, H., Zerial, M., Heldin, C.-H., and Hellberg, C. (2012). Macropinocytosis of the PDGF β-receptor promotes fibroblast transformation by H-RasG12V. *Mol. Biol. Cell* 23, 2571-2582.

387. Zieba, A., Pardali, K., Söderberg, O., Lindbom, L., Nyström, E., Moustakas, A., Heldin, C.-H., and Landegren, U. (2012). Intercellular variation in signaling through the TGF-β pathway and its relation to cell density and cell cycle phase. *Mol. Cell. Proteomics* 11, M111.013482, 1-9.

388. Ekman, M., Mu, Y., Lee, S.Y., Edlund, S., Kozakai, T., Thakur, N., Tran, H., Qian, J., Groeden, J., Heldin, C.-H., and Landström, M. (2012). APC and Smad7 link TGFβ type I receptors to the microtubule system to promote cell migration. *Mol. Biol. Cell* 23, 2109-2121.

389. Sundqvist, A., Zieba, A., Vasilaki, E., Herrera Hidalgo, C., Söderberg, O., Koinuma, D., Miyazono, K., Heldin, C.-H., Landegren, U., ten Dijke, P., and van Dam, H. (2013). Specific interactions between Smad proteins and AP-1 components determine TGFβ-induced breast cancer cell invasion. *Oncogene* 32, 3606-3615.

390. Porsch, H., Bernert, B., Mehić, M., Theocharis, A.D., Heldin, C.H., and Heldin, P. (2013). Efficient TGFβ-induced epithelial-mesenchymal transition depends on hyaluronan synthase HAS2. *Oncogene* 32, 4355-4365.

391. Termén, S., Tan, E.-J., Heldin, C.-H., and Moustakas, A. (2013). p53 regulates epithelial-mesenchymal transition induced by transforming growth factor β. *J. Cell. Physiol.* 228, 801-813.

392. Razmara, M., Heldin, C.-H., and Lennartsson, J. (2013). Platelet-derived growth factor-induced Akt phosphorylation requires mTOR/Rictor and phospholipase C-γ1, whereas S6 phosphorylation depends on mTOR/Raptor and phospholipase D. *Cell Commun. Signal.* 11, 3.

393. Sadowski, Ł., Jastrzebski, K., Kalaidzidis, Y., Heldin, C.-H., Hellberg, C., and Miaczynska, M. (2013). Dynamin inhibitors impair endocytosis and mitogenic signaling of PDGF. *Traffic* 14, 725-736.

394. Lennartsson, J., Ma, H., Wardega, P., Pelka, K., Engström, U., Hellberg, C., and Heldin, C.-H. (2013). The Fer tyrosine kinase is important for platelet-derived growth factor-BB-induced signal transducer and activator of transcription 3 (STAT3) protein phosphorylation, colony formation in soft agar, and tumor growth *in vivo*. *J. Biol. Chem.* 288, 15736-15744.

395. Savary, K., Caglayan, D., Caja, L., Tzavlaki, K., Bin Nayeem, S., Bergström, T., Jiang, Y., Uhrbom, L., Forsberg-Nilsson, K., Westermark, B., Heldin, C.-H., Ferletta, M., and Moustakas, A. (2013). Snail depletes the tumorigenic potential of glioblastoma. *Oncogene* 32, 5409-5420.

396. Gudey, S.K., Sundar, R., Mu, Y., Wallenius, A., Zang, G., Bergh, A., Heldin, C.-H., and Landström, M. (2014). TRAF6 stimulates the tumor-promoting effects of TGFβ type I receptor through polyubiquitination and activation of presenilin 1. *Science Signaling,* 7, ra2.

397. Enroth, S., Andersson, R., Bysani, M., Wallerman, O., Termen, S., Tuch, B.B., De La Vega, F.M., Heldin, C.-H., Moustakas, A., Komorowski, J., and Wadelius, C. (2014). Nucleosome regulatory dynamics in response to TGFβ. *Nucl. Acids Res.* 42, 6921-6934.

398. Porsch, H., Mehić, M., Olofsson, B., *Heldin, P., and *Heldin, C.-H. (2014). Platelet-derived growth factor b-receptor, transforming growth factor b type I receptor, and CD44 protein modulate each other's signaling and stability. *J. Biol. Chem.* 289, 19747-19757. *Equal contribution.

399. Dahl, M., Maturi, V., Lönn, P., Papoutsoglou, P., Zieba, A., Vanlandewijck, M., van der Heide, L.P., Watanabe, Y., Söderberg, O., Hottiger, M.O., Heldin, C.-H., and Moustakas, A. (2014). Fine tuning of Smad protein function by poly(ADP-ribose) polymerases and poly (ADP-ribose) glycohydrolase during transforming growth factor β signaling. *PLoS ONE* 9, e103651.

400. Eger, G., Papadopoulos, N., Lennartsson, J., and Heldin, C.-H. (2014). NR4A1 promotes PDGF-BB-induced cell colony formation in soft agar. *PLoS ONE* 9, e109047.

401. Thakur, N., Gudey, S.K., Marcusson, A., Fu, J.Y., Bergh, A., Heldin, C.-H., and Landström, M. (2014). TGFβ-induced invasion of prostate cancer cells is promoted by c-Jun-dependent transcriptional activation of Snail1. *Cell Cycle* 13, 2400–2414.

402. Tan, E.-J., Kahata, K., Idås, O., Thuault, S., Heldin, C.-H., and Moustakas, A. (2015). The high mobility group A2 protein epigenetically silences the Cdh1 gene during epithelial-to-mesenchymal transition. *Nucl. Acids Res.* 43, 162-178.

403. Sundar, R., Gudey, S.K., Heldin, C.-H., and Landström, M. (2015). TRAF6 promotes TGFb-induced invasion and cell-cycle regulation via Lys63-linked polyubiquitination of Lys178 in TGFβ type I receptor. *Cell Cycle* 14, 554-565.

404. Carthy, J.M., Sundqvist, A., Heldin, A., van Dam, H., Kletsas, D., Heldin, C.-H., and Moustakas, A. (2015). Tamoxifen inhibits TGFβ-mediated activation of myofibroblasts by blocking non-Smad signaling through Erk1/2. *J. Cell. Physiol*. 230, 3084-3092.

405. Ma, H., Wardęga, P., Razmara, M., Kłosowska-Wardęga, A., Jurek, A., Engström, U., Lennartsson, J., and Heldin, C.-H. (2015). Histidine-domain-containing protein tyrosine phosphatase regulates platelet-derived growth factor receptor intracellular sorting and degradation. *Cell.Signal.* 27, 2209-2219.

406. Vanlandewijck, M., Lebouvier, T., Mae, M., Nahar, K., Hornemann, S., Kenkel, D., Cunha, S., Lennartsson, J., Boss, A., Heldin, C.-H., Keller, A., and Betsholtz, C. (2015). Functional characterization of germline mutations in *PDGFB* and *PDGFRB* in primary familial brain calcification. *PLoS One* 10, e0143407.

407. Yakymovych, I., Yakymovych, M., Mu, Y., Zang, G., Bergh, A., *Landström, M., and *Heldin, C.-H. (2015). CIN85 modulates TGFβ signaling by promoting the presentation of TGFb receptors on the cell surface. *J. Cell Biol.* 210, 319-332. *equal contribution.

408. Carthy, J., Engström, U., Heldin, C.-H., and Moustakas, A. (2016). Commercially available preparations of recombinant Wnt3a contain non-Wnt related activities which may activate TGFβ signaling. *J. Cell. Biochem.* 117, 938-945.

409. Song, J.Q., Mu, Y., Li, C., Bergh, A., Heldin, C.-H., and Landström, M. (2016). APPL1 and APPL2 proteins promote TGFβ-induced nuclear transport of the TGFβ type I receptor intracellular domain. *Oncotarget* 7, 279-292.

410. Morikawa, M., Koinuma, D., Mizutani, A., Kawasaki, N., Holmborn, K., Sundqvist, A., Tsytsumi, S., Watabe, T., Aburatani, H., Heldin, C.-H., and Miyazono, K. (2016). BMP sustains embryonic stem cell self-renewla through distinct functions of different Kruppel-like factors. *Stem Cell Reports* 6, 64-73.

411. Raja, E., Tzavlaki, K., Vuilleumier, R., Edlund, K., Zieba, A., Morén, A., Watanabe, Y., Voytyuk, I., Botling, J., Söderberg, O., Micke, P., Pyrowolakis, G., Heldin, C.-H., and Moustakas, A. (2016). The protein kinase LKB1 negatively regulates bone morphogenetic protein receptor signaling. *Oncotarget* 7, 279-292.

412. Rorsman, C., Tsioumpekou, M., Heldin, C.-H., and Lennartsson, J. (2016). The ubiquitin ligases c-Cbl and Cbl-b negatively regulate PDGF-BB-induced chemotaxis by affecting PDGFRβ downregulation and signaling. *J. Biol. Chem*. 291, 11608-11618.

413. Carthy, J., Stöter, M., Bellomo, C., Vanlandewijck, M., Heldin, A., Morén, A., Kardassis, D., Gahman, T.C., Shiau, A.K., Bickle, M., Zerial, M., Heldin, C.-H., and Moustakas, A. (2016). Chemical inhibitors of epithelial plasticity reveal a nuclear receptor pathway controlling myofibroblast differentiation. *Scientific Reports* 6, 29868.

414. Vasilaki, E., Morikawa, M., Koinuma, D., Mizutani, A., Hirano, Y., Ehata, S., Sundqvist, A., Kawasaki, N., Cedervall, J., Olsson, A.-K., Aburutani, H., Moustakas, A., Miyazono, K., and Heldin, C.-H. (2016). Ras and TGF-β signaling enhance cancer progression by promoting the DNp63 transcriptional program. *Science Signaling* 9, ra84.

415. Tsioumpekou, M., Papadopoulos, N., Burovic, F., Heldin, C.-H., and Lennartsson, J. (2016). Platelet-derived growth factor (PDGF)-BB-induced activation of Erk5 MAP-kinase in smooth muscle cells is dependent on Mekk2, Mek1/2, PKC and PI3-kinase, and affects BMP signaling. *Cell. Sign.* 9, 1422-1431.

416. Watanabe, Y., Papoutsoglou, P., Maturi, V., Tsubakihara, Y., Hottiger, M.O., Heldin, C.-H., and Moustakas, A. (2016). Regulation of bone morphogenetic protein signaling by ADP-ribosylation. *J. Biol. Chem.* 291, 12706-12723.

417. Okita, Y., Kimura, M., Xie, R., Chen, C., Sheng, L.T., Kojima, Y., Suzuki, H., Muratani, M., Saitoh, M., Semab, K., Heldin, C.-H., and Kato, M. (2017). The transcription factor MafK induces EMT and malignant progression of triple negative breast cancer cells through its target GPNMB. *Science Signaling* 10, eaak9397.

418. Hamidi, A., Song, J, Thakur, N., Itoh, S., Marcusson, A., Bergh, A., *Heldin, C.-H., and *Landström, M. (2017). TGFβ promotes PI3K-AKT signaling and prostate cancer cell migration through the TRAF6-mediated ubiquitination of p85α. *Science Signaling* 10, eeal4186. *equal contribution.

419. Burmakin, M., Van Wieringen, T., Olsson, P.O., Stuhr, L., Åhgren, A., Heldin, C.-H., Reed, R., Rubin, K., and Hellberg, C. (2017). Imatinib increases oxygen delivery in extracellular matrix-rich but not in matrix-poor experimental carcinoma. *J. Transl. Res.* 15, 47.

420. Mehic, M., de Sá, V.K., Hebestreit, S., Heldin, C.-H., and Heldin, P. (2017). The deubiquitinating enzymes USP4 and USP17 target hyaluronan synthase 2 and differentially affetc its function. *Oncogenesis* 6, e348.

421. Guday, S.K., Sundar, R., Heldin, C.-H., Bergh, A., and Landström, K. (2017). Pro-invasive properties of Snail1 are regulated by sumoylation in response to TGFβ stimulation in cancer. *Oncotarget* 8, 97703-97726.

422. Sundqvist, A., Morikawa, M., Ren, J., Vasilaki, E., Kawasaki, N., Kobayashi, M., Koinuma, D., Aburatani, H., Miyazono, K., Heldin, C.-H., van Dam, H., and ten Dijke, P. (2018). JUNB governs a feed-forward network of TGFβ signaling that aggravates breast cancer invasion. *Nucl. Acids Res*. 46, 1180-1195.

423. Bellomo, C., Caja, L., Fabregat, I., Mikulitis, W., Heldin, C.-H., and Moustakas, A. (2018). Snail mediates crosstalk between TGFβ and LXRα in hepatocellular carcinoima. *Cell Death Diff.* 25, 885-903.

424. Kawasaki, N., Isogaya, K., Dan, S., Yamori, T., Takano, H., Yao, R., Morishita, Y., Taguchi, L., Morikawa, M., Heldin, C.-H., Noda, T., Ehata, S., Miyazono, K., and Koinuma, D. (2018). TUFT1 interacts with RABGAP1 and regulates mTORC1 signaling. *Cell Discovery*. 4, 1.

425. Vanlandewijck, M., Dadras, M.S., Lomnytska, M., Mahzabin, T., Miller, M.L., Busch, C., Brunak, S., Heldin, C.-H., and Moustakas, A. (2018). The protein kinase SIK downregulates the polarity protein Par3. *Oncotarget* 9, 5716-5735.

426. Maturi, V., Morén, A., Enroth, S., Heldin, C.-H., and Moustakas, A. (2018). Genome-wide binding of transcription factor Snail1 in triple-negative breast cancer cells. *Mol. Oncol.* 12, 1153-1174.

427. Maturi, V., Enroth, S., Heldin, C.-H., and Moustakas, A. (2018). Genome-wide binding of transcription factor ZEB1 in trippel-negative breast cancer cells. *J. Cell. Physiol.* 233, 7113-7127.

428. Papadopoulos, N., Lennartsson. J., and Heldin, C.-H. (2018). PDGFRb translocates to the nucleus and regulates chromatin remodeling via TATA element-modifying factor 1. *J. Cell Biol.* 217, 1701-1717.

429. Caja, L., Tzavlaki, K., Dahdras, M.S., Tan, E.-J., Hatem, G., Maturi, V., Morén, A., Wik, L., Watanabe, Y., Savary, K., Kamali-Moghaddam, M., Uhrbom, L., Heldin, C.-H., and Moustakas, A. (2018). Snail regulates BMP and TGFβ pathways to control the differentiation status of glioma-initiating cells. *Oncogene* 37, 2515-2531.

430. Thijssen, V.L., Paulis, Y.W.J., Nowak-Sliwinska, P., Deumelandt, K., Hosaka, K., Soutekouw, P.M.M.B., Cimpean, A., Raica, M., Pauwels, P., van den Oord, J., Tjan-Heijnen, V.C.G., Hendrix, M.J., Heldin, C.-H., Cao, Y., and Griffoien, A.W. (2018). Targeting PDGF-mediated recruitement of pericytes blocks vascular mimicry and tumor growth. *J.Pathol.* 246, 447-458.

431. Kolliopoulos, C., Lin, C.-Y., Heldin, C.-H., Moustakas, A., and Heldin, P. (2019). *Has2* natural antisense RNA and Hmga2 promote Has2 expression during TGFβ-induced EMT in breast cancer. *Matrix Biology* 80, 29-45.

432. Kolliopoulos, C., Raja, E., Razmara, M., Heldin, P., Heldin, C.-H., and Moustakas, A., and van der Heide, L. (2019). Transforming growth factor β (TGFβ) induces NUAK kinase expression to fine-tune its signaling output. *J. Biol. Chem.* 294, 4119-4136.

433. Morén, A., Bellomo, C., Tsubikihara, Y., Kardassis, D., Mikulitis, Wi, Heldin, C.-H., and Moustakas, A. (2019). LXRα limits TGFb-dependent hepatocellular carcinoma associated fibroblast differentiation. *Oncogenesis* 8, 36.

434. Sundqvist, A., Voytyuk, O., Hamdi, M., Popeijus, H., van der Burgt, C., Janssen, J., Martens, J., Moustakas, A., Heldin, C.-H., ten Dijke, P., and van Dam, H. (2019). JNK-dependent cJun phosphorylation mitigates TGFβ- and EGF-induced pre-malignant breast cancer cell invasion by suppressing AP-1-mediated transcriptional responses. *Cells* 8, 1481.

435. Morikawa, M., Mitani, M., Holmborn, K., Kato, T., Koinuma, D., Maruyama, J., Vasilaki, E., Sawada, H., Kobayashi, M., Ozawa, T., Morishita, Y., Bessho, Y., Maeda, S., Ledin, J., Aburatani, H., Kageyama, R., Maruyama, K., Heldin, C.-H., and Miyazono, K. (2019). The ALK-1/SMAD/ATOH8 axis attenuates hypoxic responses and protects against the development of pulmonary artery hypertension. *Science Signaling* 12, eaay4430,

436. Papoutsoglou, P., Tsubikihara, Y., Caja, L., Palis, P., Ameur, A., Heldin, C.-H., and Moustakas, A. (2019). The *TGFB2-AS1* lncRNA regulates TGF-β signaling by modulating corepressor activity. *Cell Reports* 28, 3182-3198.

437. Lin, C.-Y., Kolliopoulos, C., Huang, C.-H., Tenhunen, J., Heldin, C.-H., Chen, Y.-H., and Heldin, P. (2019). High levels of serum hyaluronan is an early predictor of dengue warning signs and perturbs vascular integrity. *EBioMedicine* 48, 425-441.

438. Yin, R., Eger, G., Sarri, N., Rorsman, C., Heldin, C.-H., and Lennartsson, J. (2019). Dual specificity phosphatase (DUSP)-4 is induced by platelet-derived growth factor-BB in an Erk1/2- STAT3- and p53-dependent manner. *Biochem. Biophys.Res.Commun*. 519, 469-474.

439. Zarei, O., Sarri, N., Dastmalchi, S., Zokai, F., Papadopoulos, N., Lennartsson, J., Heldin, C.-H., and Hamze-Mivehroud, M. (2020). Structure-based discovery of novel small molecule inhibitors of platelet-derived growth factor-B. *Bioorg. Chem.* 94, 103374.

440. Tsioumpekou, M., Cunha, S., Ma, H., Åhgren, A., Cedervall, J., Olsson, A.-K., Heldin, C.-H., and Lennartsson, J. (2020). Specific targeting of PDGFRβ in the stroma inhibits growth and angiogenesis in tumors with high PDGF-BB expression. *Theranostics* 10, 1122-1135.

441. Thakur, N., Hamidi, A., Itoh, S., Bergh, A., Heldin, C.-H., and Landström, M. (2020). Smad7 promotes TGF-b-induced transcription of c-Jun and HDAC6 promoting invasion of prostate cancer cells. *iScience* 23, 101470.

442. Sundqvist, A., Vasilaki, E., Voytyuk, O., Bai, Y., Morikawa, M., Moustakas, A., Miyazono, K., Heldin, C.-H., ten Dijke, P., and van Dam, H. (2020). TGFβ and EGF signaling orchestrates the AP-1 and p63 transcriptional regulation of breast cancer invasiveness. *Oncogene* 39, 4436-4449.

443. Zhang, Y., Cedervall, J., Hamidi, A., Herre, M., Viitaniemi, K., D'Amico, G., Miao, Z., Unnithan, R.V.M., Vaccaro, A., van Hooren, L., Georganaki, M., Thulin, Å., Qiao, Q., Andrae, J., Siegbahn, A., Heldin, C.-H., Alitalo, K., Betsholtz, C., Dimberg, A., and Olsson, A.-K. (2020). Platelet-specific PDGFB ablation impairs vessel integrity and promotes metastasis. *Cancer Research* 80, 3345-3358.

444. Fukuda, T., Fukuda, R., Tanabe, R., Koinuma, D., Koyama, H., Hashizume, Y., Moustakas, A., *Miyazono, K., and *Heldin, C.-H. (2020) BMP signaling is a therapeutic target in ovarian cancer. *Cell Death Discov.* 6, 139. *equal contribution.

445. Fukuda, T., Fukuda, R., Miyazono, K., and Heldin, C.-H. (2021). Tumor promoting effect of BMP signaling in endometrial cancer. *Int. J. Mol. Sci.* 22, 7882.

446. Dadras, M.S., Caja, L., Mezheyeuski, A., Liu, S., Gélabert, C., Gomez-Puerto, M.C., Gallini, R., Rubin, C.-J., ten Dijke, P., Heldin, C.-H., and Moustakas, A. (2021). The polarity protein Par3 coordinates positively self-renewal and negatively invasiveness in glioblastoma. *Cell Death Dis.* 12, 932.

447. Papoutsoglou, P., Mendes Rodrigues-Jr., D., Morén, A., Bergman, A., Pontén, F., Coulouarn, C., Caja, L., Heldin, C.-H., and Moustakas, A. (2021) The non-coding *MIR100HG* RNA enhances the autocrine function of transforming growth factor β signaling. *Oncogene* 40, 3748-3765.

448. Kolliopoulos, C., Chatzopoulos, A., Skandalis, S.S., Heldin, C.-H., and Heldin, P. (2021). TRAF4/6 is needed for CD44 cleavage and migration via RAC1 activation. *Cancers,* 13, 1021.

449. Fukuda, T., Fukuda, R., Koinuma, D., Moustakas, A., Miyazono, K., and Heldin, C.-H. (2021). BMP2-induction of FN14 promotes protumorigenic signaling in gynecologic cancer cells. *Cellular Signaling* 87, 110146.

450. Tanabe, R., Miyazono, K., Todo, T., Saito, N., Iwata, C., Komuro, A., Sakai, S., Raja, E., Koinuma, D., Morikawa, M., Westermark, B., and Heldin, C.-H. (2022). PRRX1 induced by BMP signalning decreases tumorigenesis by epigenetically regulating glioma-initiating cell properties via DNA methyltransferase 3A. *Mol. Oncol.* 16, 269-288.

451. Caja, L., Dadras, M.S., Mezheyenski, A., Mendez Rodrigues, D.Jr., Liu, S., Webb, A., Gomez-Puerto, M.C., ten Dijke, P., Heldin, C.-H., and Moustakas, A. (2022). The protein kinase LKB1 promotes self-renewal and blocks invasiveness in glioblastoma. *J. Cell. Phyiol.* 237, 743-752.

452. Sarri, N., Wang, K., Tsioumpekou, M., Castillejo-López, C., Lennartsson, J., Heldin, C.-H., and Papadopoulos, N. (2022) Deubiquitinating enzymes USP4 and USP17 fine-tune the trafficking of PDGFRβ and affect PDGF-BB-induced STAT3 signaling. *Cell. Mol. Life. Sci.* 79, 85.

453. Karalis, T., Shiau, A.K., Gahman, T.C., Skandalis, S.S., Heldin, C.-H., and Heldin, P. (2022). Identification of a small moilecule inhibitor of hyaluronan synthesis, DDIT, targeting breast cancer cells. *Cancers* 14, 5800.

454. Kolliopoulos, K., Ali, M., Castillejo-Lopez, C., Heldin, C.-H., and Heldin, P. (2022). CD44 depletion in glioblastoma cells suppresses growth and stemness, and induces senescence. *Cancers* 14, 3747.

455. Song, J., Zhou, Y., Yakymovych, I., Li, C., Heldin, C.-H., and Landström, M. (2022). The ubiquitin ligase TRAF6 and TGFβ type I receptor form a complex with Aurora kinase B contributing to mitotic progression and cytokinesis in cancer cells. *EBioMedicine* 82, 104155.

456. Tsirigoti, C., Ali, M.M., Maturi, V., Heldin, C.-H., and Moustakas, A. (2022) Loss of SNAI1 induces cellular plasticity in invasive triple-negative breast cancer cells. *Cell Death. Dis.* 13, 832.

457. Yakymovych, I., Yakymovych, M., Hamidi, A., Landström, M., Heldin, C.-H. (2022). The type II TGF-β receptor phosphorylates Tyr^{182} in the type I receptor to activate downstream Src signaling. *Science Signaling* 15, eabp9521.

458. Tsubikihara, Y., Ohata, Y., Okita, Y., Younis, S., Eriksson, J., Sellin, M., Ren, J., ten Dijke, P., Miyazono, K., Hikita, A., Imamura, T., Kato, M., Heldin, C.-H., and Moustakas, A. (2022) TGFβ selects for pro-stemness over pro-invasive phenotypes duting cancer cell epithelial-mesenchymal transition. *Mol. Oncol.* 16, 2330-2354.

459. Lin, C.-Y., Basu, K., Ruusala, A., Kozlova, I., Li, Y.-S., Skandalis, S., Heldin, C.-H., and Heldin, P. (2022). Hyaluronan-induced CD44-iASPP interaction affects fibroblast migration and survival. *Cancers* 23, 1082.

460. Tzavlaki, K., Ohata, Y., Morén, A., Watanabe, Y., Eriksson, J., Tsuchiya, M., Kubo, Y., Yamamoto, K., Selin, M., Kato, M., Caja, L., Heldin, C.-H., and Moustakas, A. (2023). The liver kinase B1 supports mammary epithelial morphogenesis by inhibiting critical factors that mediate epithelial-mesenchymal transition. *J. Cell. Physiol*. 238, 790-812.

461. Sarri, N., Papadopoulos, N., Lennartsson, J., and Heldin, C.-H. (2023). The E3 ligase TRIM21 regulates basal levels of PDGFRβ. *Int. J. Mol. Sci*. 24, 7782.

462. Wang, K., Papadopoulos, N., Hamidi, A., Lennartsson, J., and Heldin, C.-H. (2023). SUMOylation of the PDGF receptor a affects signaling via PLCγ and STAT3, and cell proliferation. *BMC Cell Mol. Biol*. 24, 19

463. Gélabert, C., Papoutsoglou, P., Golan, I.C., Ahlström, E., Ameur, A., Heldin, C.-H., Caja, L., and Moustakas, A. (2023). The long non-coding RNA *LINC00707* interacts with Smad proteins to regulate TGFβ signaling and cancer cell invasion. *Cell Commun.Signal.* 21, 127.

464. Rubin Sander, M., Tsiatsiou, A.K., Wang, K., Papadopoulos, N., Rorsman, C., Olsson, F., Heldin, J., Söderberg, O., Heldin, C.-H., and Lennartsson, J. (2024). PDGF-induced internatization promotes proteolytic cleavage of PDGFRβ in mesenchymal cells. *Growth Factors* 42, 147-160.

465. Vasilaki, E., Ali, M.M., Bai, Y., Sundqvist, A., Moustakas, A., and Heldin, C.-H. (2024). DNp63 bookmarks and creates an accessible epigenetiuc environment for TGFβ-induced cancer cell stemness and invasiveness. *Cell Commun.Signal.* 22, 411

466. Voytyuk, O., Ohata, Y., Moustakas, A. ten Dijke, P., and Heldin, C.-H. (2024). Smad7 palmitoylation by the S-acyltransferase ZDHHC17 enhances its inhibitory effect on TGF-β signaling. *J.Biol.Chem.* 300, 107462.

467. Mendes Rodrigues, D., Jr., Tsirigoti, C., Psatha, K., Kletsas, D., Aivaliotis, M., Heldin, C.-H., and Moustakas, A. (2025). TGF-β induces cholestrol accumulation to regulate the secretion of tumor-derived extracellular vesicles. *J. Exp. Clin. Cancer Res.* 44, 42.

468. Ohata, Y., Ali, M.M., Tsubikihara, Y., Itoh, Y., Rosèn, G., Bergström, T., Morén, A., Golan-Cancela, I.G., Nakada, A., Voytyuk, O., Tsuchia, M., Fukui, R., Yamamoto, K., Martin-Rubio, P., Sancho, P., Strell, C., Micke, P., Wechsler-Reya, R.J., Hashizume, Y., Miyazono, K., Caja, L., Heldin, C.-H., Swartling, F.J., and Moustakas, A. (2025). The transcription factor LHX2 mediates and enhances oncogenic BMP signaling in medulloblastoma. *Cell Death Diff*. (in press).

469. Tzavlaki, K., Dadras, M.S., Mezheyeuski, A., Morén, A., Heldin, C.-H., Moustakas, A., and Caja, L. (2025). Epigenetic coupling of CXXC5 to histone methyl transferase KMT2C under the control of TGFβ regulates stemness genes in glioblastoma. (submitted).

470. Tsirigoti, C., Ali, M., Mendes Rodrigues, Jr., D., Johansson, S., Heldin, C.-H., and Moustakas, A. (2025). SNAI1 ablation alters integrin-mediated adhesion and endocytic fate. (submitted).

471. Mendes Rodrigues, Jr., D., Ali, M.,M., Itoh, Y., Ferreira, M.S., Heldin, J., Fu, H., Hoelz, A., Heldin, C.-H., and Moustakas, A. (2025). SMAD nuclear accumulation relies of nucleoporin RanBP2 and the long non-coding RNA *VIM-AS1* during TGF-β signaling. *Nucl. Acid Res.* (in press).

472. Yashaswini, C. N., Mitran, B., Papadopoulos, N., Wegrzniak, O., Löfblom, J., Nordström, H., Velikyan, A., Abouzayed, A., Johansson, L., Hagmar, P., Wagner, M., Frejd, F., Korsgren, O., Heldin, C.-H., Friedman, S., and Eriksson, O. (2025) PDGFRβ targeted positron emission tomography as a non-invasive biomarker for activated hepatic strem cells - last steps before clinical translation. *EJNMMI Radiopharmacy and Chemistry* (in press).

473. Ali, M.M., Itoh, Y., Badji, A.P., Gallant, S., Tsirigoti, C., Bai, Y, Filipek-Gorniok, B., Miyazawa, K., Heldin, C.-H., and Moustakas, A. (2025). TGFβ signaling promotes cell cycle progression and resistance to the CDK4/6 inhibitor palbociclib through SOX4 transcriptional modulation in breast cancer cells. *Cell Death Dis*. (in press)..

474. Abouzayed, A., Olsson, H., Papadopoulos, N., Mitran, B., Mallapura, H., Akter, T., Velikyan, I., Korsgren, O., Heldin, C.-H., Löfblom, J., Wagner, M., and Eriksson, O. (2025). Increased affinity and tissue retention by dimerization of ATH001 radiopharmaceutical targeting PDGFRβ. (submitted).

475. Larsson, P.F., Schmidt, A., Mu, Y., Zang G.**,** Song, J., Aripaka, K., Rahkimova, O., Ericsson, M., Halin Bergström, S., Yuan,W., Bogdan, D., Zhang, A., Welti, J., de Bono, J., Bergh, A., Heldin, C.-H., and Landström, M. (2025). Targeting oncogenic TβRI signaling inhibits prostate cancer growth and metastasis. (submitted).

476. Bai, Y., Ali, M.M., van Dinther, M., ten Dijke, P., Moustakas, A., Sundqvist, A., and Heldin, C.-H. (2025). Opposing effects of Rho-associated coiled-coil kinase 1 (ROCK1) and ROCK2 in TGF-β-SMAD signaling. (submitted).

477. Papadopoulos, N., Sarri, N., Lennartsson, J., and Heldin, C.-H. (2025). G3BP1 is a SWI/SNF-bound transcriptional regulator of growth signaling pathways. (submitted).

478. Zhao, C., Yakymovych, I. Yakymovych, M., and Heldin, C.-H. (2025). Inhibition of SHP2 enhances the growth inhibitory effect of TGF-β in breast cancer cells. (submitted).

REVIEW ARTICLES

2025-12-22

1. Wasteson, Å., Amadò, R., Ingmar, B., and Heldin, C.-H. (1975). Degradation of chondroitin sulphate by lysosomal enzymes from embryonic chick cartilage. In: *Protides of the Biological Fluids* (Peeters, H., ed.), Pergamon Press, New York, Vol. 22, pp. 431-435.

2. Heldin, C.-H., Westermark, B., and Wasteson, Å. (1979). Purification and characterization of human growth factors. In: *Hormones and Cell Culture* (Sato,G.H., and Ross, R., eds.), Cold Spring Harbor Conferences on Cell Proliferation, Vol. 6, pp. 17-31.

3. Busch, C., Ljungman, C., Heldin, C.-H., Waskson, E., and Öbrink, B. (1979). Surface properties of cultured endothelial cells. In: *Haemostasis* (Brakman, P., ed.), S. Karger, Basel, Vol. 8, pp. 142-148.

4. Heldin, C.-H. (1980). Studies on growth factors for human cultured cells. *Acta Universitatis Upsaliensis, Abstracts of Uppsala Dissertations from the Faculty of Medicine* 359, 1-44.

5. Heldin, C.-H., Wasteson, Å., and Westermark, B. (1981). Specific binding of ^{125}I-labeled platelet-derived growth factor to cultured cells. In: *The Biology of Normal Human Growth* (Ritzén, M., et al., ed.), Raven Press, pp. 23-31.

6. Nistér, M., Heldin, C.-H., Wasteson, Å., and Westermark, B. (1982). A platelet-derived growth factor analog produced by a human clonal glioma cell line. *Ann. N.Y. Acad. Sci.* 397, 25-33.

7. Westermark, B., Heldin, C.-H., Ek, B., Johnsson, A., Mellström, K., Nistér, M., and Wasteson, Å. (1983). Biochemistry and biology of platelet-derived growth factor. In: *Growth and Maturation Factors* (Guroff, G., ed.), John Wiley & Sons, Inc., New York, Vol. 1, pp. 73-115.

8. Heldin, C.-H., Westermark, B., Mellström, K., Johnsson, A., Ek, B., Nistér, M., Betsholtz, C., Rönnstrand, L., and Wasteson, Å. (1983). Platelet-derived growth factor: Structural and functional aspects. In: *Survey and Synthesis of Pathology Research*, S. Karger AG, Basel, Vol. 1, pp. 153-164.

9. Heldin, C.-H., Ek, B., and Rönnstrand, L. (1983). Characterization of the fibroblast receptor for platelet-derived growth factor. *Cell Biol. Int. Rep.* 7, 543-544.

10. Wasteson, Å., Heldin, C.-H., and Westermark, B. (1983). Platelet-derived growth factor: Studier av en tillväxtfaktors verkningsmekanism och funktion. *MFR informerar* 4, no 1, 4-7.

11. Betsholtz, C., Heldin, C.-H., Wasteson, Å., and Westermark, B. (1983). Pure platelet-derived growth factor stimulates human fibroblasts to proliferate in plasma-free culture. In: *Hormonally Defined Media* (Fischer, G., and Wieser, R.J., eds.), Proceedings of Life Sciences, Springer-Verlag, Heidelberg, pp. 103-105.

12. Waterfield, M.D., Scrace, G.T., Whittle, N., Stockwell, P.A., Stroobant, P., Johnsson, A., Wasteson, Å., Westermark, B., Heldin, C.-H., Huang, J.S., and Deuel, T.F. (1984). Relationship between the transforming protein of simian sarcoma virus and platelet-derived growth factor. In: *Cancer Cells*, Cold Spring Harbor Laboratories, New York, Vol. 1, pp. 25-33.

13. Westermark, B., Wasteson, Å., and Heldin, C.-H. (1984). Platelet-derived growth factor. In: *Hormones and Cell Regulation* (Dumont, J.E., and Nunez, J., eds.), Elsevier Science Publishers, Amsterdam, Vol. 8, pp. 9-16.

14. Ek, B., Rönnstrand, L., and Heldin, C.-H. (1984). Stimulation of tyrosine phosphorylation by platelet-derived growth factor. *Biochem. Soc. Trans.* 12, 759-762.

15. Heldin, C.-H., Wasteson, Å., and Westermark, B. (1984). Platelet-derived growth factor vid normal och malign celltillväxt. *Läkartidningen* 81, 3107-3109 and Nordisk Medicin 99, 319-322.

16. Heldin, C.-H., and Westermark, B. (1984). Growth factors: Mechanism of action and relation to oncogenes. *Cell* 37, 9-20.

17. Heldin, C.-H., Wasteson, Å., and Westermark, B. (1985). Platelet-derived growth factor. *Mol. Cell. Endocrinol.* 39, 169-187.

18. Westermark, B., Johnsson, A., Betsholtz, C., Wasteson, Å., and Heldin, C.-H. (1985). Platelet-derived growth factor: Comments on the structural and functional relationship with the transforming protein of simian sarcoma virus. In: *Molecular Biology of Tumor Cells* (Wahren, B., et al., ed.), Raven Press, New York, pp. 87-94.

19. Heldin, C.-H., Betsholtz, C., Johnsson, A., Nistér, M., Ek, B., Rönnstrand, L., Wasteson, Å., and Westermark, B. (1985). Platelet-derived growth factor: Mechanism of action and relation to oncogenes. *J. Cell Sci. Suppl.* 3, 65-76.

20. Heldin, C.-H. (1985). Tillväxtfaktorers verkningsmekanism - En nyckel till onkogenprodukters funktion? *Kungl. Vetenskaps-Societetens (Uppsala) Årsbok*, 37-41.

21. Westermark, B., Nistér, M., and Heldin, C.-H. (1985). Growth factors and oncogenes in human malignant glioma. In: *Neurologic Clinics* (Vick, N.A., and Bigner, D.D., eds.), W.B. Saunders, Philadelphia, Vol. 3, pp. 785-799.

22. Westermark, B., and Heldin, C.-H. (1985). Platelet-derived growth factor in normal and pathological cell growth. In: *Inflammation Basic Mechanisms, Tissue Injury Principles and Clinical Models* (Venge, P., and Lindbom, A., eds.), Almqvist and Wiksell International, pp. 255-270.

23. Heldin, C.-H., Wasteson, Å., and Westermark, B. (1986). Platelet-derived growth factor, its receptor and mechanism of action. In: *Mechanisms of Insulin Action* (Belfrage, P., Donnér, J., and Strålfors, P., eds.), The Fernström Foundation Series, Elsevier Science Publishers (Biomedical Division), Amsterdam, Vol. 7, pp. 109-121.

24. Westermark, B., and Heldin, C.-H. (1986). Platelet-derived growth factor as a mediator of normal and neoplastic cell proliferation. *Med. Oncol. & Tumor Pharmacother.* 3, 177-183.

25. Heldin, C.-H., Betsholtz, C., Johnsson, A., and Westermark, B. (1986). Role of PDGF-like growth factors in malignant transformation. *Cancer Rev.* 2, 34-47.

26. Heldin, C.-H., and Westermark, B. (1986). Role of PDGF-like growth factors in autocrine stimulation of growth of normal and transformed cells. In: *Oncogenes and Growth Control* (Kahn, P., and Graf, T., eds.), Springer-Verlag, Heidelberg, pp. 43-50.

27. Heldin, C.-H., and Westermark, B. (1986). Platelet-derived growth factor: Structure, function, and role in autocrine stimulation of growth. In: *Cell Cycle and Oncogenes* (Gallwitz, D., and Tanner, W., eds.), Springer-Verlag, Heidelberg, pp. 137-144.

28. Westermark, B., Johnsson, A., Betsholtz, C., and Heldin, C.-H. (1987). Biological properties of simian sarcoma virus and its oncogene product. In: *Contr. Oncol.*, Karger, Basel, Vol. 24, pp. 51-61.

29. Heldin, C.-H., Johnsson, A., Ek, B., Wennergren, S., Rönnstrand, L., Hammacher, A., Faulders, B., Wasteson, Å., and Westermark, B. (1987). Purification of human platelet-derived growth factor. *Meth. Enzymol.* 147, 3-13.

30. Westermark, B., Betsholtz, C., Johnsson, A., and Heldin, C.-H. (1987). Acute transformation by simian sarcoma virus is mediated by an externalized PDGF-like growth factor. In: *Viral Carcinogenesis* (Kjeldgaard, N.O., and Forchhammer, J., eds.), Munksgaard, Copenhagen, pp. 445-457.

31. Fellström, B., Klareskog, L., Larsson, E., Tufveson, G., Wahlberg, J., Rönnstrand, L., Heldin, C.-H., Terracio, L., and Rubin, K. (1987). Tissue distribution of macrophages, class II transplantation antigens, and receptors for platelet-derived growth factor in normal and rejected human kidneys. *Transpl. Proc.* 19, 3625-3627.

32. Westermark, B., and Heldin, C.-H. (1987). Platelet-derived growth factor. In: *Highlights in Endocrinology* (Christiansen, C., and Juel Riis, B., eds.), Munksgaard, Copenhagen, pp. 211-216.

33. Westermark, B., and Heldin, C.-H. (1987). Structure and function of platelet-derived growth factor. *Acta Med. Scand., Suppl.* 715, 19-23.

34. Heldin, C.-H., and Westermark, B. (1987). PDGF-like growth factors in autocrine stimulation of growth. *J. Cell. Phys. Suppl.* 5, 31-34.

35. Heldin, C.-H., Betsholtz, C., Claesson-Welsh, L., and Westermark, B. (1987). Subversion of growth regulatory pathways in malignant transformation. *Biochim. Biophys. Acta* 907, 219-244.

36. Westermark, B., Nistér, M., and Heldin, C.-H. (1987). Oncogenes, growth factors and the pathogenesis of human glioma: The 1986 Engelhardt lecture. In: *Brain Oncology* (Chatel, M., Darcel, F., and Pecker, J., eds.), Martinus Nijhoff Publishers, Dordrecht, pp. 7-13.

37. Westermark, B., and Heldin, C.-H. (1987). Platelet-derived growth factor: structure, function and biological responses. In: *"Tissue Fibrosis: Immune Cells and Mediators", Local Immunity* (Revillard, J.-P., and Wierzbicki, N., eds.), Fondation Franco-Allemande, Suresnes, France, Vol. 3, pp. 73-83.

38. Heldin, C.-H., and Westermark, B. (1987). Role of PDGF-like growth factors in cell transformation. In: *Theories of Cacinogenesis* (Iversen, O.H., ed.), Hemisphere Publishing Corporation, Washington, pp. 81-91.

39. Westermark, B., and Heldin, C.-H. (1988). Activation of proto-oncogenes coding for growth factors or growth factor receptors. In: *Cellular Oncogene Activation* (Klein, G., ed.), Marcel Dekker, Inc., New York, pp. 149-180.

40. Claesson-Welsh, L., Eriksson, A., Severinsson, L., Westermark, B., and Heldin, C.-H. (1988). Structural features of A and B type PDGF receptors. In: *Progress in Endocrinology 1988* (Imura, H., et al., ed.), Elsevier Science Publishers B.V. (Biomedical Division), pp. 503-508.

41. Heldin, C.-H., and Westermark, B. (1988). Tillväxtfaktorer och onkgener. *Läkartidningen* 85, 497-499.

42. Heldin, C.-H., Hammacher, A., Nistér, M., and Westermark, B. (1988). Structural and functional aspects of platelet-derived growth factor. *Br. J. Cancer* 57, 591-593.

43. Heldin, C.-H., and Westermark, B. (1988). Platelet-derived growth factor and its relation to oncogenes. *ISI Atlas of Science: Immunology*, 44-48.

44. Westermark, B., Betsholtz, C., Claesson-Welsh, L., Nistér, M., and Heldin, C.-H. (1988). Molecular mimicry within the platelet-derived growth factor family: Identification of three isoforms that bind to two distinct but related cell surface receptors. In: *Molecular Mimicry in Health and Disease* (Lernmark, Å., Dyrberg, T., Terenius, L., and Hökfelt, B., eds.), Elsevier Science Publishers B.V. (Biomedical Division), Amsterdam, pp. 135-144.

45. Westermark, B., and Heldin, C.-H. (1989). Platelet-derived growth factor: structural and functional aspects. *J. Internal Medicine* 225, 55-58.

46. Heldin, C.-H., and Rönnstrand, L. (1989). The platelet-derived growh factor receptor. In: *Receptor Phosphorylation* (Moudgil, V.K., ed.), CRC Press, Boca Raton, FL, pp. 149-162.

47. Westermark, B., Claesson-Welsh, L., and Heldin, C.-H. (1989). Structural and functional aspects of the receptors for platelet-derived growth factor. *Prog. Growth Factor Res.* 1, 253-266.

48. Heldin, C.-H., and Westermark, B. (1989). Growth factors as transforming proteins. *Eur. J. Biochem.* 184, 487-496.

49. Betsholtz, C., Rorsman, F., Bywater, M., Heldin, C.-H., and Westermark, B. (1989). Platelet-derived growth factor - Structural and functional aspects of the A-chain gene. In: *Advances in Growth Hormone and Growth Factor Research* (Müller, E.E., Cocchi, D., and Locatelli, V., eds.), Pythagora Press, Roma-Milano and Springer Verlag, Heidelberg, pp. 181-190.

50. Westermark, B., and Heldin, C.-H. (1989). Platelet-derived growth factor and its role in mitogenesis and transformation. In: *Cell to Cell Signals in Mammalian Development* (de Laat, S.W., et al., ed.) NATO ASI Series, Springer-Verlag, Heidelberg, Vol. H26, pp. 261-269.

51. Heldin, C.-H., and Westermark, B. (1989). Platelet-derived growth factor: Three isoforms and two receptor types. *Trends in Genetics* 5, 108-111.

52. Heldin, C.-H., and Westermark, B. (1989). Platelet-derived growth factors: A family of isoforms that bind to two distinct receptors. In: *Growth Factors. British Medical Bulletin* (Waterfield, M., ed.), Churchill Livingstone, Vol. 45, pp. 453-464.

53. Claesson-Welsh, L., and Heldin, C.-H. (1989). Platelet-derived growth factor. Three isoforms that bind to two distinct cell surface receptors. *Acta Oncologica* 28, 331-334.

54. Heldin, C.-H., and Westermark, B. (1989). Wachstumsfaktoren und Zelltransformation. In: *Endokrinologie* (Hesch, H.D., ed.), Urban und Schwarzenberg, München, pp. 370-374.

55. Nistér, M., Betsholtz, C., Heldin, C.-H., and Westermark, B. (1989). Platelet-derived growth factor. In: *Growth Factors and Oncogenes* (Bolla, M., Chambaz, E.M., and Vrousos, C., eds.), Colloque INSERM/John Libbey Eurotext Ltd., Vol. 190, pp. 25-33.

56. Betsholtz, C., Nistér, M., Rorsman, F., Heldin, C.-H., and Westermark, B. (1989). Structural and functional aspects of platelet-derived growth factor and its role in the pathogenesis of glioblastoma. *Mol. Chem. Neuropath.* 10, 27-36.

57. Westermark, B., and Heldin, C.-H. (1989). Growth factors and their receptors. *Current Opinion in Cell Biology* 1, 279-285.

58. Westermark, B., Nistér, M., Heldin, N.-E., and Heldin, C.-H. (1990). Oncogene expression and control of growth in malignant brain tumours. In: *Neuro-oncology. Primary malignant brain tumours* (Thomas, D.G.T., ed.), Edward Arnold Publishers, London, pp. 26-39.

59. Heldin, C.-H., and Westermark, B. (1990). Autocrine stimulation of growth of normal and transformed cells. In: *Growth Factors, Differentiation Factors, and Cytokines* (Habenicht, A., ed.), Springer-Verlag, Heidelberg, pp. 267-278.

60. Heldin, C.-H., and Westermark, B. (1990). Role of platelet-derived growth factor in autocrine and paracrine stimulation of normal and malignant cells. In: *Malignant Cell Secretion* (Krsmanovic, V., and Whitfield, J.F., eds.), CRC Press, Inc., Boca Raton, FL, pp. 45-56.

61. Heldin, C.-H., and Westermark, B. (1990). Growth factors and their receptors. In: *Handbook of Experimental Pharmacology, Carcinogenesis and Mutagenesis* (Cooper, C.S., and Grover, P.L., eds.), Springer Verlag, Heidelberg, Vol. 94 part II, pp. 353-379.

62. Miyazono, K., and Heldin, C.-H. (1990). Platelet-derived endothelial cell growth factor. In: *Handbook of Experimental Pharmacology. Peptide Growth Factors and Their Receptors II* (Sporn, M.B., and Roberts, A.B., eds.), Springer-Verlag, Heidelberg, Vol. 95/II, pp. 125-133.

63. Miyazono, K., Yuki, K., Takaku, F., Wernstedt, C., Kanzaki, T., Olofsson, A., Hellman, U., and Heldin, C.-H. (1990). Latent Forms of TGF-b: Structure and Biology. *Ann. N.Y. Acad. Sci.* 593, 51-58.

64. Heldin, C.-H., Claesson-Welsh, L., and Westermark, B. (1990). Platelet-derived growth factor and its receptors. In: *Growth Factors: From Genes to Clinical Application* (Sara, V.R., et al., ed.), Raven Press, New York, pp. 41-50.

65. Heldin, C.-H., and Rönnstrand, L. (1990). Platelet-derived growth factor B type receptor. In: *Receptor Purification* (Litwack, G., ed.), Humana Press, Clifton, NJ, Vol. 1, pp. 303-314.

66. Heldin, C.-H., Miyazono, K., Claesson-Welsh, L., and Westermark, B. (1990). Two platelet-derived mitogens with potentially different roles in vessel wall biology. In: *Applied Cardiovascular Biology 1989* (Zilla, P., Fasol, R., and Callow, A., eds.), Karger, S., Basel, Vol. 1, pp. 12-21.

67. Westermark, B., Claesson-Welsh, L., and Heldin, C.-H. (1990). Structural and functional aspects of platelet-derived growth factor and its receptors. *Proceedings of Ciba Foundation Symposium no 150 on Proto-oncogenes in Cell Development*. Wiley J. & Sons, Chichester, pp. 6-22.

68. Kriz, R., Lin, L.-L., Sultzman, L., Ellis, C., Heldin, C.-H., Pawson, T., and Knopf, J. (1990). Phospholipase C isozymes: structural and functional similarities. Proto-oncogenes in Cell Development. *CIBA Found. Symp.* Wiley, J. & Sons, Chichester, pp. 112-127.

69. Heldin, C.-H., and Westermark, B. (1990). Signal transduction by the receptors for platelet-derived growth factor. *J. Cell Sci.* 96, 193-196.

70. Betsholtz, C., Rorsman, F., Westermark, B., Östman, A., and Heldin, C.-H. (1990). Analogous alternative splicing. *Nature* 344, 299.

71. Heldin, C.-H., and Westermark, B. (1990). Platelet-derived growth factor: mechanism of action and possible in vivo function. *Cell Regulation* 1, 555-566.

72. Heldin, C.-H., Miyazono, K., Claesson-Welsh, L., and Westermark, B. (1990). Growth regulatory proteins from human platelets. In: *Genetic Basis for Carcinogenesis: Tumor Suppressor Genes and Oncogenes* (Knudson, A.G., Jr., et al., ed.), Japan Sci. Soc. Press, Tokyo/Taylor & Francis Ltd., London, pp. 81-92.

73. Heldin, C.-H., and Westermark, B. (1990). Structural and functional aspects of platelet-derived growth factor and its receptors. In: *Oncogenes in Cancer Diagnostics, Contrib. Oncol.* (Bartram, C.R., Munk, K., and Schwab, M., eds.), Karger, Basel, Vol. 39, pp. 115-124.

74. Betsholtz, C., Nistér, M., Heldin, C.-H., and Westermark, B. (1990). Platelet-derived growth factor: Role in gliogenesis and in the development of glioblastoma. In: *Trophic Factors and the Nervous System* (Horrocks, L.A., et al., ed.), Raven Press, Ltd., New York, pp. 35-45.

75. Siegbahn, A., Claesson-Welsh, L., Heldin, C.-H., and Westermark, B. (1990). Induction of chemotaxis by PDGF-BB through the B type receptor requires a functional receptor protein tyrosine kinase activity. In: *Molecular and Cellular Biology of Cytokines*, Wiley-Liss, Inc., pp. 259-264.

76. Miyazono, K., Usuki, K., and Heldin, C.-H. (1990). Structural and functional properties of platelet-derived endothelial cell growth factor. In: *Growth Factors in Health and Disease* (Westermark, B., Betsholtz, C., and Hökfelt, B., eds.), Elsevier Science Publishers B.V., pp. 281-288.

77. Heldin, C.-H., and Westermark, B. (1991). Platelet-derived growth factor and autocrine mechanisms of oncogenic processes. In: *CRC Critical Reviews in Oncogenesis*, Vol. 2, pp. 109-124.

78. Heldin, C.-H., Hellman, U., Ishikawa, F., and Miyazono, K. (1991). Purification, cloning, and expression of platelet-derived endothelial cell growth factor. In: *Methods in Enzymology. Peptide Growth Factors. Part C* (Barnes, D., Mather, J.P., and Sato, G.H., eds.), Methods in Enzymology, Academic Press, Inc, San Diego, Vol. 198, pp. 383-391.

79. Claesson-Welsh, L., Eriksson, A., Westermark, B., and Heldin, C.-H. (1991). Cloning and expression of human platelet-derived growth factor a and b receptors. In: *Methods in Enzymology. Peptide Growth Factors. Part C* (Barnes, D., Mather, J.P., and Sato, G.H., eds.), *Methods in Enzymology*, Academic Press, Inc, San Diego, Vol. 198, pp. 72-77.

80. Rönnstrand, L., and Heldin, C.-H. (1991). Purification of platelet-derived growth factor β receptor from porcine uterus. In: *Methods in Enzymology*, Vol. 200, pp. 371-378.

81. Miyazono, K., and Heldin, C.-H. (1991). Latent forms of TGF-β: molecular structure and mechanisms of activation. In: *Proceedings of Ciba Foundation Symposium no 157 on Clinical Applications of TGF-β*, Wiley, Chichester, pp. 81-92.

82. Heldin, C.-H., and Westermark, B. (1991). PDGF/PDGF receptor files. *Cancer Cells* 3, 252-254.

83. Heldin, C.-H., Usuki, K., and Miyazono, K. (1991). Platelet-derived endothelial cell growth factor. *J. Cell. Biochem.* 47, 208-210.

84. Westermark, B., and Heldin, C.-H. (1991). Platelet-derived growth factor in autocrine transformation. *Cancer Res.* 51, 5087-5092.

85. Heldin, C.-H. (1991). SH2-domains: elements that control protein interactions during signal transduction. *TIBS* 16, 450-452.

86. Miyazono, K., Usuki, K., and Heldin, C.-H. (1991). Platelet-derived endothelial cell growth factor. *Prog. Growth Factor Res.* 3, 207-217.

87. Heldin, C.-H., Östman, A., Eriksson, A., Siegbahn, A., Claesson-Welsh, L., and Westermark, B. (1992). Platelet-derived growth factor: Isoform-specific signalling via heterodimeric or homodimeric receptor complexes. *Kidney Int.* 41, 571-574.

88. Heldin, C.-H. (1992). Structural and functional studies on platelet-derived growth factor. *EMBO J.* 11, 4251-4259.

89. Miyazono, K., and Heldin, C.-H. (1992). Structure, function and possible clinical application of transforming growth factor-β. *J. Dermatol.* 19, 644-647.

90. Miyazono, K., and Heldin, C.-H. (1993). The mechanism of action of transforming growth factor-β. In: *Gastroenterol. Jpn*, Vol. 28, suppl. 4, pp. 81-85.

91. Miyazono, K., Ichijo, H., and Heldin, C.-H. (1993). Transforming growth factor-β: Latent forms, binding proteins and receptors. *Growth Factors* 8, 11-22.

92. Heldin, C.-H., and Westermark, B. (1993). Possible *in vivo* effect and clinical utility of platelet-derived growth factor (PDGF) and PDGF antagonists. *Transpl. Proc.* 25, 2072-2074.

93. Waltenberger, J., Miyazono, K., Funa, K., Wanders, A., Fellström, B., and Heldin, C.-H. (1993). Transforming growth factor-β and organ transplantation. *Transpl. Proc.* 25, 2038-2040.

94. Heldin, C.-H., Östman, A., and Westermark, B. (1993). Structure of platelet-derived growth factor: Implications for functional properties. *Growth Factors* 8, 245-252.

95. Westermark, B., and Heldin, C.-H. (1993). Platelet-derived growth factor: structure, function and implications in normal and malignant cell growth. *Acta Oncologica* 32, 101-105.

96. Heldin, C.-H. (1993). Purification and structure of PDGF. In: *Biology of platelet-derived growth factor. Cytokines* (Westermark, B., and Sorg, C., eds.), Karger, S. AG, Basel, Vol. 5, pp. 1-10.

97. Heldin, C.-H., Claesson-Welsh, L., Miyazono, K., and Westermark, B. (1993). Growth factors: In vivo function and mechanism of action. In: *Growth Factors and the cardiovascular system* (Cummins, P., ed.), Kluwer Academic Publishers, Dordrecht, pp. 1-15.

98. Kato, M., Hellman, U., Wernstedt, C., Miyazono, K., Heldin, C.-H., and Funa, K. (1994). Characterization of keratinocytes-derived autocrine growth inhibitors. In: *Proceedings of the XVI Internationl Cancer Congress in New Delhi* (Rao, R.S., Deo, M.G., Sanghvi, L.D., and Mittra, I., eds.), Monduzzi Editore, Bologna, pp. 3035-3039.

99. Miyazono, K., ten Dijke, P., Ichijo, H., and Heldin, C.-H. (1994). Receptors for transforming growth factor-β. *Adv. Immunol.* 55, 181-220.

100. ten Dijke, P., Franzén, P., Yamashita, H., Ichijo, H., Heldin, C.-H., and Miyazono, K. (1994). Serine/threonine kinase receptors. *Prog. Growth Factor Res.* 5, 55-72.

101. Miyazono, K., ten Dijke, P., Yamashita, H., and Heldin, C.-H. (1994). Receptors for transforming growth factor-b. In: *Horizon in Cytokine Research. The Third International Mochida Memorial Symposium 1993* (Takaku, F., ed.), Shobunsha Co., Ltd., Tokyo, pp. 87-96.

102. Miyazono, K., ten Dijke, P., Yamashita, H., and Heldin, C.-H. (1994). Signal transduction via serine/threonine kinase receptors. *Seminars in Cell Biology* 5, 389-398.

103. Heldin, C.-H., and Westermark, B. (1994). Platelet-derived growth factor (PDGF). In: *Guidebook to Cytokines and their Receptors* (Nicola, N., ed.), Oxford University Press, Oxford, pp. 202-204.

104. Heldin, C.-H., and Claesson-Welsh, L. (1994). Receptors for platelet-derived growth factor (PDGF). In: *Guidebook to Cytokines and their Receptors* (Nicola, N., ed.), Oxford University Press, Oxford, pp. 205-207.

105. Westermark, B., Heldin, C.-H., and Nistér, M. (1995). Platelet-derived growth factor in human glioma. *GLIA* 15, 257-263.

106. Heldin, C.-H. (1995). Dimerization of cell surface receptors in signal transduction. *Cell* 80, 213-223.

107. Fredholm, B.B., and Heldin, C.-H. (1995). Ny serie: Tillväxtfaktorer. *Läkartidningen* 92, 1454-1457.

108. Fredholm, B.B., and Heldin, C.-H. (1995). Tillväxtfaktorer - mekanismerna klarnar. *Läkartidningen* 92, 1459-1467.

109. Heldin, C.-H., and Miyazono, K. (1995). Transforming growth factor-β. Intressant kandidat för klinisk användning. *Läkartidningen* 92, 1569-1572.

110. Heldin, C.-H., and Westermark, B. (1996). Role of platelet-derived growth factor *in vivo*. In: *The Molecular and Cellular Biology of Wound Repair* (Clark, R.A.F., ed.), Plenum Press, New York, pp. 249-273.

111. Heldin, C.-H., Östman, A., and Westermark, B. (1996). Platelet-derived growth factor. In: *Growth Factors and Cytokines in Health and Disease* (LeRoith, D., and Bondy, C., eds.), JAI Press Inc., Greenwich, CT, Vol. 1A, pp. 123-145.

112. Yamashita, H., ten Dijke, P., Heldin, C.-H., and Miyazono, K. (1996). Bone morphogenetic protein receptors. *Bone* 19, 569-574.

113. Saras, J., and Heldin, C.-H. (1996). PDZ domains bind carboxy-terminal sequences of target proteins. *Trends. Biol. Sci.* 21, 455-458.

114. Heldin, C.-H. (1996). Protein tyrosine kinase receptors. In: *Cancer Surveys* (Parker, P., and Pawson, T., eds.), Cold Spring Harbor Press, New York, Vol. 27, pp. 7-24.

115. ten Dijke, P., Miyazono, K., and Heldin, C.-H. (1996). Signaling via hetero-oligomeric complexes of type I and type II serine/threonine kinase receptors. *Curr. Opin. Cell Biol.* 8, 139-145.

116. Heldin, C.-H., and Östman, A. (1996). Ligand-induced dimerization of growth factor receptors: variations on the theme. *Cytokine & Growth Factor Reviews* 7, 3-10.

117. Heldin, C.-H., and Purton, M., eds. (1996). Signal Transduction. *Modular Texts in Molecular and Cell Biology*, Chapman and Hall, London.

118. Derynck, R., Gelbart, W.M., Harland, R.M., Heldin, C.-H., Kern, S.E., Massagué, J., Melton, D.A., Mlodzik, M., Padgett, R.W., Roberts, A.B., Smith, J., Thomsen, G.H., Vogelstein, B., and Wang, X.-F. (1996). Nomenclature: Vertebrate mediators of TGFβ family signals. *Cell* 87, 173.

119. Heldin, C.-H., Claesson-Welsh, L., Miyazono, K., and Westermark, B. (1997). Growth regulatory proteins and their receptors. In: *Encyclopedia of Cancer Biology* (Bertino, J.R., ed.), Academic Press, Inc., San Diego, CA, Vol. II, pp. 772-782.

120. Heldin, C.-H., and Rönnstrand, L. (1997). Growth factor receptors in cell transformation. In: *Frontiers in Molecular Biology - Oncogenes and Tumor Suppressor Genes* (Peters, G., and Vousden, K., eds.), Oxford University Press, Oxford, pp. 55-85.

121. Heldin, C.-H., Miyazono, K., and ten Dijke, P. (1997). TGF-β signalling from cell membrane to nucleus through SMAD proteins. *Nature* 390, 465-471.

122. Heldin, C.-H. (1997). Members of the transforming growth factor-β superfamily signal through serine/threonine kinase receptors. *Jpn. J. Cancer Res.* 88, 1232-1233.

123. Miyazono, K., ten Dijke, P., Souchelnytskyi, S., Nakao, A., Imamura, T., Hanai, J.-i., Kawabata, M., and Heldin, C.-H. (1997). Transforming growth factor-β receptors and signal transduction. In: *Inhibin, Activin and Follistatin. Regulatory Functions in System and Cell Biology. A Serono Symposia S.A. Publication* (Aono, T., Sugino, H., and Vale, W.W., eds.), Springer-Verlag, New York, pp. 277-284.

124. Heldin, C.-H. (1997). Simultaneous induction of stimulatory and inhibitory signals by PDGF. *FEBS Lett.* 410, 17-21.

125. Betsholtz, C., and Heldin, C.-H. (1998). Platelet-derived growth factor: A regulator of connective tissue development and reaction. In: *Connective Tissue Biology: Integration and Reductionism* (Reed, R., and Rubin, K., eds.), Wenner-Gren International Series, Portland Press, London, pp. 179-193.

126. Heldin, C.-H. (1998). Common themes in intracellular signal transduction. *Oncology in Practice* 1, 6-8.

127. Heldin, C.-H., Östman, A., and Rönnstrand, L. (1998). Signal transduction via platelet-derived growth factor receptors. *Biochim. Biophys. Acta* 1378, F79-F113.

128. Piek, E., Heldin, C.-H., and ten Dijke, P. (1999). Specificity, diversity, and regulation in TGF-β superfamily signaling. *FASEB J.* 13, 2105-2124.

129. ten Dijke, P., and Heldin, C.-H. (1999). Signal transduction. An anchor for activation. *Nature* 397, 109-111.

130. Heldin, C.-H., and ten Dijke, P. (1999). SMAD destruction turns off signalling. *Nature Cell Biol.* 1, E195-E197.

131. Heldin, C.-H., and Westermark, B. (1999). Mechanism of action and *in vivo* role of platelet-derived growth factor. *Physiol. Rev.* 79, 1283-1316.

132. ten Dijke, P., Piek, E., and Heldin, C.-H. (1999). Bone morphogenetic proteins and their receptors. In: *Encyclopedia of Life Sciences.*, John Wiley & Sons, Ltd., Chichester, Vol. http://www.els.net/ [doi:10.1038/npg.els.0002330].

133. Heldin, C.-H. (2000). Platelet-derived growth factor. In: *An Encyclopedic Reference of Vascular Biology and Pathology*, Springer Verlag, pp. 218-222.

134. Miyazono, K., ten Dijke, P., and Heldin, C.-H. (2000). TGF-β signaling by Smad proteins. *Adv. Immunol.* 75, 115-157.

135. ten Dijke, P., Miyazono, K., and Heldin, C.-H. (2000). Signaling inputs converge on nuclear effectors in TGF-b signaling. *Trends. Biol. Sci.* 25, 64-70.

136. Heldin, C.-H. (2000). Signal transduction: Overview. In: *Nature Encyclopedia of Life Sciences*, Nature Publishing Group, London, Vol. September.

137. Heldin, C.-H., Moustakas, A., Souchelnytskyi, S., Itoh, S., and ten Dijke, P. (2001). Signal transduction mechanisms for members of the TGF-β superfamily. In: *TGF-b and Related Cytokines in Inflammation* (Breit, S.N., and Wahl, S., eds.), Birkhäuser Verlag AG, Basel, pp. 11-40.

138. Souchelnytskyi, S., Rönnstrand, L., Heldin, C.-H., and ten Dijke, P. (2001). Phosphorylation of Smad signaling proteins by receptor serine/threonine kinases. In: *Methods in Molecular Biology: Protein Kinase Protocols* (Reith, A.D., ed.), Humana Press Inc., Totowa, NJ, Vol. 124, pp. 107-120.

139. Östman, A., and Heldin, C.-H. (2001). Involvement of platelet-derived growth factor in disease: development of specific antagonists. *Adv. Cancer Res.* 80, 1-38.

140. Heldin, C.-H. (2001). Platelet-derived growth factor. In: *Encyclopedic Reference of Cancer* (Schwab, M., ed.), Springer-Verlag, Berlin Heidelberg, pp. 701-703.

141. Moustakas, A., Souchelnytskyi, S., and Heldin, C.-H. (2001). Smad regulation in TGF-β signal transduction. *J. Cell Sci.* 114, 4359-4369.

142. Heldin, C.-H., and Ericsson, J. (2001). Signal transduction: RIPping tyrosine kinase receptors apart. *Science* 294, 2111-2113.

143. Heldin, C.-H. (2001). Growth factor regulation of kinases. In: *Data mining in Structural biology. Ernst Schering Research Foundation Workshop. Signal transduction and beyond* (Schlichting, I., and Egner, U., eds.), Springer Verlag, Berlin, Vol. 34, pp. 1-18.

144. Rönnstrand, L., and Heldin, C.-H. (2001). Mechanisms of platelet-derived growth factor-induced chemotaxis. *Int. J. Cancer* 91, 757-762.

145. Heldin, C.-H. (2001). Signal transduction: multiple pathways, multiple options for therapy. *Stem Cells* 19, 295-303.

146. Heldin, C.-H. (2002). Platelet-derived growth factor. In: *Wiley Encyclopedia of Molecular Medicine* (Creighton, T., ed.), John Wiley and Sons, Inc., New York, Vol. 5, pp. 2520-2522.

147. Moustakas, A., Pardali, K., Gal, A., and Heldin, C.-H. (2002). Mechanisms of TGF-β signaling in regulation of cell growth and differentiation. *Immunol. Lett.* 82, 85-91.

148. Souchelnytskyi, S., Moustakas, A., and Heldin, C.-H. (2002). TGF-β signaling from a three-dimensional perspective: insight into selection of partners. *Trends Cell Biol.* 12, 304-307.

149. Moustakas, A., and Heldin, C.-H. (2002). From mono- to oligo-Smads: The heart of the matter in TGF-β signal transduction. *Genes Dev.* 16, 1867-1871.

150. Heldin, C.-H., Eriksson, U., and Östman, A. (2002). New members of the platelet-derived growth factor family of mitogens. *Arch. Biochem. Biophys.* 398, 284-290.

151. Heldin, C.-H. (2002). Perturbation of stimulatory and inhibitory pathways in malignancies. *Pezcoller Foundation Journal* 19, 2-13.

152. ten Dijke, P., and Heldin, C.-H. (2003). TGF-β receptors. In: *Cytokine Reference* (Oppenheim, J.J., and Feldmann, M., eds.), Academic Press, pp. 1871-1884.

153. Heldin, C.-H. (2003). Protein tyrosine kinase receptor signaling overview. In: *Handbook of Cell Signaling* (Bradshaw, R., and Dennis, E., eds.), Academic Press, San Diego, CA, Vol. 1, pp. 391-396.

154. Heldin, C.-H. (2003). Platelet-derived growth factor (PDGF). In: *Encyclopedia of hormones* (Henry, H.L., and Norman, A.W., eds.), Elsevier Science Ltd, New York, Vol. 3, pp. 231-237.

155. Pietras, K., Sjöblom, T., Rubin, K., Heldin, C.-H., and Östman, A. (2003). PDGF receptors as cancer drug targets. *Cancer Cell* 3, 439-443.

156. Moustakas, A., and Heldin, C.-H. (2003). The nuts and bolts of IRF structure. *Nat. Struct. Biol.* 10, 874-876.

157. Moustakas, A., and Heldin, C.-H. (2003). Ecsit-ement on the crossroads of Toll and BMP signal transduction. *Genes Dev.* 17, 2855-2859.

158. Östman, A., and Heldin, C.-H. (2004). Platelet-derived growth factor (PDGF). In: *Encyclopedia of Endocrine Diseases* (Martini, L., ed.), Academic Press, San Diego, USA, Vol. 4, pp. 690-696.

159. Heldin, C.-H. (2004). Platelet-derived growth factor - an introduction. *Cytokine & Growth Factor Reviews* 15, 195-196.

160. Heldin, C.-H., ed. (2004). Thematic issue on platelet-derived growth factor. *Cytokine & Growth Factor Reviews*, Vol. 15, pp. 195-289.

161. Heldin, C.-H. (2004). Development and possible clinical use of antagonists for PDGF and TGF-β. *Ups. J. Med. Sci.* 109, 165-178.

162. Heldin, C.-H., Rubin, K., Pietras, K., and Östman, A. (2004). High interstitial fluid pressure - an obstacle in cancer therapy. *Nat. Rev. Cancer* 4, 806-813.

163. Sjöblom, T., Pietras, K., Östman, A., and Heldin, C.-H. (2005). Platelet-derived growth factor: Normal function, role in disease, and application of PDGF antagonists. In: *Protein Tyrosine Kinases: From Inhibitors to Useful Drugs* (Fabbro, D., and McCormick, F., eds.), Cancer Drug Discovery and Development, Humana Press Inc., Totowa, NJ, USA, pp. 161-186.

164. Moustakas, A., and Heldin, C.-H. (2005). Non-Smad TGF-β signals. *J. Cell. Sci.* 118, 3573-3584.

165. van Bezooijen, R.L., Heldin, C.-H., and ten Dijke, P. (2006). Bone morphogenetic proteins and their receptors. In: *Encyclopedia of Life Sciences*, John Wiley & Sons, Ltd., Chichester, http://mrw.interscience.wiley.com/emrw/9780470015902/search/firstpage [doi:10.1038/npg.els.0004197].

166. Moustakas, A., Souchelnytskyi, S., and Heldin, C.-H. (2006). Serine/threonine kinase receptors. In: *Encyclopedic Reference of Genomics and Proteomics in Molecular Medicine* (Ruckpaul, K., and Ganten, D., eds.), Springer Verlag, Vol. part 18 [doi:10.1007/3-540-29623-9_3130], pp. 1603-1608.

167. Heldin, C.-H. (2006). Tyrosine kinases, receptor-linked - platelet-derived growth factor receptors. In: *Sigma-RBI Handbook of Receptor Classification and Signal Transduction* (Watling, K., ed.), Sigma-RBI, pp. 292-294.

168. ten Dijke, P., and Heldin, C.-H. (2006). The Smad family. In: *Smad Signal Transduction. Smads in Proliferation, Differentiation and Disease* (ten Dijke, P., and Heldin, C.-H., eds.), Proteins and Cell Regulation, Springer, Dordrecht, The Netherlands, Vol. 5, pp. 1-13.

169. ten Dijke, P., and Heldin, C.-H., eds. (2006). Smad Signal Transduction. Smads in Proliferation, Differentiation and Disease. *Proteins and Cell Regulation*, Springer, Dordrecht, The Netherlands, Vol. 5, pp. 1-473.

170. Heldin, C.-H., and Moustakas, A. (2006). A new twist in Smad signalig. *Dev. Cell* 10, 685-686.

171. Ekman, S., Bergqvist, M., Heldin, C.-H., and Lennartsson, J. (2007). Activation of growth factor receptors in esophageal cancer – implications for therapy. *Oncologist* 12, 1165-1177.

172. Moustakas, A., and Heldin, C.-H. (2007). Signaling networks guiding epithelial–mesenchymal transitions during embryogenesis and cancer progression. *Cancer Sci.* 98, 1512–1520.

173. Östman, A., and Heldin, C.-H. (2007). PDGF receptors as targets in tumor treatment. In: *Adv. Cancer Res.* (Vande Woude, G.F., and Klein, G., eds.), Academic Press, Vol. 97, pp. 247-274.

174. Heldin, C.-H., and ten Dijke, P. (2007). Cell regulation: Cellular signaling. *Curr. Opin. Cell Biol.* 19, 109-111.

175. Heldin, C.-H., Lennartsson, J., and Hellberg, C. (2008). Feedback Control: The role of negative feedback in signal transduction control. *Eur. J. Hum. Genet.* 16, 769-770.

176. Heldin, C.-H. (2008). Preface. Transforming growth factor-b in cancer. In: *Transforming Growth Factor-β in Cancer Therapy* (Jakowlew, S.B., ed.) Cancer Treatment and Therapy, Humana Press, Vol. 2, pp. vii-viii.

177. Heldin, C.-H. (2008). Platelet-derived growth factor. In: *Encyclopedia of Cancer* (Schwab, M., ed.), Springer-Verlag, Berlin, pp. 2355-2358, doi: 10.1007/978-3-642-27841-9_4,511-2.

178. Heldin, C.-H. (2008). TGF-b signaling from receptors to Smads. In: *The TGF-β Family* (Derynck, R., and Miyazono, K., eds.), Cold Spring Harbor Laboratory Press, Woodbury, N.Y., pp. 259-285.

179. Moustakas, A., and Heldin, C.-H. (2008). Dynamic control of TGF-β signaling and its links to the cytoskeleton. *FEBS Lett.* 582, 2051-2065.

180. Heldin, C.-H. (2008). The European Research Council — a new opportunity for European science. *Nature Rev. Mol. Cell. Biol.* 9, 417-420.

181. Heldin, C.-H., Landström, M., and Moustakas, A. (2009). Mechanism of TGF-β signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition. *Curr. Opin. Cell Biol.* 21, 166-176.

182. Moustakas, A., and Heldin, C.-H. (2009). The regulation of TGFβ signal transduction. *Development* 136, 3699-3714.

183. Thakur, N., Sorrentino, A., Heldin, C.-H., and Landström, M. (2009). TGF-β uses the E3-ligase TRAF6 to turn on the kinase TAK1 to kill prostate cancer cells. *Future Oncology* 5, 1-3.

184. Heldin, C.-H. (2010). Protein tyrosine kinase receptor signaling overview. In: *Handbook of Cell Signaling* (Bradshaw, R.A., and Dennis, E.A., eds.), Academic Press, San Diego, Vol. 3, pp. 419-426.

185. Hellberg, C., Östman, A., and Heldin, C.-H. (2010). PDGF and Vessel Maturation. In: *Resent Results in Cancer Research - Angiogenesis Inhibition* (Liersch, R., Berdel, W.E., and Kessler, T., eds.), Recent Results in Cancer Research, Springer Verlag, Berlin Heidelberg, Vol. 180, pp. 103-114.

186. Hellberg, C., and Heldin, C.-H. (2011). Role of PDGF in tumor stroma interactions. In: *Tumor Associated Fibroblasts and their Matrix* (Mueller, M.M., and Fusenig, N.E., eds.), The Tumor Microenvironment, Springer Verlag, Heidelberg, pp. 257-266.

187. Moustakas, A., and Heldin, C.-H. (2012). Induction of epithelial-mesenchymal transition by transforming growth factor β. *Semin. Cancer Biol.* 22, 446-454.

188. Heldin, C.-H., Vanlandewijck, M., and Moustakas, A. (2012). Regulation of EMT by TGFβ in cancer. *FEBS Lett.* 586, 1959-1970.

189. Heldin, C.-H., and Moustakas, A. (2012). Role of Smads in TGFβ signaling. *Cell Tissue Res.* 347, 21-36.

190. Heldin, C.-H. (2012). Autocrine PDGF stimulation in malignancies. *Ups. J. Med. Sci.* 117, 83-91.

191. Heldin, C.-H. (2013). Targeting the PDGF signaling pathway in tumor treatment. *Cell Commun. Signal.* 11, 97.

192. Morikawa, M., Koinuma, D., Miyazono, K., and Heldin, C.-H. (2013). Genome-wide mechanisms of Smad binding. *Oncogene* 32, 1609-1615.

193. Moustakas, A., and Heldin, C.-H. (2013). Coordination of TGF-β signaling by ubiquitylation. *Mol. Cell* 51, 555-556.

194. Heldin, C.-H. (2013). Transforming growth factor-b signaling. In: *TGF-β in Human Disease* (Moustakas, A., and Miyazawa, K., eds.), Springer, Japan, Vol. VIII, pp. 3-32.

195. Heldin, C.-H., and Scott, J. (2013). Tony Pawson 1952-2013. Obituary. *Nature Cell Biol.* 15, 1134.

196. Östman, A., and Heldin, C.-H. (2014). Platelet-derived growth factor. In: *Molecular Oncology: Causes of Cancer and Targets for Treatment* (Gelmann, E.P., Sawers, C.L., and Rauscher III, F.J., eds.), Cambridge University Press, Cambridge, pp. 135-143.

197. Heldin, C.-H., and Lennartsson, J. (2014). Structural and functional properties of platelet-derived growth factor and stem cell factor receptors. In: *Signaling by Receptor Tyrosine Kinases* (Schlessinger, J., and Lemmon, M., eds.), Cold Spring Harb. Perspect. Biol. , Vol. doi: 10.1101/cshperspect.a009100, pp. 207-225.

198. Heldin, C.-H. (2014). Targeting the PDGF signaling pathway in the treatment of non-malignant diseases. *J. Neuroimmune Pharmacol.* 9, 69-79.

199. Heldin, C.H. (2014). Tony Pawson (1952-2013). Obituary. *Growth Factors* 32, 174-175.

200. Heldin, C.-H., Lu, B., Evans, R., and Gutkind, J.S. (2016). Signals and receptors. *Cold Spring Harbor Perspectives in Biology* 8, a005900.

201. Heldin, C.-H. (2016). Platelet-derived growth factor. In: *Cancer Therapeutic Targets* (Marshall, J.L., ed.), Springer Verlag, doi: 10.1007/978-1-4614-6613-0_16-3.

202. Heldin, C.-H., and Lennartsson, J. (2016). Receptor tyrosine kinases and their ligands. In: *Encyclopedia of Cell Biology* (Bradshaw, R.A., and Stahl, P.D., eds.), Elsevier, Academic Press, Waltham, MA, Vol. 3, pp. 8-21.

203. Heldin, C.-H., and Moustakas, A. (2016). Signaling receptors for TGF-β family members. In: *The TGFβ Family* (Derynck, R., and Miyazono, K., eds.), Cold Spring Harbor Perspectives in Biology, 8, a022053.

204. Heldin, C.-H. (2016). Platelet-derived growth factor receptors. In: *The Receptor Tyrosine Kinase Handbook* (Wheeler, D.L., and Yarden, Y., eds.), Springer Verlag, (in press).

205. Moustakas, A., and Heldin, C.-H. (2016). Mechanisms of TGFβ-induced epithelial-mesenchymal transition. *J. Clin. Med*. 5, 63.

206. Christian, J., and Heldin, C.-H. (2017). TGFβ superfamily in Lisbon: navigating through development and disease. *Development* 144, 4476-4480.

207. Yakymovych, I., Yakymovych, M., and Heldin, C.-H. (2018). Intracellular trafficking of transforming growth factor receptors. *Acta Biochim. Biophys. Sinica* 50, 3-11.

208. Heldin, C.-H., Lennartsson, J., and Westermark, B. (2018). Involvement of platelet-derived growth factor ligands and receptors in tumorigenesis. *J. Int. Med*. 283, 16-44.

209. Heldin, P., Kolliopoulos, C., Lin, C.-Y., and Heldin, C.-H. (2020). Involvement of hyaluronan and CD44 in cancer and viral infections. *Cell. Sign*. 65, 109427.

210. Sanchez-Duffhues, G., Williams, E., Goumans, M.-J., Heldin, C.-H., and ten Dijke, P. (2020). Bone morphogenetic protein receptors; structure, function and targeting by small molecules. *Bone* 138, 115472.

211. Mendes Rodrigues, D. Jr., Tsirigoti, C., Lim, S.K., Heldin, C.-H., and Moustakas, A. (2022). Extracellular vesicles and transforming growth factor β signaling in cancer. *Frontiers in Cell and Developmental Biology* 10, 849938.

212. ten Dijke, P., Miyazono, K., Heldin, C.-H., and Moustakas., A. (2024). Special Issue: TGF-β and epithelial-mesenchymal transition in cancer. *Seminars in Cancer* 102-103, 1-3.

213. Westermark, B., and Heldin, C.-H. (2024). Special Issue: frontiers in recent advances in cancer diagnosis and treatment. *Uppsala J. Med. Sci.* 129, e129.